

Advances in leishmaniasis

Lancet, The

366, 1561-1577

DOI: [10.1016/s0140-6736\(05\)67629-5](https://doi.org/10.1016/s0140-6736(05)67629-5)

Citation Report

#	ARTICLE	IF	CITATIONS
2	INFECTIONS IN THE DESERT. , 2001, , 135-149.		0
3	Treatment options for visceral leishmaniasis. Expert Review of Anti-Infective Therapy, 2006, 4, 187-197.	2.0	49
4	Beyond the walls of the nucleus: the role of histones in cellular signaling and innate immunity This paper is one of a selection of papers published in this Special Issue, entitled 27th International West Coast Chromatin and Chromosome Conference, and has undergone the Journal's usual peer review process.. Biochemistry and Cell Biology, 2006, 84, 589-595.	0.9	137
5	Identification and Characterization of a Protein-tyrosine Phosphatase in Leishmania. Journal of Biological Chemistry, 2006, 281, 36257-36268.	1.6	39
6	Leishmaniasis cutánea crónica atípica. Respuesta a miltefosina oral. FMC Formacion Medica Continuada En Atencion Primaria, 2006, 13, 377-378.	0.0	0
7	Sandflies and leishmaniasis. Lancet, The, 2006, 367, 112.	6.3	14
8	Miltefosine: oral treatment of leishmaniasis. Expert Review of Anti-Infective Therapy, 2006, 4, 177-185.	2.0	66
9	Sodium Antimony Gluconate Induces Generation of Reactive Oxygen Species and Nitric Oxide via Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Activation in Leishmania donovani-Infected Macrophages. Antimicrobial Agents and Chemotherapy, 2006, 50, 1788-1797.	1.4	167
10	Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. Acta Tropica, 2006, 99, 83-87.	0.9	16
11	Structure of Leishmania mexicana Phosphomannomutase Highlights Similarities with Human Isoforms. Journal of Molecular Biology, 2006, 363, 215-227.	2.0	38
13	Unresponsiveness to Glucantime Treatment in Iranian Cutaneous Leishmaniasis due to Drug-Resistant Leishmania tropica Parasites. PLoS Medicine, 2006, 3, e162.	3.9	231
14	ORAL FLUCONAZOLE TREATMENT FOR EXTENSIVE CUTANEOUS LEISHMANIASIS IN AN 11-YEAR-OLD CHILD. Pediatric Infectious Disease Journal, 2006, 25, 1083-1084.	1.1	8
15	A combined proteomic and transcriptomic approach to the study of stage differentiation in Leishmania infantum. Proteomics, 2006, 6, 3567-3581.	1.3	148
16	Proteomic analysis of antigens from Leishmania infantum promastigotes. Proteomics, 2006, 6, 4187-4194.	1.3	38
17	Milia complicating successfully treated cutaneous leishmaniasis in three children. British Journal of Dermatology, 2006, 155, 860-861.	1.4	7
18	Leishmaniasis, Chagas disease and Human African Trypanosomiasis revisited: Disease Control Priorities in Developing Countries. Tropical Medicine and International Health, 2006, 11, 1339-1340.	1.0	4
19	Structurally diverse 5-substituted pyrimidine nucleosides as inhibitors of Leishmania donovani promastigotes in vitro. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5047-5051.	1.0	20
22	Stage specific gene expression and cellular localization of two isoforms of the serine hydroxymethyltransferase in the protozoan parasite Leishmania. Molecular and Biochemical Parasitology, 2006, 150, 63-71.	0.5	20

#	ARTICLE	IF	CITATIONS
23	Serological tests for visceral leishmaniasis. <i>BMJ: British Medical Journal</i> , 2006, 333, 711-712.	2.4	14
24	Case report and literature review of leishmaniasis as a cause of leg ulceration in the United Kingdom. <i>Journal of Wound Care</i> , 2006, 15, 389-391.	0.5	2
25	Antileishmanial Activity of Quinovic Acid Glycosides and Cadambine Acid Isolated from <i>Nauclea diderrichii</i> . <i>Planta Medica</i> , 2006, 72, 1396-1402.	0.7	28
26	In Vivo Induced Antigen Technology (IVIAT) and Change Mediated Antigen Technology (CMAT). <i>Infectious Disorders - Drug Targets</i> , 2006, 6, 327-334.	0.4	7
27	Leishmaniasis. <i>Postgraduate Medical Journal</i> , 2006, 82, 649-657.	0.9	56
28	Evidence for <i>Leishmania</i> (<i>Viannia</i>) Parasites in the Skin and Blood of Patients Before and After Treatment. <i>Journal of Infectious Diseases</i> , 2006, 194, 503-511.	1.9	52
29	Modulation of <i>Leishmania</i> ABC Protein Gene Expression through Life Stages and among Drug-Resistant Parasites. <i>Eukaryotic Cell</i> , 2006, 5, 1713-1725.	3.4	97
30	Leukotrienes Are Essential for the Control of <i>Leishmania amazonensis</i> Infection and Contribute to Strain Variation in Susceptibility. <i>Journal of Immunology</i> , 2006, 177, 3201-3208.	0.4	114
31	Fumarate Is an Essential Intermediary Metabolite Produced by the Procyclic <i>Trypanosoma brucei</i> . <i>Journal of Biological Chemistry</i> , 2006, 281, 26832-26846.	1.6	53
32	Artemisinin triggers induction of cell-cycle arrest and apoptosis in <i>Leishmania donovani</i> promastigotes. <i>Journal of Medical Microbiology</i> , 2007, 56, 1213-1218.	0.7	174
33	Role of the ABC Transporter PRP1 (ABCC7) in Pentamidine Resistance in <i>Leishmania</i> Amastigotes. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3030-3032.	1.4	53
34	Immunopathology of Leishmaniasis: An Update. <i>International Journal of Immunopathology and Pharmacology</i> , 2007, 20, 435-445.	1.0	66
35	Stearylamine-bearing cationic liposomes kill <i>Leishmania</i> parasites through surface exposed negatively charged phosphatidylserine. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 103-110.	1.3	35
36	Bio-available Zn ²⁺ in the growth medium as a cue for <i>Leishmania</i> to express its protective surface protease. <i>Annals of Tropical Medicine and Parasitology</i> , 2007, 101, 89-93.	1.6	0
37	Identification of Serine Proteases from <i>Leishmania braziliensis</i> . <i>Zeitschrift Fur Naturforschung - Section C Journal of Biosciences</i> , 2007, 62, 373-381.	0.6	22
38	<i>In Vitro</i> Activity of 10-Deacetylbaocatin III against <i>Leishmania donovani</i> Promastigotes and Intracellular Amastigotes. <i>Planta Medica</i> , 2007, 73, 1081-1088.	0.7	28
39	Diagnosis Please Comment. <i>Radiology</i> , 2007, 242, 319-319.	3.6	1
40	Leishmaniasis. <i>Postgraduate Medical Journal</i> , 2007, 83, 649-657.	0.9	98

#	ARTICLE	IF	CITATIONS
41	Correspondence Idiopathic CD4+ Lymphocytopenia Disclosed after the Diagnosis of Visceral Leishmaniasis. <i>Clinical Infectious Diseases</i> , 2007, 44, 1522-1523.	2.9	9
42	<i>Dicrocoelium dendriticum</i> or <i>Dicrocoelium hospes</i> . <i>Clinical Infectious Diseases</i> , 2007, 44, 1522-1522.	2.9	22
43	Engineering the rRNA decoding site of eukaryotic cytosolic ribosomes in bacteria. <i>Nucleic Acids Research</i> , 2007, 35, 6086-6093.	6.5	84
44	In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 802-810.	1.3	55
45	Amphotericin B Treatment for Indian Visceral Leishmaniasis: Response to 15 Daily versus Alternate-Day Infusions. <i>Clinical Infectious Diseases</i> , 2007, 45, 556-561.	2.9	80
46	Aloe vera leaf exudate induces a caspase-independent cell death in <i>Leishmania donovani</i> promastigotes. <i>Journal of Medical Microbiology</i> , 2007, 56, 629-636.	0.7	45
47	Lack of CXCR3 Delays the Development of Hepatic Inflammation but Does Not Impair Resistance to <i>Leishmania donovani</i> . <i>Journal of Infectious Diseases</i> , 2007, 195, 1713-1717.	1.9	25
48	Increased levels of thiols protect antimony unresponsive <i>Leishmania donovani</i> field isolates against reactive oxygen species generated by trivalent antimony. <i>Parasitology</i> , 2007, 134, 1679-1687.	0.7	94
49	Infectious Diseases of the Head and Neck. <i>American Journal of Clinical Pathology</i> , 2007, 128, 35-67.	0.4	29
50	Detection and Identification of <i>Leishmania</i> Species from Clinical Specimens by Using a Real-Time PCR Assay and Sequencing of the Cytochrome b Gene. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2110-2115.	1.8	82
51	Comparisons of Mutants Lacking the Golgi UDP-Galactose or GDP-Mannose Transporters Establish that Phosphoglycans Are Important for Promastigote but Not Amastigote Virulence in <i>Leishmania major</i> . <i>Infection and Immunity</i> , 2007, 75, 4629-4637.	1.0	50
52	Role of Imiquimod and Parenteral Meglumine Antimoniate in the Initial Treatment of Cutaneous Leishmaniasis. <i>Clinical Infectious Diseases</i> , 2007, 44, 1549-1554.	2.9	91
53	Visceral leishmaniasis causes fever and decompensation in patients with cirrhosis. <i>Gut</i> , 2007, 56, 893-894.	6.1	14
54	A Proteomics Screen Implicates HSP83 and a Small Kinetoplastid Calpain-related Protein in Drug Resistance in <i>Leishmania donovani</i> Clinical Field Isolates by Modulating Drug-induced Programmed Cell Death. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 88-101.	2.5	149
55	Host Odor Synergizes Attraction of Virgin Female <i>Lutzomyia longipalpis</i> (Diptera: Psychodidae). <i>Journal of Medical Entomology</i> , 2007, 44, 779-787.	0.9	32
56	Treatment of Bolivian Mucosal Leishmaniasis with Miltefosine. <i>Clinical Infectious Diseases</i> , 2007, 44, 350-356.	2.9	126
57	Evaluation of a Microculture Method for Isolation of <i>Leishmania</i> Parasites from Cutaneous Lesions of Patients in Peru. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3680-3684.	1.8	39
59	OPSOCLONUS-MYOCLONUS SYNDROME ASSOCIATED WITH GROUP A STREPTOCOCCAL INFECTION. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 358-359.	1.1	10

#	ARTICLE	IF	CITATIONS
60	A CASE OF INTERLEUKIN-12 RECEPTOR β -1 DEFICIENCY WITH RECURRENT LEISHMANIASIS. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 366-368.	1.1	41
61	EFFECTIVENESS OF EARLY INITIATION OF PROTEASE INHIBITOR-SPARING ANTIRETROVIRAL REGIMEN IN HUMAN IMMUNODEFICIENCY VIRUS-1 VERTICALLY INFECTED INFANTS. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 359-361.	1.1	22
62	ACTIVE TUBERCULOSIS AMONG ADOLESCENTS IN TORONTO, CANADA. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 355-356.	1.1	20
63	SUCCESSFUL MEDICAL TREATMENT OF CUTANEOUS ASPERGILLOSIS IN A PREMATURE INFANT USING LIPOSOMAL AMPHOTERICIN B, VORICONAZOLE AND MICALFUNGIN. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 364-366.	1.1	56
64	MYCOBACTERIUM SIMIAE CERVICAL LYMPHADENITIS. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 362-363.	1.1	16
65	INTRODUCTION OF HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE INTO ROUTINE IMMUNIZATION IN GHANA AND ITS IMPACT ON BACTERIAL MENINGITIS IN CHILDREN YOUNGER THAN FIVE YEARS. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 356-358.	1.1	17
66	Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan. <i>Vaccine</i> , 2007, 25, 2716-2722.	1.7	40
67	Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. <i>Vaccine</i> , 2007, 25, 6544-6556.	1.7	91
68	Cutaneous leishmaniasis. <i>Clinics in Dermatology</i> , 2007, 25, 203-211.	0.8	194
69	Interferon, a growing cytokine family: 50 years of interferon research. <i>Biochimie</i> , 2007, 89, 713-718.	1.3	93
70	Structural insights on the small subunit of DNA topoisomerase I from the unicellular parasite <i>Leishmania donovani</i> . <i>Biochimie</i> , 2007, 89, 1517-1527.	1.3	12
71	Antileishmanial 2-substituted quinolines: In vitro behaviour towards biological components. <i>Biomedicine and Pharmacotherapy</i> , 2007, 61, 441-450.	2.5	22
73	Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 335.e1-335.e29.	0.6	112
74	Cutaneous leishmaniasis. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 581-596.	4.6	1,130
75	<i>Leishmania</i> and the Leishmaniases: A Parasite Genetic Update and Advances in Taxonomy, Epidemiology and Pathogenicity in Humans. <i>Advances in Parasitology</i> , 2007, 64, 1-458.	1.4	245
76	Parasiticidal effect of α -aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells. <i>Experimental Dermatology</i> , 2007, 16, 651-660.	1.4	100
77	Host Odor Synergizes Attraction of Virgin Female <i>Lutzomyia longipalpis</i> (Diptera: Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.9	30
78	Photodynamic therapy for cutaneous leishmaniasis: the effectiveness of topical phenothiaziniums in parasite eradication and Th1 immune response stimulation. <i>Photochemical and Photobiological Sciences</i> , 2007, 6, 1067-1075.	1.6	61

#	ARTICLE	IF	CITATIONS
79	Molecular Diagnosis of Leishmaniasis: Current Status and Future Applications. <i>Journal of Clinical Microbiology</i> , 2007, 45, 21-25.	1.8	342
80	Racemoside A, an anti-leishmanial, water-soluble, natural steroidal saponin, induces programmed cell death in <i>Leishmania donovani</i> . <i>Journal of Medical Microbiology</i> , 2007, 56, 1196-1204.	0.7	72
81	Cutaneous leishmaniasis: therapeutic strategies and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2689-2699.	0.9	30
82	Inhibition of <i>Plasmodium falciparum</i> Choline Kinase by Hexadecyltrimethylammonium Bromide: a Possible Antimalarial Mechanism. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 696-706.	1.4	64
83	Cutaneous leishmaniasis treatment. <i>Travel Medicine and Infectious Disease</i> , 2007, 5, 150-158.	1.5	187
84	Synthesis and Biological Evaluation of Fluorescent Leishmanicidal Analogues of Hexadecylphosphocholine (Miltefosine) as Probes of Antiparasite Mechanisms. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5994-6003.	2.9	26
85	SENSITIVITY OF LEISHMANIA BRAZILIENSIS PROMASTIGOTES TO MEGLUMINE ANTIMONIATE (GLUCANTIME) IS HIGHER THAN THAT OF OTHER LEISHMANIA SPECIES AND CORRELATES WITH RESPONSE TO THERAPY IN AMERICAN TEGUMENTARY LEISHMANIASIS. <i>Journal of Parasitology</i> , 2007, 93, 688-693.	0.3	33
86	Genomic organization and expression of the HSP70 locus in New and Old World <i>Leishmania</i> species. <i>Parasitology</i> , 2007, 134, 369.	0.7	31
87	Effects of Brazilian propolis on <i>Leishmania amazonensis</i> . <i>Memorias Do Instituto Oswaldo Cruz</i> , 2007, 102, 215-220.	0.8	54
88	DNA Vaccines against Protozoan Parasites: Advances and Challenges. <i>Journal of Biomedicine and Biotechnology</i> , 2007, 2007, 1-11.	3.0	61
89	Deletion Study of DNA Topoisomerase IB from <i>Leishmania donovani</i> : Searching for a Minimal Functional Heterodimer. <i>PLoS ONE</i> , 2007, 2, e1177.	1.1	11
90	Visceral leishmaniasis in eastern Africa – current status. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2007, 101, 1169-1170.	0.7	48
91	Synthesis and antileishmanial activity of 6-mono-substituted and 3,6-di-substituted acridines obtained by acylation of proflavine. <i>European Journal of Medicinal Chemistry</i> , 2007, 42, 1277-1284.	2.6	56
92	The Ugi reaction in the generation of new nucleosides as potential antiviral and antileishmanial agents. <i>Bioorganic Chemistry</i> , 2007, 35, 121-136.	2.0	27
93	Development of a SPE/HPLC/DAD method for the determination of antileishmanial 2-substituted quinolines and metabolites in rat plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 854, 230-238.	1.2	5
94	Antipromastigote activity of the malabaricones of <i>Myristica malabarica</i> (rampatri). <i>Phytotherapy Research</i> , 2007, 21, 592-595.	2.8	21
95	The skin as interface in the transmission of arthropod-borne pathogens. <i>Cellular Microbiology</i> , 2007, 9, 1630-1640.	1.1	51
96	Trafficking of <i>Leishmania donovani</i> promastigotes in non-lytic compartments in neutrophils enables the subsequent transfer of parasites to macrophages. <i>Cellular Microbiology</i> , 2007, 10, 070726014633002-???.	1.1	100

#	ARTICLE	IF	CITATIONS
97	Courtship behaviour in the sandfly <i>Lutzomyia longipalpis</i> , the New World vector of visceral leishmaniasis. <i>Medical and Veterinary Entomology</i> , 2007, 21, 332-338.	0.7	14
98	A novel ATP-binding cassette transporter from <i>Leishmania</i> is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids. <i>Molecular Microbiology</i> , 2007, 64, 1141-1153.	1.2	78
99	Molecular genetic analysis of purine nucleobase transport in <i>Leishmania major</i> . <i>Molecular Microbiology</i> , 2007, 64, 1228-1243.	1.2	40
100	Cutaneous pseudolymphoma in association with <i>Leishmania donovani</i> . <i>British Journal of Dermatology</i> , 2007, 157, 1042-1043.	1.4	22
101	Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages. <i>Parasite Immunology</i> , 2007, 29, 229-239.	0.7	66
102	Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004. <i>Tropical Medicine and International Health</i> , 2007, 12, 1540-1544.	1.0	20
103	Clinical manifestations and classification of Old World cutaneous leishmaniasis. <i>International Journal of Dermatology</i> , 2007, 46, 132-142.	0.5	93
104	Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 070209222700140-???.	1.3	3
105	Successful treatment of a married couple for American leishmaniasis with miltefosine. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 22, 070619172136005-???.	1.3	9
106	Adverse reaction to specific immunotherapy for house-dust mite in a patient with <i>Anisakis</i> allergy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 22, 070622103247006-???.	1.3	1
108	Cutaneous <i>Leishmania</i> infection: progress in pathogenesis research and experimental therapy. <i>Experimental Dermatology</i> , 2007, 16, 340-346.	1.4	53
109	<i>Leishmania amazonensis</i> : Anionic currents expressed in oocytes upon microinjection of mRNA from the parasite. <i>Experimental Parasitology</i> , 2007, 116, 163-170.	0.5	8
110	Characterization of the RNA polymerase II and III complexes in <i>Leishmania major</i> . <i>International Journal for Parasitology</i> , 2007, 37, 491-502.	1.3	35
111	Comparative genomics: From genotype to disease phenotype in the leishmaniasis. <i>International Journal for Parasitology</i> , 2007, 37, 1173-1186.	1.3	103
112	Antimony in the environment: A review focused on natural waters. III. Microbiota relevant interactions. <i>Earth-Science Reviews</i> , 2007, 80, 195-217.	4.0	214
113	Consequences of the natural propensity of <i>Leishmania</i> and HIV-1 to target dendritic cells. <i>Trends in Parasitology</i> , 2007, 23, 317-324.	1.5	17
116	Oligopeptidase B from <i>L. amazonensis</i> : molecular cloning, gene expression analysis and molecular model. <i>Parasitology Research</i> , 2007, 101, 853-863.	0.6	20
117	Oligopeptidase B from <i>Leishmania amazonensis</i> : molecular cloning, gene expression analysis and molecular model. <i>Parasitology Research</i> , 2007, 101, 865-875.	0.6	21

#	ARTICLE	IF	CITATIONS
118	Glucantime-resistant <i>Leishmania tropica</i> isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. <i>Parasitology Research</i> , 2007, 101, 1319-1322.	0.6	69
119	In vitro antileishmanial activity of resveratrol and its hydroxylated analogues against <i>Leishmania major</i> promastigotes and amastigotes. <i>Parasitology Research</i> , 2007, 102, 91-97.	0.6	73
121	Metabolism of 2-substituted quinolines with antileishmanial activity studied in vitro with liver microsomes, hepatocytes and recombinantly expressed enzymes analyzed by LC/MS. <i>Toxicology</i> , 2007, 235, 27-38.	2.0	13
123	Role of <i>Mycobacterium vaccae</i> in the protection induced by first generation <i>Leishmania</i> vaccine against murine model of leishmaniasis. <i>Parasitology Research</i> , 2008, 103, 21-28.	0.6	15
124	Evaluation of PCR assay in diagnosis and identification of cutaneous leishmaniasis: a comparison with the parasitological methods. <i>Parasitology Research</i> , 2008, 103, 1159-1162.	0.6	62
125	Phosphoproteomic analysis of <i>Leishmania donovani</i> pro- and amastigote stages. <i>Proteomics</i> , 2008, 8, 350-363.	1.3	92
126	Proteomic approaches for discovery of new targets for vaccine and therapeutics against visceral leishmaniasis. <i>Proteomics - Clinical Applications</i> , 2008, 2, 372-386.	0.8	16
127	Visceral leishmaniasis among liver transplant recipients: An overview. <i>Liver Transplantation</i> , 2008, 14, 1816-1819.	1.3	25
128	Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 865, 55-62.	1.2	50
129	Immunological features of visceral leishmaniasis may mimic systemic lupus erythematosus. <i>Clinical Biochemistry</i> , 2008, 41, 65-68.	0.8	29
130	The influence of copper, selenium and zinc on the response to the Montenegro skin test in subjects vaccinated against American cutaneous leishmaniasis. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2008, 102, 64-69.	0.7	10
131	Azaterphenyl diamidines as antileishmanial agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 247-251.	1.0	26
132	Synthesis of BODIPY-labeled alkylphosphocholines with leishmanicidal activity, as fluorescent analogues of miltefosine. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 6336-6339.	1.0	37
133	Contrasting human cytokine responses to promastigote whole-cell extract and the <i>Leishmania</i> analogue receptor for activated C kinase antigen of <i>L. amazonensis</i> in natural infection versus immunization. <i>Clinical and Experimental Immunology</i> , 2008, 153, 369-375.	1.1	12
134	Transgenic <i>Leishmania</i> and the immune response to infection. <i>Parasite Immunology</i> , 2008, 30, 255-266.	0.7	34
135	Improving the prediction of mRNA extremities in the parasitic protozoan <i>Leishmania</i> . <i>BMC Bioinformatics</i> , 2008, 9, 158.	1.2	19
136	Simultaneous gene expression profiling in human macrophages infected with <i>Leishmania major</i> parasites using SAGE. <i>BMC Genomics</i> , 2008, 9, 238.	1.2	68
137	Genome-wide gene expression profiling analysis of <i>Leishmania major</i> and <i>Leishmania infantum</i> developmental stages reveals substantial differences between the two species. <i>BMC Genomics</i> , 2008, 9, 255.	1.2	122

#	ARTICLE	IF	CITATIONS
138	Characterization of <i>Leishmania (Leishmania) amazonensis</i> promastigotes resistant to pentamidine. <i>Experimental Parasitology</i> , 2008, 120, 98-102.	0.5	29
139	Coordinate regulation of a family of promastigote-enriched mRNAs by the 3'UTR PRE element in <i>Leishmania mexicana</i> . <i>Molecular and Biochemical Parasitology</i> , 2008, 157, 54-64.	0.5	20
140	A protein of the leucine-rich repeats (LRRs) superfamily is implicated in antimony resistance in <i>Leishmania infantum</i> amastigotes. <i>Molecular and Biochemical Parasitology</i> , 2008, 158, 95-99.	0.5	20
141	Distinct mitochondrial HSP70 homologues conserved in various <i>Leishmania</i> species suggest novel biological functions. <i>Molecular and Biochemical Parasitology</i> , 2008, 160, 157-162.	0.5	15
142	Functional analysis and complex gene rearrangements of the folate/biopterin transporter (FBT) gene family in the protozoan parasite <i>Leishmania</i> . <i>Molecular and Biochemical Parasitology</i> , 2008, 162, 155-164.	0.5	23
143	Diagnosis and treatment of cutaneous leishmaniasis. <i>Expert Review of Dermatology</i> , 2008, 3, 315-327.	0.3	4
144	Drug Targets in Kinetoplastid Parasites. <i>Advances in Experimental Medicine and Biology</i> , 2008, , .	0.8	4
145	Alternative and Complementary Antileishmanial Treatments: Assessment of the Antileishmanial Activity of 27 Lebanese Plants, Including 11 Endemic Species. <i>Journal of Alternative and Complementary Medicine</i> , 2008, 14, 157-162.	2.1	20
146	The innate immune response against <i>Leishmania</i> parasites. <i>Immunobiology</i> , 2008, 213, 377-387.	0.8	142
147	In vivo activity of perifosine against <i>Leishmania amazonensis</i> . <i>Acta Tropica</i> , 2008, 108, 20-25.	0.9	17
149	Immunization strategies against visceral leishmaniasis with the nucleosomal histones of <i>Leishmania infantum</i> encoded in DNA vaccine or pulsed in dendritic cells. <i>Vaccine</i> , 2008, 26, 2537-2544.	1.7	32
150	Epitope mapping and protective immunity elicited by adenovirus expressing the <i>Leishmania</i> amastigote specific A2 antigen: Correlation with IFN- γ and cytolytic activity by CD8+ T cells. <i>Vaccine</i> , 2008, 26, 4585-4593.	1.7	58
151	Cysteine proteinase type III is protective against <i>Leishmania infantum</i> infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals. <i>Vaccine</i> , 2008, 26, 5822-5829.	1.7	44
152	Characterization of the 5' region of the <i>Leishmania infantum</i> LORIEN/MAT2 gene cluster and role of LORIEN flanking regions in post-transcriptional regulation. <i>Biochimie</i> , 2008, 90, 1325-1336.	1.3	4
153	In Pursuit of Natural Product Leads: Synthesis and Biological Evaluation of 2-[3-hydroxy-2-[(3-hydroxypyridine-2-carbonyl)amino]phenyl]benzoxazole-4-carboxylic acid (A-33853) and Its Analogues: Discovery of <i>N</i> -(2-Benzoxazol-2-ylphenyl)benzamides as Novel Antileishmanial Chemotypes. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7344-7347.	2.9	72
154	Protozoan Diseases: Leishmaniasis. , 2008, , 367-371.		2
155	The <i>Leishmania</i> HSP20 Is Antigenic during Natural Infections, but, as DNA Vaccine, It does not Protect BALB/c Mice against Experimental <i>L. amazonensis</i> Infection. <i>Journal of Biomedicine and Biotechnology</i> , 2008, 2008, 1-9.	3.0	31
156	Drug delivery systems against leishmaniasis? Still an open question. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 805-823.	2.4	60

#	ARTICLE	IF	CITATIONS
157	The Relationship between Leishmaniasis and AIDS: the Second 10 Years. <i>Clinical Microbiology Reviews</i> , 2008, 21, 334-359.	5.7	754
158	New Treatment Approach in Indian Visceral Leishmaniasis: Single-Dose Liposomal Amphotericin B Followed by Short-Course Oral Miltefosine. <i>Clinical Infectious Diseases</i> , 2008, 47, 1000-1006.	2.9	174
159	Synthesis and Antiprotozoal Activity of Cationic 2-Phenylbenzofurans. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6927-6944.	2.9	36
160	Increased Levels of Interleukin-10 and IgG3 Are Hallmarks of Indian Post-Kala-Azar Dermal Leishmaniasis. <i>Journal of Infectious Diseases</i> , 2008, 197, 1762-1771.	1.9	70
161	Modulation of Gene Expression in Human Macrophages Treated with the Anti- <i>Leishmania</i> Pentavalent Antimonial Drug Sodium Stibogluconate. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 526-533.	1.4	35
162	Conservation of the pro-apoptotic nuclease activity of endonuclease G in unicellular trypanosomatid parasites. <i>Journal of Cell Science</i> , 2008, 121, 99-109.	1.2	85
163	gp63 in Stable Cationic Liposomes Confers Sustained Vaccine Immunity to Susceptible BALB/c Mice Infected with <i>Leishmania donovani</i> . <i>Infection and Immunity</i> , 2008, 76, 1003-1015.	1.0	109
164	T Cells from <i>Leishmania major</i> -Susceptible BALB/c Mice Have a Defect in Efficiently Up-Regulating CXCR3 upon Activation. <i>Journal of Immunology</i> , 2008, 181, 4613-4620.	0.4	22
165	Fishing for Anti- <i>Leishmania</i> Drugs: Principles and Problems. <i>Advances in Experimental Medicine and Biology</i> , 2008, 625, 48-60.	0.8	9
166	Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of <i>Leishmania braziliensis</i> and <i>Leishmania chagasi</i> infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 365-368.	1.3	65
167	The AP3 adaptor is involved in the transport of membrane proteins to acidocalcisomes of <i>Leishmania</i> . <i>Journal of Cell Science</i> , 2008, 121, 561-570.	1.2	54
168	Immunization with a Toll-Like Receptor 7 and/or 8 Agonist Vaccine Adjuvant Increases Protective Immunity against <i>Leishmania major</i> in BALB/c Mice. <i>Infection and Immunity</i> , 2008, 76, 3777-3783.	1.0	94
169	<i>Leishmania pifanoi</i> Proteoglycolipid Complex P8 Induces Macrophage Cytokine Production through Toll-Like Receptor 4. <i>Infection and Immunity</i> , 2008, 76, 2149-2156.	1.0	47
170	Comparison of the Effects of <i>Leishmania major</i> or <i>Leishmania donovani</i> Infection on Macrophage Gene Expression. <i>Infection and Immunity</i> , 2008, 76, 1186-1192.	1.0	81
173	The Epidemiological Transition: The Current Status of Infectious Diseases in the Developed World versus the Developing World. <i>Science Progress</i> , 2008, 91, 1-37.	1.0	45
174	Asymptomatic infection in family contacts of patients with human visceral leishmaniasis in TrÃs Lagoas, Mato Grosso do Sul State, Brazil. <i>Cadernos De Saude Publica</i> , 2008, 24, 2827-2833.	0.4	19
175	Synthesis of limonene β -amino alcohol derivatives in support of new antileishmanial therapies. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2008, 103, 773-777.	0.8	10
176	Visceral Leishmaniasis Revealing Chronic Granulomatous Disease in a Child. <i>International Journal of Immunopathology and Pharmacology</i> , 2008, 21, 739-743.	1.0	6

#	ARTICLE	IF	CITATIONS
177	Concurrent Chagas's disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 659-663.	0.9	23
178	Use of Oral Miltefosine for Cutaneous Leishmaniasis in Canadian Soldiers Returning from Afghanistan. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2008, 19, 394-396.	0.7	29
179	Skin Ulcer and Pyoderma. , 0, , 141-150.		0
180	Tropical Medicine for Expeditions. , 0, , 206-231.		0
181	Other Infectious Diseases Related to Travel. , 2009, , 290-411.		12
182	Genus-specific kinetoplast-DNA PCR and parasite culture for the diagnosis of localised cutaneous leishmaniasis: applications for clinical trials under field conditions in Brazil. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2009, 104, 992-997.	0.8	9
183	Effect of Topical Liposomes Containing Paromomycin Sulfate in the Course of <i>Leishmania major</i> Infection in Susceptible BALB/c Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2259-2265.	1.4	68
184	Immunological Determinants of Clinical Outcome in Peruvian Patients with Tegumentary Leishmaniasis Treated with Pentavalent Antimonials. <i>Infection and Immunity</i> , 2009, 77, 2022-2029.	1.0	22
185	Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature. <i>Immunotherapy</i> , 2009, 1, 765-776.	1.0	37
186	9-O-Acetylated Sialoglycoproteins Are Important Immunomodulators in Indian Visceral Leishmaniasis. <i>Vaccine Journal</i> , 2009, 16, 889-898.	3.2	13
187	Parasite Susceptibility to Amphotericin B in Failures of Treatment for Visceral Leishmaniasis in Patients Coinfected with HIV Type 1 and <i>Leishmania infantum</i> . <i>Clinical Infectious Diseases</i> , 2009, 48, e16-e22.	2.9	107
188	Ubiquitin Conjugation of Open Reading Frame F DNA Vaccine Leads to Enhanced Cell-Mediated Immune Response and Induces Protection against Both Antimony-Susceptible and -Resistant Strains of <i>Leishmania donovani</i> . <i>Journal of Immunology</i> , 2009, 183, 7719-7731.	0.4	34
189	Intracellular Localization of the ABC Proteins of <i>Leishmania</i> and Their Role in Resistance to Antimonials. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2646-2649.	1.4	45
190	Signal transducer and activator of transcription 1 in T cells plays an indispensable role in immunity to <i>Leishmania major</i> by mediating Th1 cell homing to the site of infection. <i>FASEB Journal</i> , 2009, 23, 3990-3999.	0.2	13
191	Coexistence of Leishmaniasis and Hodgkin's Lymphoma in a Lymph Node. <i>Journal of Clinical Oncology</i> , 2009, 27, e184-e185.	0.8	12
192	Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature. <i>Annals of Tropical Medicine and Parasitology</i> , 2009, 103, 455-459.	1.6	6
193	Antiprotozoal Agents: An Overview. <i>Anti-Infective Agents in Medicinal Chemistry</i> , 2009, 8, 345-366.	0.6	29
194	Cutaneous leishmaniasis: disease susceptibility and pharmacogenetic implications. <i>Pharmacogenomics</i> , 2009, 10, 451-461.	0.6	2

#	ARTICLE	IF	CITATIONS
195	First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e491.	1.3	65
196	Identification of the <i>Leishmania major</i> Proteins LmjF07.0430, LmjF07.0440, and LmjF27.2440 as Components of Fatty Acid Synthase II. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-8.	3.0	12
197	Synthetic Sex Pheromone Attracts the Leishmaniasis Vector &Lutzomyia longipalpis& (Diptera: Psychodidae) to Traps in the Field. <i>Journal of Medical Entomology</i> , 2009, 46, 428-434.	0.9	52
198	One of the Many Faces of Immune Reconstitution Inflammatory Syndrome. <i>Clinical Infectious Diseases</i> , 2009, 48, 764-765.	2.9	3
199	Protein disulfide isomerase (PDI) associates with NADPH oxidase and is required for phagocytosis of <i>Leishmania chagasi</i> promastigotes by macrophages. <i>Journal of Leukocyte Biology</i> , 2009, 86, 989-998.	1.5	96
200	9-O-acetylated sialic acids enhance entry of virulent <i>Leishmania donovani</i> promastigotes into macrophages. <i>Parasitology</i> , 2009, 136, 159-173.	0.7	17
201	Laboratory Diagnosis of Infections Due to Blood and Tissue Parasites. <i>Clinical Infectious Diseases</i> , 2009, 49, 1103-1108.	2.9	78
202	One of the Many Faces of Immune Reconstitution Inflammatory Syndrome. <i>Clinical Infectious Diseases</i> , 2009, 48, 836-839.	2.9	1
203	Whole-genome comparative RNA expression profiling of axenic and intracellular amastigote forms of <i>Leishmania infantum</i> . <i>Molecular and Biochemical Parasitology</i> , 2009, 165, 32-47.	0.5	95
204	The role of host genetics in leishmaniasis. <i>Trends in Parasitology</i> , 2009, 25, 383-391.	1.5	105
206	Down regulation of KMP-11 in <i>Leishmania infantum</i> axenic antimony resistant amastigotes as revealed by a proteomic screen. <i>Experimental Parasitology</i> , 2009, 123, 51-57.	0.5	47
207	<i>Leishmania donovani</i> : A glycosyl dihydropyridine analogue induces apoptosis like cell death via targeting pteridine reductase 1 in promastigotes. <i>Experimental Parasitology</i> , 2009, 123, 258-264.	0.5	16
208	Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated <i>Leishmania donovani</i> promastigotes involves Th1 immunity and down-regulation of IL-10. <i>European Journal of Immunology</i> , 2009, 39, 2146-2160.	1.6	28
209	Efficacy of the tubercidin antileishmania action associated with an inhibitor of the nucleoside transport. <i>Parasitology Research</i> , 2009, 104, 223-228.	0.6	14
210	Identification and chromosomal localization of one locus of <i>Leishmania (L.) major</i> related with resistance to itraconazole. <i>Parasitology Research</i> , 2009, 105, 471-478.	0.6	6
211	Synthesis, characterization and evaluation of antileishmanial activity of copper(II) with fluorinated β -hydroxycarboxylate ligands. <i>BioMetals</i> , 2009, 22, 1095-1101.	1.8	19
212	UDP-Gal: N-acetylglucosamine 1 \rightarrow 4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis. <i>Glycoconjugate Journal</i> , 2009, 26, 663-673.	1.4	9
213	<i>In vitro</i> sensitivity of <i>Leishmania (Viannia) braziliensis</i> and <i>Leishmania (Leishmania) amazonensis</i> Brazilian isolates to meglumine antimoniate and amphotericin B. <i>Tropical Medicine and International Health</i> , 2009, 15, 68-76.	1.0	61

#	ARTICLE	IF	CITATIONS
214	Treatment of Old World cutaneous leishmaniasis with dapsone, itraconazole, cryotherapy, and imiquimod, alone and in combination. <i>International Journal of Dermatology</i> , 2009, 48, 862-869.	0.5	25
215	Imported Leishmaniasis: A Heterogeneous Group of Diseases. <i>Journal of Travel Medicine</i> , 2009, 16, 395-401.	1.4	48
216	Cutaneous and mucocutaneous leishmaniasis. <i>Dermatologic Therapy</i> , 2009, 22, 491-502.	0.8	237
217	An in silico immunological approach for prediction of CD8+ T cell epitopes of <i>Leishmania major</i> proteins in susceptible BALB/c and resistant C57BL/6 murine models of infection. <i>Infection, Genetics and Evolution</i> , 2009, 9, 344-350.	1.0	19
218	Vaccine development against <i>Trypanosoma cruzi</i> and <i>Leishmania</i> species in the post-genomic era. <i>Infection, Genetics and Evolution</i> , 2009, 9, 1075-1082.	1.0	42
219	Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. <i>Veterinary Parasitology</i> , 2009, 165, 1-18.	0.7	475
220	Synthesis and antiprotozoal activities of dicationic bis(phenoxyethyl)benzenes, bis(phenoxyethyl)naphthalenes, and bis(benzyloxy)naphthalenes. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 3543-3551.	2.6	21
221	DNA and heparin chaperone the refolding of purified recombinant replication protein A subunit 1 from <i>Leishmania amazonensis</i> . <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2009, 1790, 119-125.	1.1	7
223	Recombinant outer membrane vesicles to augment antigen-specific live vaccine responses. <i>Vaccine</i> , 2009, 27, 6748-6754.	1.7	39
224	Recombinant <i>Leishmania tarentolae</i> expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. <i>Vaccine</i> , 2009, 28, 53-62.	1.7	91
225	Maternal and perinatal outcomes of visceral leishmaniasis (kala-azar) treated with sodium stibogluconate in eastern Sudan. <i>International Journal of Gynecology and Obstetrics</i> , 2009, 107, 208-210.	1.0	22
226	High efficacy of integrated preventive measures against zoonotic cutaneous leishmaniasis in northern Afghanistan, as revealed by Quantified Infection Rates. <i>Acta Tropica</i> , 2009, 110, 28-34.	0.9	20
227	Identification of genetic markers in Sodium Antimony Gluconate (SAG) sensitive and resistant Indian clinical isolates of <i>Leishmania donovani</i> through amplified fragment length polymorphism (AFLP). <i>Acta Tropica</i> , 2009, 110, 80-85.	0.9	21
228	Stimulation of <i>Leishmania tropica</i> protein kinase CK2 activities by platelet-activating factor (PAF). <i>Acta Tropica</i> , 2009, 111, 247-254.	0.9	18
229	Artesunate plus sulfamethoxypyrazine/pyrimethamine for the treatment of cutaneous leishmaniasis: a double-blind, placebo-controlled clinical trial. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 380-381.	1.1	10
230	Re: a VIM-1-metallo- β -lactamase-producing <i>Klebsiella pneumoniae</i> clinical isolate in an acute hospital in Germany. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 381.	1.1	1
231	Multidrug resistance related to class 1 integrons in human <i>Salmonella enterica</i> serotype Typhimurium isolates and emergence of atypical sul3-associated integrons. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 381-383.	1.1	5
232	Transfusion Transmission of Parasites. , 0, , 760-772.		1

#	ARTICLE	IF	CITATIONS
233	Searching for virulence factors in the non-pathogenic parasite to humans <i>Leishmania tarentolae</i> . <i>Parasitology</i> , 2009, 136, 723-735.	0.7	34
234	Neglected Tropical Diseases: Multi-Target-Directed Ligands in the Search for Novel Lead Candidates against <i>Trypanosoma</i> and <i>Leishmania</i> . <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7339-7359.	2.9	199
235	Molecular Basis of Antimony Treatment in Leishmaniasis. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2603-2612.	2.9	244
236	Effect of Oral Treatment with the Essential Oil from <i>Chenopodium ambrosioides</i> against Cutaneous Leishmaniasis in BALB/c Mice, Caused by <i>Leishmania amazonensis</i> . <i>Research in Complementary Medicine</i> , 2009, 16, 334-338.	2.2	24
237	Structure-Activity Study of Pentamidine Analogues as Antiprotozoal Agents. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2016-2035.	2.9	54
238	Drug Discovery for Neglected Diseases: View of A Public-Private Partnership. , 0, , 33-43.		6
239	Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant <i>Leishmania infantum</i> . <i>Nucleic Acids Research</i> , 2009, 37, 1387-1399.	6.5	153
240	Holiday souvenirs from the Mediterranean: Three instructive cases of visceral leishmaniasis. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 777-781.	1.5	8
241	<i>Leishmania</i> OligoC-TesT as a Simple, Rapid, and Standardized Tool for Molecular Diagnosis of Cutaneous Leishmaniasis in Peru. <i>Journal of Clinical Microbiology</i> , 2009, 47, 2560-2563.	1.8	22
242	<i>Leishmania</i> vaccines: from leishmanization to the era of DNA technology. <i>Bioscience Horizons</i> , 2009, 2, 73-82.	0.6	42
243	Polyclonal hypergammaglobulinemia and high smooth-muscle autoantibody titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis. <i>International Journal of Infectious Diseases</i> , 2009, 13, e157-e160.	1.5	27
244	Protein-energy malnutrition as a risk factor for visceral leishmaniasis: a review. <i>Parasite Immunology</i> , 2009, 31, 587-596.	0.7	69
245	<i>Leishmania</i> . , 2009, , 663-673.		6
246	<i>Leishmania</i> Exploit Sex. <i>Science</i> , 2009, 324, 187-189.	6.0	18
247	Current Treatment for Cutaneous Leishmaniasis: A Review. <i>American Journal of Therapeutics</i> , 2009, 16, 178-182.	0.5	81
248	Study of the stress proteins secreted by <i>Leishmania donovani</i> after treatment with edelfosine, mitelfosine and ilmofosine, and morphological alterations analyzed by electronic microscopy. <i>Parasite</i> , 2009, 16, 215-221.	0.8	0
249	Perpetuation of <i>Leishmania</i> : some novel insight into elegant developmental programs. <i>Veterinary Research</i> , 2009, 40, 38.	1.1	6
250	Photochemistry-based immune modulation in the treatment of cutaneous leishmaniasis. , 2009, , .		1

#	ARTICLE	IF	CITATIONS
251	Visceral Leishmaniasis Mimicking Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2010, 16, 203-204.	0.5	14
253	Effect of Elatol, Isolated from Red Seaweed <i>Laurencia dendroidea</i> , on <i>Leishmania amazonensis</i> . <i>Marine Drugs</i> , 2010, 8, 2733-2743.	2.2	81
254	In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 58, 1043-1054.	1.2	29
255	Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 59, 41-49.	1.2	25
256	Neglected tropical diseases. <i>British Medical Bulletin</i> , 2010, 93, 179-200.	2.7	265
257	The Ribosomal A-site: Decoding, Drug Target, and Disease. <i>Israel Journal of Chemistry</i> , 2010, 50, 60-70.	1.0	10
258	Synthesis of 2-(pyrimidin-2-yl)-1-phenyl-2,3,4,9-tetrahydro-1H- β -carbolines as antileishmanial agents. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 3274-3280.	2.6	35
259	Synthesis, structural elucidation and in vitro antiparasitic activity against <i>Trypanosoma cruzi</i> and <i>Leishmania chagasi</i> parasites of novel tetrahydro-1-benzazepine derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4721-4739.	1.4	39
260	Homology modeling and atomic level binding study of <i>Leishmania</i> MAPK with inhibitors. <i>Journal of Molecular Modeling</i> , 2010, 16, 475-488.	0.8	26
261	Serine protease activities in <i>Leishmania (Leishmania) chagasi</i> promastigotes. <i>Parasitology Research</i> , 2010, 107, 1151-1162.	0.6	13
262	Treatment of visceral leishmaniasis in children in the Central-West Region of Brazil. <i>Infection</i> , 2010, 38, 261-267.	2.3	14
263	The <i>Leishmania amazonensis</i> TRF (TTAGGG repeat-binding factor) homologue binds and co-localizes with telomeres. <i>BMC Microbiology</i> , 2010, 10, 136.	1.3	18
264	Structure-function analysis of the highly conserved charged residues of the membrane protein FT1, the main folic acid transporter of the protozoan parasite <i>Leishmania</i> . <i>Biochemical Pharmacology</i> , 2010, 79, 30-38.	2.0	13
265	<i>Leishmania (Leishmania) amazonensis</i> infection: Muscular involvement in BALB/c and C3H.HeN mice. <i>Experimental Parasitology</i> , 2010, 124, 315-318.	0.5	7
266	<i>Leishmania donovani</i> : Oral therapy with glycosyl 1,4-dihydropyridine analogue showing apoptosis like phenotypes targeting pteridine reductase 1 in intracellular amastigotes. <i>Experimental Parasitology</i> , 2010, 125, 310-314.	0.5	14
267	Genotypically distinct strains of <i>Leishmania major</i> display diverse clinical and immunological patterns in BALB/c mice. <i>Infection, Genetics and Evolution</i> , 2010, 10, 969-975.	1.0	11
268	Proteomics of trypanosomatids of human medical importance. <i>Journal of Proteomics</i> , 2010, 73, 845-867.	1.2	44
269	Synthesis and biological evaluation of indolyl glyoxylamides as a new class of antileishmanial agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 6191-6194.	1.0	17

#	ARTICLE	IF	CITATIONS
270	Synthesis and Antileishmanial Activity of Lipidic Amino Alcohols. <i>Chemical Biology and Drug Design</i> , 2010, 75, 233-235.	1.5	17
271	Complementary medicinal chemistry-driven strategies toward new antitrypanosomal and antileishmanial lead drug candidates. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 58, 51-60.	2.7	32
272	Tropical medicine rounds: Treatment of acute cutaneous leishmaniasis with intralesional injection of meglumine antimoniate: comparison of conventional technique with mesotherapy gun. <i>International Journal of Dermatology</i> , 2010, 49, 1034-1037.	0.5	10
273	Selective inactivation of <i>SIDER2</i> retroposon-mediated mRNA decay contributes to stage- and species-specific gene expression in <i>Leishmania</i> . <i>Molecular Microbiology</i> , 2010, 77, 471-491.	1.2	16
274	Localization and induction of the A2 virulence factor in <i>Leishmania</i> : evidence that A2 is a stress response protein. <i>Molecular Microbiology</i> , 2010, 77, 518-530.	1.2	60
275	Screening <i>Leishmania donovani</i> -specific genes required for visceral infection. <i>Molecular Microbiology</i> , 2010, 77, 505-517.	1.2	42
276	Carbohydrate vaccines: developing sweet solutions to sticky situations?. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 308-324.	21.5	524
277	The stage-regulated HASPB and SHERP proteins are essential for differentiation of the protozoan parasite <i>Leishmania major</i> in its sand fly vector, <i>Phlebotomus papatasi</i> . <i>Cellular Microbiology</i> , 2010, 12, 1765-1779.	1.1	82
278	Cutaneous leishmaniasis in a child treated with oral fluconazole. <i>Australasian Journal of Dermatology</i> , 2010, 51, 195-197.	0.4	12
279	Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1158-1165.	2.7	21
280	Expanded infectious diseases screening program for Hispanic transplant candidates. <i>Transplant Infectious Disease</i> , 2010, 12, 336-341.	0.7	41
281	<i>Molecular Pathology and Infectious Diseases.</i> , 2010, , 99-106.		2
283	Clinical and Demographic Stratification of Test Performance: A Pooled Analysis of Five Laboratory Diagnostic Methods for American Cutaneous Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 83, 345-350.	0.6	49
284	High Affinity S-Adenosylmethionine Plasma Membrane Transporter of <i>Leishmania</i> Is a Member of the Folate Biopterin Transporter (FBT) Family. <i>Journal of Biological Chemistry</i> , 2010, 285, 19767-19775.	1.6	27
285	Treatment strategies for mucocutaneous leishmaniasis. <i>Journal of Global Infectious Diseases</i> , 2010, 2, 147.	0.2	28
286	Climate Change and Risk of Leishmaniasis in North America: Predictions from Ecological Niche Models of Vector and Reservoir Species. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e585.	1.3	252
287	Therapeutic Glucocorticoid-Induced TNF Receptor-Mediated Amplification of CD4+T Cell Responses Enhances Antiparasitic Immunity. <i>Journal of Immunology</i> , 2010, 184, 2583-2592.	0.4	17
288	<i>Skin Infections.</i> , 2010, , 519-616.		8

#	ARTICLE	IF	CITATIONS
289	Immunostimulatory Properties of Dendritic Cells after <i>Leishmania donovani</i> Infection Using an In Vitro Model of Liver Microenvironment. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e703.	1.3	10
290	Diagnostic Accuracy of the <i>Leishmania</i> OligoC-TesT and NASBA-Oligochromatography for Diagnosis of Leishmaniasis in Sudan. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e776.	1.3	30
291	Reticular erythematous mucinosis syndrome with telangiectasias. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2010, 76, 86.	0.2	2
292	<i>Leishmania</i> -Specific Surface Antigens Show Sub-Genus Sequence Variation and Immune Recognition. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e829.	1.3	28
293	<i>Thrichomys laurentius</i> (Rodentia; Echimyidae) as a Putative Reservoir of <i>Leishmania infantum</i> and <i>L. braziliensis</i> : Patterns of Experimental Infection. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e589.	1.3	23
294	CD8 Cells of Patients with Diffuse Cutaneous Leishmaniasis Display Functional Exhaustion: The Latter Is Reversed, In Vitro, by TLR2 Agonists. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e871.	1.3	107
295	Antileishmanial activity of an essential oil from the leaves and flowers of <i>Achillea millefolium</i> . <i>Annals of Tropical Medicine and Parasitology</i> , 2010, 104, 475-483.	1.6	35
296	Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India. <i>Future Microbiology</i> , 2010, 5, 1301-1303.	1.0	16
297	A Travel Misadventure - Visceral Leishmaniasis in an Immunocompetent Patient. <i>Journal of the Royal Army Medical Corps</i> , 2010, 156, 169-171.	0.8	1
298	Proteases and phosphatases during <i>leishmania</i> -macrophage interaction: Paving the road for pathogenesis. <i>Virulence</i> , 2010, 1, 314-318.	1.8	22
299	Vaccination with TAT-Antigen Fusion Protein Induces Protective, CD8+ T Cell-Mediated Immunity Against <i>Leishmania Major</i> . <i>Journal of Investigative Dermatology</i> , 2010, 130, 2602-2610.	0.3	31
300	Synthesis and Antiprotozoal Activity of Cationic 1,4-Diphenyl-1 <i>H</i> -1,2,3-triazoles. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 254-272.	2.9	147
301	Comparative in vivo expression of amastigote up regulated <i>Leishmania</i> genes in three different forms of Leishmaniasis. <i>Parasitology International</i> , 2010, 59, 262-264.	0.6	15
302	Leishmanicidal activity of <i>Himatanthus sucuuba</i> latex against <i>Leishmania amazonensis</i> . <i>Parasitology International</i> , 2010, 59, 173-177.	0.6	30
303	Detection and Species Identification of <i>Leishmania</i> DNA from Filter Paper Lesion Impressions for Patients with American Cutaneous Leishmaniasis. <i>Clinical Infectious Diseases</i> , 2010, 50, e1-e6.	2.9	62
304	Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 419-433.	2.0	363
305	The effect of C-terminal domain deletion on the catalytic activity of <i>Leishmania donovani</i> surface proteinase GP63: Role of Ser446 in proteolysis. <i>Biochimie</i> , 2010, 92, 1876-1885.	1.3	9
306	Evaluation of 4 polymerase chain reaction protocols for cultured <i>Leishmania</i> spp. typing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 401-409.	0.8	18

#	ARTICLE	IF	CITATIONS
309	The yeast permease Acr3p is a dual arsenite and antimonite plasma membrane transporter. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2010, 1798, 2170-2175.	1.4	34
310	Requirement of SIRP \pm for protective immunity against <i>Leishmania major</i> . <i>Biochemical and Biophysical Research Communications</i> , 2010, 401, 385-389.	1.0	5
311	Amplified fragment length polymorphism (AFLP) analysis is useful for distinguishing <i>Leishmania</i> species of visceral and cutaneous forms. <i>Acta Tropica</i> , 2010, 113, 202-206.	0.9	23
312	Cutaneous and mucocutaneous leishmaniasis: emerging therapies and progress in disease management. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 557-569.	0.9	24
313	Analysis of Stage-Specific Expression of Basic Proteins in <i>Leishmania infantum</i> . <i>Journal of Proteome Research</i> , 2010, 9, 3842-3853.	1.8	43
314	Efficacy of Miltefosine for the Treatment of American Cutaneous Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 83, 351-356.	0.6	90
315	New delivery strategies for the old pentavalent antimonial drugs. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 1343-1358.	2.4	69
316	Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. <i>New England Journal of Medicine</i> , 2010, 362, 504-512.	13.9	371
317	Immunomodulators: use in combined therapy against leishmaniasis. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 739-742.	2.0	29
318	Polymerase Chain Reaction Detection of <i>Leishmania</i> kDNA from the Urine of Peruvian Patients with Cutaneous and Mucocutaneous Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 84, 556-561.	0.6	26
319	Localized Leishmanial Lymphadenopathy: An Unusual Manifestation of Leishmaniasis in a Traveler in Southern Europe. <i>Vector-Borne and Zoonotic Diseases</i> , 2011, 11, 1213-1215.	0.6	15
322	A Serological and Molecular Study of <i>Leishmania infantum</i> Infection in Cats from the Island of Ibiza (Spain). <i>Vector-Borne and Zoonotic Diseases</i> , 2011, 11, 239-245.	0.6	64
323	Substrate Preferences and Catalytic Parameters Determined by Structural Characteristics of Sterol 14 α -Demethylase (CYP51) from <i>Leishmania infantum</i> . <i>Journal of Biological Chemistry</i> , 2011, 286, 26838-26848.	1.6	92
324	<i>In Silico</i> Screening, Structure-Activity Relationship, and Biologic Evaluation of Selective Pteridine Reductase Inhibitors Targeting Visceral Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 659-666.	1.4	28
325	A Platform for the Detection of Trypanosomes via Selective Small Molecule Recognition. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 555-558.	1.3	2
326	Comparison of different primers for PCR-based diagnosis of cutaneous leishmaniasis. <i>Brazilian Journal of Infectious Diseases</i> , 2011, 15, 204-210.	0.3	17
327	Identification of <i>Leishmania</i> spp. by Molecular Amplification and DNA Sequencing Analysis of a Fragment of rRNA Internal Transcribed Spacer 2. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3143-3149.	1.8	91
328	Innate Immunity and <i>Leishmania</i> Vaccination Strategies. <i>Dermatologic Clinics</i> , 2011, 29, 89-102.	1.0	25

#	ARTICLE	IF	CITATIONS
329	Bone marrow leishmaniasis: a review of situation in Thailand. Asian Pacific Journal of Tropical Medicine, 2011, 4, 757-759.	0.4	7
330	Photodynamic Therapy Using Methylene Blue to Treat Cutaneous Leishmaniasis. Photomedicine and Laser Surgery, 2011, 29, 711-715.	2.1	67
331	Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. International Journal of Nanomedicine, 2011, 6, 835.	3.3	68
332	Metabolic Pathways Required for the Intracellular Survival of <i>Leishmania</i> . Annual Review of Microbiology, 2011, 65, 543-561.	2.9	125
333	Non-Invasive Cytology Brush PCR Diagnostic Testing in Mucosal Leishmaniasis: Superior Performance to Conventional Biopsy with Histopathology. PLoS ONE, 2011, 6, e26395.	1.1	37
334	In vitro antileishmanial activity and cytotoxicity of essential oil from <i>Lippia sidoides</i> Cham. Parasitology International, 2011, 60, 237-241.	0.6	112
335	Antiparasitic Therapy. Mayo Clinic Proceedings, 2011, 86, 561-583.	1.4	118
336	Fucoidan cures infection with both antimony-susceptible and -resistant strains of <i>Leishmania donovani</i> through Th1 response and macrophage-derived oxidants. Journal of Antimicrobial Chemotherapy, 2011, 66, 618-625.	1.3	50
337	A novel mechanism for an old drug: Amphotericin B in the treatment of visceral leishmaniasis. Biochemical and Biophysical Research Communications, 2011, 416, 7-12.	1.0	100
338	<i>Leishmania major</i> MAP kinase 10 is protective against experimental <i>L. major</i> infection. Vaccine, 2011, 29, 8783-8787.	1.7	9
340	Visceral leishmaniasis: elimination with existing interventions. Lancet Infectious Diseases, The, 2011, 11, 322-325.	4.6	109
341	Kinetoplastid Parasites. Topics in Medicinal Chemistry, 2011, , 181-241.	0.4	6
342	Identification of the HSP70-II gene in <i>Leishmania braziliensis</i> HSP70 locus: genomic organization and UTRs characterization. Parasites and Vectors, 2011, 4, 166.	1.0	25
343	Recent advances in leishmaniasis treatment. International Journal of Infectious Diseases, 2011, 15, e525-e532.	1.5	262
344	Comparative Chemical, Cytotoxicity and Antileishmanial Properties of Essential Oils from <i>Chenopodium ambrosioides</i> . Natural Product Communications, 2011, 6, 1934578X1100600.	0.2	22
347	Prevalence of cutaneous leishmaniasis during 2010 in Mazandaran Province, Iran. African Journal of Microbiology Research, 2011, 5, .	0.4	3
348	Dermatology and Global Health Meet Pharmacogenomics: Cutaneous Leishmaniasis. Current Pharmacogenomics and Personalized Medicine, 2011, 9, 14-24.	0.2	0
349	Clinical Manifestations and Distribution of Cutaneous Leishmaniasis in Pakistan. Journal of Tropical Medicine, 2011, 2011, 1-8.	0.6	24

#	ARTICLE	IF	CITATIONS
350	Antileishmanial Patents Antileishmanial Current Drugs and Relevant Patents. Recent Patents on Anti-infective Drug Discovery, 2011, 6, 1-26.	0.5	14
351	Potency, Efficacy and Durability of DNA/DNA, DNA/Protein and Protein/Protein Based Vaccination Using gp63 Against Leishmania donovani in BALB/c Mice. PLoS ONE, 2011, 6, e14644.	1.1	70
352	Visceral Leishmaniasis in Muzaffarpur District, Bihar, India from 1990 to 2008. PLoS ONE, 2011, 6, e14751.	1.1	40
353	Intracellular Eukaryotic Parasites Have a Distinct Unfolded Protein Response. PLoS ONE, 2011, 6, e19118.	1.1	45
354	Visceral Leishmaniasis in Liver Transplant Recipients From an Endemic Area. Transplantation, 2011, 91, 806-808.	0.5	14
355	A combined luciferase imaging and reverse transcription polymerase chain reaction assay for the study of Leishmania amastigote burden and correlated mouse tissue transcript fluctuations. Cellular Microbiology, 2011, 13, 81-91.	1.1	37
356	Promastigote to amastigote differentiation of Leishmania is markedly delayed in the absence of PERK eIF2alpha kinase-dependent eIF2alpha phosphorylation. Cellular Microbiology, 2011, 13, 1059-1077.	1.1	54
357	Cutaneous leishmaniasis in a Japanese returnee from West Africa successfully treated with liposomal amphotericin B. Journal of Dermatology, 2011, 38, 1062-1065.	0.6	10
358	CD4+ T cells defined by their V β 2 T cell receptor expression are associated with immunoregulatory profiles and lesion size in human leishmaniasis. Clinical and Experimental Immunology, 2011, 165, 338-351.	1.1	16
359	Visceral leishmaniasis: immunology and prospects for a vaccine. Clinical Microbiology and Infection, 2011, 17, 1462-1470.	2.8	87
360	Clinical pleiomorphism in human leishmaniases, with special mention of asymptomatic infection. Clinical Microbiology and Infection, 2011, 17, 1451-1461.	2.8	101
362	Research priorities for the control of phlebotomine sand flies. Journal of Vector Ecology, 2011, 36, S10-S16.	0.5	52
363	Multilocus genotyping reveals a polyphyletic pattern among naturally antimony-resistant Leishmania braziliensis isolates from Peru. Infection, Genetics and Evolution, 2011, 11, 1873-1880.	1.0	16
364	Oligopeptidase B deficient mutants of Leishmania major. Molecular and Biochemical Parasitology, 2011, 175, 49-57.	0.5	37
365	A proteomics view of programmed cell death mechanisms during host-parasite interactions. Journal of Proteomics, 2011, 75, 246-256.	1.2	4
366	Plant derived therapeutics for the treatment of Leishmaniasis. Phytomedicine, 2011, 18, 1056-1069.	2.3	154
367	Activity-guided isolation of antileishmanial compounds from Piper hispidum. Phytochemistry Letters, 2011, 4, 363-366.	0.6	28
368	Mechanisms of resistance and susceptibility to experimental visceral leishmaniasis: BALB/c mouse versus syrian hamster model. Veterinary Research, 2011, 42, 39.	1.1	82

#	ARTICLE	IF	CITATIONS
369	A possible role for <i>Phlebotomus</i> (<i>Anaphlebotomus</i>) <i>rodhaini</i> (Parrot, 1930) in transmission of <i>Leishmania donovani</i> . <i>Parasites and Vectors</i> , 2011, 4, 238.	1.0	26
370	Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against <i>Leishmania major</i> infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. <i>Experimental Parasitology</i> , 2011, 127, 627-636.	0.5	39
371	Expression of a <i>Leishmania donovani</i> nucleotide sugar transporter in <i>Leishmania major</i> enhances survival in visceral organs. <i>Experimental Parasitology</i> , 2011, 129, 337-345.	0.5	15
372	Mechanisms of immunity to <i>Leishmania major</i> infection in mice: The contribution of DNA vaccines coding for two novel sets of histones (H2Aâ€“H2B or H3â€“H4). <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2011, 34, 381-386.	0.7	13
373	GC-MS analysis and antileishmanial activities of two Turkish propolis types. <i>Parasitology Research</i> , 2011, 108, 95-105.	0.6	41
374	Screening natural products database for identification of potential antileishmanial chemotherapeutic agents. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2011, 3, 217-231.	2.2	17
375	<i>Leishmania infantum</i> HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation. <i>Parasites and Vectors</i> , 2011, 4, 150.	1.0	51
376	New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas. <i>Drug Development Research</i> , 2011, 72, 451-462.	1.4	3
377	Trimethoxy-chalcone derivatives inhibit growth of <i>Leishmania braziliensis</i> : Synthesis, biological evaluation, molecular modeling and structureâ€“activity relationship (SAR). <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 5046-5052.	1.4	47
378	Toll-like receptor 4 polymorphisms predispose to cutaneous leishmaniasis. <i>Microbes and Infection</i> , 2011, 13, 226-231.	1.0	30
379	Anti-Leishmanial activity of homo- and heteroleptic bismuth(III) carboxylates. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 454-461.	1.5	51
380	Advances on Aptamers Targeting Plasmodium and Trypanosomatids. <i>Current Medicinal Chemistry</i> , 2011, 18, 5003-5010.	1.2	10
381	A Species-Specific Approach to the Use of Non-Antimony Treatments for Cutaneous Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 84, 109-117.	0.6	20
382	Toll-Like Receptors Participate in Macrophage Activation and Intracellular Control of <i>Leishmania</i> (<i>Viannia</i>) <i>panamensis</i> . <i>Infection and Immunity</i> , 2011, 79, 2871-2879.	1.0	60
383	Enhancement of Experimental Cutaneous Leishmaniasis by <i>Leishmania</i> Molecules Is Dependent on Interleukin-4, Serine Protease/Esterase Activity, and Parasite and Host Genetic Backgrounds. <i>Infection and Immunity</i> , 2011, 79, 1236-1243.	1.0	9
384	Comparison of gene expression patterns among <i>Leishmania braziliensis</i> clinical isolates showing a different <i>in vitro</i> susceptibility to pentavalent antimony. <i>Parasitology</i> , 2011, 138, 183-193.	0.7	37
385	Structural Basis of Molecular Recognition of the <i>Leishmania</i> Small Hydrophilic Endoplasmic Reticulum-associated Protein (SHERP) at Membrane Surfaces. <i>Journal of Biological Chemistry</i> , 2011, 286, 9246-9256.	1.6	7
386	Combination Therapy with Paromomycin-Associated Stearylamine-Bearing Liposomes Cures Experimental Visceral Leishmaniasis through Th1-Biased Immunomodulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1661-1670.	1.4	40

#	ARTICLE	IF	CITATIONS
387	Vaccines for Leishmaniasis: From proteome to vaccine candidates. <i>Hum Vaccin</i> , 2011, 7, 10-15.	2.4	35
388	Isotopomer Profiling of <i>Leishmania mexicana</i> Promastigotes Reveals Important Roles for Succinate Fermentation and Aspartate Uptake in Tricarboxylic Acid Cycle (TCA) Anaplerosis, Glutamate Synthesis, and Growth. <i>Journal of Biological Chemistry</i> , 2011, 286, 27706-27717.	1.6	84
389	Diagnostic Performance of Filter Paper Lesion Impression PCR for Secondarily Infected Ulcers and Nonulcerative Lesions Caused by Cutaneous Leishmaniasis. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1097-1100.	1.8	22
390	Therapy of vector-borne protozoan infections in nonendemic settings. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 583-608.	2.0	3
391	Chromosome and gene copy number variation allow major structural change between species and strains of <i>Leishmania</i> . <i>Genome Research</i> , 2011, 21, 2129-2142.	2.4	380
392	Gene Expression Profiling and Molecular Characterization of Antimony Resistance in <i>Leishmania amazonensis</i> . <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1167.	1.3	69
393	In Silico Analysis of Six Known <i>Leishmania</i> major Antigens and In Vitro Evaluation of Specific Epitopes Eliciting HLA-A2 Restricted CD8 T Cell Response. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1295.	1.3	56
394	Critical Roles for LIGHT and Its Receptors in Generating T Cell-Mediated Immunity during <i>Leishmania donovani</i> Infection. <i>PLoS Pathogens</i> , 2011, 7, e1002279.	2.1	26
395	Why cutaneous leishmaniasis could not be prevented completely? An open discussion. <i>Annals of Tropical Medicine and Public Health</i> , 2011, 4, 52.	0.1	1
396	Therapeutic Efficacy Evaluation of Metronidazole and Some Antifungal Agents with Meglumine Antimoniate on Visceral Leishmaniasis by Real-Time Light-Cycler (LC) PCR in BALB/c Mice. <i>Tropical Journal of Pharmaceutical Research</i> , 2011, 10, .	0.2	4
397	Antileishmanial and Antitrypanosomal Activity of Triterpene Derivatives from Latex of Two Euphorbia Species. <i>Zeitschrift Fur Naturforschung - Section C Journal of Biosciences</i> , 2011, 66, 360-366.	0.6	20
399	Prediction Score for Antimony Treatment Failure in Patients with Ulcerative Leishmaniasis Lesions. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1656.	1.3	22
400	Generation of <i>Leishmania</i> Hybrids by Whole Genomic DNA Transformation. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1817.	1.3	11
401	Evaluation of an Enzyme-Linked Immunosorbent Assay Based on Crude <i>Leishmania</i> Histone Proteins for Serodiagnosis of Human Infantile Visceral Leishmaniasis. <i>Vaccine Journal</i> , 2012, 19, 1487-1491.	3.2	19
402	In Vitro and In Vivo Efficacy of Ether Lipid Edelfosine against <i>Leishmania</i> spp. and SbV-Resistant Parasites. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1612.	1.3	46
403	Distinct Transcriptional Signatures of Bone Marrow-Derived C57BL/6 and DBA/2 Dendritic Leucocytes Hosting Live <i>Leishmania amazonensis</i> Amastigotes. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1980.	1.3	11
404	Copaiba Oil: An Alternative to Development of New Drugs against Leishmaniasis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-7.	0.5	31
405	Regulatory T Cells in the Pathogenesis and Healing of Chronic Human Dermal Leishmaniasis Caused by <i>Leishmania</i> (Viannia) Species. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1627.	1.3	36

#	ARTICLE	IF	CITATIONS
406	Toll-Like Receptors in <i>Leishmania</i> Infections: Guardians or Promoters?. <i>Journal of Parasitology Research</i> , 2012, 2012, 1-12.	0.5	105
407	An Image-Based High-Content Screening Assay for Compounds Targeting Intracellular <i>Leishmania donovani</i> Amastigotes in Human Macrophages. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1671.	1.3	117
408	Consecutive Cutaneous and Visceral Leishmaniasis Manifestations Involving a Novel <i>Leishmania</i> Species in Two HIV Patients in Thailand. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 87, 76-80.	0.6	37
409	The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases - Part I. <i>Current Medicinal Chemistry</i> , 2012, 19, 2128-2175.	1.2	207
410	Serum Proteomics for Visceral Leishmaniasis: Promise of Postgenomics Diagnostics for Public Health in Developing Countries. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2012, 10, 306-313.	0.2	0
411	Cutaneous Leishmaniasis in the Nalut District, Libyan Arab Jamahiriya: A Clinico-epidemiologic Study and <i>Leishmania</i> Species Identification. <i>Journal of Parasitology</i> , 2012, 98, 1251-1256.	0.3	13
412	Efficacy of Synthetic Peptides RP-1 and AA-RP-1 against <i>Leishmania</i> Species <i>In Vitro</i> and <i>In Vivo</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 658-665.	1.4	25
413	Conventional Therapy and Promising Plant-Derived Compounds Against Trypanosomatid Parasites. <i>Frontiers in Microbiology</i> , 2012, 3, 283.	1.5	38
414	Dolabelladienetriol, a Compound from <i>Dictyota pfaffii</i> Algae, Inhibits the Infection by <i>Leishmania amazonensis</i> . <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1787.	1.3	42
415	Biomarkers for Exposure to Sand Flies Bites as Tools to Aid Control of Leishmaniasis. <i>Frontiers in Immunology</i> , 2012, 3, 121.	2.2	24
416	Protective and pathologic immune responses in human tegumentary leishmaniasis. <i>Frontiers in Immunology</i> , 2012, 3, 301.	2.2	86
417	Reactive Oxygen Species and Nitric Oxide in Cutaneous Leishmaniasis. <i>Journal of Parasitology Research</i> , 2012, 2012, 1-11.	0.5	93
418	Developments in Diagnosis and Antileishmanial Drugs. <i>Interdisciplinary Perspectives on Infectious Diseases</i> , 2012, 2012, 1-13.	0.6	47
419	Adenosine and Immune Imbalance in Visceral Leishmaniasis: The Possible Role of Ectonucleotidases. <i>Journal of Tropical Medicine</i> , 2012, 2012, 1-6.	0.6	22
420	Host-Parasite Interaction: Parasite-Derived and -Induced Proteases That Degrade Human Extracellular Matrix. <i>Journal of Parasitology Research</i> , 2012, 2012, 1-24.	0.5	83
421	<i>In Vitro</i> Antiparasitic and Apoptotic Effects of Antimony Sulfide Nanoparticles on <i>Leishmania infantum</i> . <i>Journal of Parasitology Research</i> , 2012, 2012, 1-7.	0.5	23
422	Auricular cutaneous leishmaniasis mimicking neoplastic disease. <i>Journal of Laryngology and Otology</i> , 2012, 126, 821-824.	0.4	7
423	Genome sequencing of the lizard parasite <i>Leishmania tarentolae</i> reveals loss of genes associated to the intracellular stage of human pathogenic species. <i>Nucleic Acids Research</i> , 2012, 40, 1131-1147.	6.5	135

#	ARTICLE	IF	CITATIONS
424	Natural killer cells in experimental and human leishmaniasis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2012, 2, 69.	1.8	68
425	In vitro activity of green tea extract against <i>Leishmania major</i> promastigotes. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 233-236.	0.3	14
426	Insights into the multi-equilibrium, superstructure system based on β -cyclodextrin and a highly water soluble guest. <i>International Journal of Pharmaceutics</i> , 2012, 439, 207-215.	2.6	15
427	Leishmaniasis in the United States: Treatment in 2012. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 86, 434-440.	0.6	59
428	Neglected tropical diseases: diagnosis, clinical management, treatment and control. <i>Swiss Medical Weekly</i> , 2012, 142, w13727.	0.8	181
429	Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats: Figure 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, i60-i66.	0.5	71
430	Molecular epidemiology of cutaneous leishmaniasis and heterogeneity of <i>Leishmania major</i> strains in Iran. <i>Tropical Medicine and International Health</i> , 2012, 17, 1335-1344.	1.0	46
431	New parasite inhibitors encompassing novel conformationally-locked 5'-acyl sulfamoyl adenosines. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 6121.	1.5	6
432	Evaluation of the performance of selected in-house and commercially available PCR and real-time PCR assays for the detection of <i>Leishmania</i> DNA in canine clinical samples. <i>Experimental Parasitology</i> , 2012, 131, 419-424.	0.5	16
433	Involvement of the <i>Leishmania donovani</i> virulence factor A2 in protection against heat and oxidative stress. <i>Experimental Parasitology</i> , 2012, 132, 109-115.	0.5	29
434	Evaluation of antileishmanial activity of South Indian medicinal plants against <i>Leishmania donovani</i> . <i>Experimental Parasitology</i> , 2012, 132, 180-184.	0.5	10
435	Laboratory Diagnosis of Tropical Infections. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 513-554.	1.9	9
436	A 3D assessment tool for accurate volume measurement for monitoring the evolution of cutaneous Leishmaniasis wounds. , 2012, 2012, 2025-8.		18
437	Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2576-2597.	1.3	605
438	An application of Bayesian growth mixture modelling to estimate infection incidences from repeated serological tests. <i>Statistical Modelling</i> , 2012, 12, 551-578.	0.5	3
439	Assessment of Interferon- γ Levels and Leishmanin Skin Test Results in Persons Recovered for Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 87, 70-75.	0.6	17
440	Killed but Metabolically Active <i>Leishmania infantum</i> as a Novel Whole-Cell Vaccine for Visceral Leishmaniasis. <i>Vaccine Journal</i> , 2012, 19, 490-498.	3.2	31
441	Indole Alkaloids from <i>Geissospermum reticulatum</i> . <i>Journal of Natural Products</i> , 2012, 75, 928-934.	1.5	44

#	ARTICLE	IF	CITATIONS
442	Thiol-Based Posttranslational Modifications in Parasites. Antioxidants and Redox Signaling, 2012, 17, 657-673.	2.5	23
443	Fumarate hydratase isoforms of <i>Leishmania major</i> : Subcellular localization, structural and kinetic properties. International Journal of Biological Macromolecules, 2012, 51, 25-31.	3.6	25
444	The prevalence of metal-based drugs as therapeutic or diagnostic agents: beyond platinum. Dalton Transactions, 2012, 41, 13239.	1.6	100
445	Whole chromosome aneuploidy: Big mutations drive adaptation by phenotypic leap. BioEssays, 2012, 34, 893-900.	1.2	71
446	Mitigating an undesirable immune response of inherent susceptibility to cutaneous leishmaniasis in a mouse model: the role of the pathoantigenic HISA70 DNA vaccine. Veterinary Research, 2012, 43, 59.	1.1	12
447	Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.. Trials, 2012, 13, 58.	0.7	58
448	Parasitic Liver Disease in Travelers. Infectious Disease Clinics of North America, 2012, 26, 755-780.	1.9	6
449	Analysis of Membrane-Enriched and High Molecular Weight Proteins in <i>Leishmania infantum</i> Promastigotes and Axenic Amastigotes. Journal of Proteome Research, 2012, 11, 3974-3985.	1.8	22
450	Molecular Diagnosis and Species Identification of Mucosal Leishmaniasis in Iran and Correlation with Cytological Findings. Acta Cytologica, 2012, 56, 304-309.	0.7	22
451	Preparation and evaluation of niosomes containing autoclaved <i>Leishmania major</i> : a preliminary study. Journal of Microencapsulation, 2012, 29, 219-224.	1.2	46
452	Efficacy of miltefosine treatment in <i>Leishmania amazonensis</i> -infected BALB/c mice. International Journal of Antimicrobial Agents, 2012, 39, 326-331.	1.1	22
453	Imported cutaneous leishmaniasis in a short-term traveler returning from Central Mali – The role of PCR. Travel Medicine and Infectious Disease, 2012, 10, 97-100.	1.5	10
454	A case report and literature review of “Chiclero's ulcer”. Travel Medicine and Infectious Disease, 2012, 10, 275-278.	1.5	11
455	Comparative zymographic analysis of metallopeptidase of <i>Leishmania (Viannia) peruviana</i> and <i>Leishmania (Viannia) braziliensis</i> isolates from Peru. Parasitology International, 2012, 61, 513-519.	0.6	1
456	Visceral Leishmaniasis. Infectious Disease Clinics of North America, 2012, 26, 309-322.	1.9	217
457	A Reverse Vaccinology Approach for the Identification of Potential Vaccine Candidates from <i>Leishmania</i> spp. Applied Biochemistry and Biotechnology, 2012, 167, 1340-1350.	1.4	40
458	Identification of New Antileishmanial Leads from Hits Obtained by High-Throughput Screening. Antimicrobial Agents and Chemotherapy, 2012, 56, 1182-1189.	1.4	28
459	Peptidomimetic and Organometallic Derivatives of Primaquine Active against <i>Leishmania infantum</i> . Antimicrobial Agents and Chemotherapy, 2012, 56, 5774-5781.	1.4	30

#	ARTICLE	IF	CITATIONS
460	Drug Discovery in Africa. , 2012, , .		17
461	Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib. <i>Annals of Hematology</i> , 2012, 91, 1827-1828.	0.8	9
462	Mathematical Models in Population Biology and Epidemiology. <i>Texts in Applied Mathematics</i> , 2012, , .	0.4	593
464	<i>Leishmania mexicana</i> metacaspase is a negative regulator of amastigote proliferation in mammalian cells. <i>Cell Death and Disease</i> , 2012, 3, e385-e385.	2.7	42
465	Discovery of Inhibitors of <i>Leishmania</i> Î ² -1,2-Mannosyltransferases Using a Click-Chemistry-Derived Guanosine Monophosphate Library. <i>PLoS ONE</i> , 2012, 7, e32642.	1.1	8
466	Genetic Evidence of Functional Ficolin-2 Haplotype as Susceptibility Factor in Cutaneous Leishmaniasis. <i>PLoS ONE</i> , 2012, 7, e34113.	1.1	35
467	Non-Invasive Cytology Brush PCR for the Diagnosis and Causative Species Identification of American Cutaneous Leishmaniasis in Peru. <i>PLoS ONE</i> , 2012, 7, e49738.	1.1	17
468	Computational Prediction of Protein-Protein Interactions in <i>Leishmania</i> Predicted Proteomes. <i>PLoS ONE</i> , 2012, 7, e51304.	1.1	32
469	Essential oil from leaves of <i>Lantana camara</i> : a potential source of medicine against leishmaniasis. <i>Revista Brasileira De Farmacognosia</i> , 2012, 22, 1011-1017.	0.6	21
470	A morphologically distinct <i>Phlebotomus argentipes</i> population from active cutaneous leishmaniasis foci in central Sri Lanka. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2012, 107, 402-409.	0.8	7
471	Kinetoplastid membrane protein-11 exacerbates infection with <i>Leishmania amazonensis</i> in murine macrophages. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2012, 107, 238-245.	0.8	18
472	Application of the mammalian glyceraldehyde-3-phosphate dehydrogenase gene for sample quality control in multiplex PCR for diagnosis of leishmaniasis. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2012, 18, 188-197.	0.8	15
473	Review of the current treatments for leishmaniasis. <i>Research and Reports in Tropical Medicine</i> , 2012, 3, 69.	2.8	34
474	Trypanosomatid comparative genomics: contributions to the study of parasite biology and different parasitic diseases. <i>Genetics and Molecular Biology</i> , 2012, 35, 1-17.	0.6	40
475	Footprinting of Inhibitor Interactions of<i>In Silico</i>Identified Inhibitors of Trypanothione Reductase of<i>Leishmania</i>Parasite. <i>Scientific World Journal, The</i> , 2012, 2012, 1-13.	0.8	14
476	The effect of ethanolic extract of propolis and glucose oxidase on secondary infections of cutaneous leishmaniasis. <i>African Journal of Microbiology Research</i> , 2012, 6, 6884-6887.	0.4	2
477	Canine visceral leishmaniasis: seroprevalence and risk factors in CuiabÃ¡, Mato Grosso, Brazil. <i>Brazilian Journal of Veterinary Parasitology</i> , 2012, 21, 359-365.	0.2	27
478	The cytotoxic and antileishmanial activity of extracts and fractions of leaves and fruits of <i>Azadirachta indica</i> (A Juss.). <i>Biological Research</i> , 2012, 45, 111-116.	1.5	47

#	ARTICLE	IF	CITATIONS
479	Molecular Docking and in Vitro Antileishmanial Evaluation of Chromene-2-thione Analogues. ACS Medicinal Chemistry Letters, 2012, 3, 243-247.	1.3	50
480	Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems. Expert Review of Vaccines, 2012, 11, 69-86.	2.0	22
483	Antileishmanial, antitrypanosomal, and cytotoxic screening of ethnopharmacologically selected Peruvian plants. Parasitology Research, 2012, 110, 1381-1392.	0.6	66
484	In vitro antileishmanial and antitrypanosomal activities of five medicinal plants from Burkina Faso. Parasitology Research, 2012, 110, 1779-1783.	0.6	24
485	A case of mucosal leishmaniasis of the tongue in a kidney transplant recipient. International Journal of Dermatology, 2012, 51, 597-600.	0.5	12
486	Radio-attenuated leishmanial parasites as immunoprophylactic agent against experimental murine visceral leishmaniasis. Experimental Parasitology, 2012, 130, 39-47.	0.5	9
487	Monoterpenic aldehydes as potential anti-Leishmania agents: Activity of Cymbopogon citratus and citral on <i>L. infantum</i> , <i>L. tropica</i> and <i>L. major</i> . Experimental Parasitology, 2012, 130, 223-231.	0.5	94
488	Loading hydrophilic drug in solid lipid media as nanoparticles: Statistical modeling of entrapment efficiency and particle size. International Journal of Pharmaceutics, 2012, 424, 128-137.	2.6	108
489	Synthesis and antikinoplastid activities of 3-substituted quinolinones derivatives. European Journal of Medicinal Chemistry, 2012, 52, 44-50.	2.6	29
490	Successful Treatment of Imported Mucosal Leishmania infantum Leishmaniasis With Miltefosine After Severe Hypokalemia Under Meglumine Antimoniate Treatment. Journal of Travel Medicine, 2012, 19, 124-126.	1.4	19
492	Role of trypanosomatid's arginase in polyamine biosynthesis and pathogenesis. Molecular and Biochemical Parasitology, 2012, 181, 85-93.	0.5	49
493	Trafficking and release of Leishmania metacyclic HASPB on macrophage invasion. Cellular Microbiology, 2012, 14, 740-761.	1.1	30
494	Ecotinâ€like serine peptidase inhibitor ISP1 of <i>Leishmania major</i> plays a role in flagellar pocket dynamics and promastigote differentiation. Cellular Microbiology, 2012, 14, 1271-1286.	1.1	21
495	Possible cases of leprosy and tuberculosis in medieval Sigtuna, Sweden. International Journal of Osteoarchaeology, 2012, 22, 261-283.	0.6	21
496	Leishmania (Viannia) shawi purified antigens confer protection against murine cutaneous leishmaniasis. Inflammation Research, 2012, 61, 255-263.	1.6	3
497	Knockdown of LdMC1 and Hsp70 by antisense oligonucleotides causes cell-cycle defects and programmed cell death in Leishmania donovani. Molecular and Cellular Biochemistry, 2012, 359, 135-149.	1.4	20
498	Paromomycinâ€loaded albumin microspheres: Efficacy and stability studies. Drug Testing and Analysis, 2013, 5, 468-473.	1.6	7
499	Multilocus microsatellite signature and identification of specific molecular markers for Leishmania aethiopia. Parasites and Vectors, 2013, 6, 160.	1.0	10

#	ARTICLE	IF	CITATIONS
500	Recurrent visceral leishmaniasis in an immunocompetent patient: a case report. <i>Journal of Medical Case Reports</i> , 2013, 7, 68.	0.4	6
501	The immunology of Leishmania/HIV co-infection. <i>Immunologic Research</i> , 2013, 56, 163-171.	1.3	73
502	Strategies for the design of orally bioavailable antileishmanial treatments. <i>International Journal of Pharmaceutics</i> , 2013, 454, 539-552.	2.6	50
503	Drug Resistance in Leishmania Parasites. , 2013, , .		13
504	Investigation of antileishmanial activities of TiO ₂ @Ag nanoparticles on biological properties of <i>L. tropica</i> and <i>L. infantum</i> parasites, in vitro. <i>Experimental Parasitology</i> , 2013, 135, 55-63.	0.5	69
505	Alpha tubulin genes from <i>Leishmania braziliensis</i> : genomic organization, gene structure and insights on their expression. <i>BMC Genomics</i> , 2013, 14, 454.	1.2	19
506	Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives. <i>European Journal of Medicinal Chemistry</i> , 2013, 67, 310-324.	2.6	21
507	Studies on the protective and immunomodulatory efficacy of <i>Withania somnifera</i> along with cisplatin against experimental visceral leishmaniasis. <i>Parasitology Research</i> , 2013, 112, 2269-2280.	0.6	24
508	Antimalarial and Other Antiprotozoal Products from African Medicinal Plants. , 2013, , 661-709.		12
509	Molecular mechanism underlying antileishmanial effect of oxabicyclo[3.3.1]nonanones: Inhibition of key redox enzymes of the pathogen. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 569-577.	2.0	48
510	Novel approaches for the identification of inhibitors of leishmanial dipeptidylcarboxypeptidase. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1127-1134.	2.5	2
511	Identification of antimony resistance markers in <i>Leishmania tropica</i> field isolates through a cDNA-AFLP approach. <i>Experimental Parasitology</i> , 2013, 135, 344-349.	0.5	67
512	Leishmanization revisited: Immunization with a naturally attenuated cutaneous <i>Leishmania donovani</i> isolate from Sri Lanka protects against visceral leishmaniasis. <i>Vaccine</i> , 2013, 31, 1420-1425.	1.7	38
513	A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2013 Recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). <i>Clinical Infectious Diseases</i> , 2013, 57, e22-e121.	2.9	426
514	The impact of single versus mixed <i>Schistosoma haematobium</i> and <i>S. mansoni</i> infections on morbidity profiles amongst school-children in Taveta, Kenya. <i>Acta Tropica</i> , 2013, 128, 309-317.	0.9	27
515	Intralesional Antimony for Single Lesions of Bolivian Cutaneous Leishmaniasis: Table 1.. <i>Clinical Infectious Diseases</i> , 2013, 56, 1255-1260.	2.9	60
517	Human visceral leishmaniasis: A picture from Italy. <i>Journal of Infection and Public Health</i> , 2013, 6, 465-472.	1.9	9
518	Anti-Leishmanial Activity of Novel Homo- and Heteroleptic Bismuth(III) Thiocarboxylates. <i>Australian Journal of Chemistry</i> , 2013, 66, 1297.	0.5	17

#	ARTICLE	IF	CITATIONS
519	Molecular characterization of the MRPA transporter and antimony uptake in four New World <i>Leishmania</i> spp. susceptible and resistant to antimony. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2013, 3, 143-153.	1.4	40
520	<i>Parasitic Zoonoses.</i> , 2013, , .		6
521	Genotoxicity and antileishmanial activity evaluation of <i>Physalis angulata</i> concentrated ethanolic extract. <i>Environmental Toxicology and Pharmacology</i> , 2013, 36, 1304-1311.	2.0	26
522	<i>Protozoonoses.</i> , 2013, , 15-40.		0
523	Human Exposure to Antimony. IV. Contents in Human Blood. <i>Critical Reviews in Environmental Science and Technology</i> , 2013, 43, 2071-2105.	6.6	26
524	<i>In vitro</i> Leishmanicidal and Cytotoxic Activities of the Glycoalkaloids from <i>Solanum lycocarpum</i> (<i>Solanaceae</i>) Fruits. <i>Chemistry and Biodiversity</i> , 2013, 10, 642-648.	1.0	30
525	Identification of proteins interacting with HSP70 mRNAs in <i>Leishmania braziliensis</i> . <i>Journal of Proteomics</i> , 2013, 94, 124-137.	1.2	21
528	Antiparasitic effects of gold nanoparticles with microwave radiation on promastigotes and amastigotes of <i>Leishmania major</i> . <i>International Journal of Hyperthermia</i> , 2013, 29, 79-86.	1.1	46
529	Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives. <i>Future Medicinal Chemistry</i> , 2013, 5, 1877-1888.	1.1	73
530	115kDa serine protease confers sustained protection to visceral leishmaniasis caused by <i>Leishmania donovani</i> via IFN- γ induced down-regulation of TNF- α mediated MMP-9 activity. <i>Immunobiology</i> , 2013, 218, 114-126.	0.8	30
531	Live Attenuated <i>Leishmania donovani</i> p27 Gene Knockout Parasites Are Nonpathogenic and Elicit Long-Term Protective Immunity in BALB/c Mice. <i>Journal of Immunology</i> , 2013, 190, 2138-2149.	0.4	94
532	Efficacy of biogenic selenium nanoparticles against <i>Leishmania major</i> : In vitro and in vivo studies. <i>Journal of Trace Elements in Medicine and Biology</i> , 2013, 27, 203-207.	1.5	125
533	TTAS a new stilbene derivative that induces apoptosis in <i>Leishmania infantum</i> . <i>Experimental Parasitology</i> , 2013, 133, 37-43.	0.5	15
534	In vitro growth inhibitory effects of 13,28-epoxyoleanane triterpene saponins in cancer cells. <i>Phytochemistry Letters</i> , 2013, 6, 128-134.	0.6	9
535	<i>Classical Versus Novel Treatment Regimens.</i> , 2013, , 301-319.		2
536	Palladium(II) imine ligands cyclometallated complexes with a potential leishmanicidal activity on <i>Leishmania (L.) amazonensis</i> . <i>Medicinal Chemistry Research</i> , 2013, 22, 1049-1056.	1.1	11
537	Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of <i>Leishmania donovani</i> . <i>Parasitology Research</i> , 2013, 112, 825-828.	0.6	50
538	<i>Molecular Diagnostics and Parasitic Disease.</i> <i>Clinics in Laboratory Medicine</i> , 2013, 33, 461-503.	0.7	40

#	ARTICLE	IF	CITATIONS
539	Neolignan Licarin A presents effect against <i>Leishmania</i> (<i>Leishmania</i>) major associated with immunomodulation in vitro. <i>Experimental Parasitology</i> , 2013, 135, 307-313.	0.5	36
540	Genetic diversity of <i>Leishmania</i> major strains isolated from different clinical forms of cutaneous leishmaniasis in southern Iran based on minicircle kDNA. <i>Infection, Genetics and Evolution</i> , 2013, 19, 226-231.	1.0	56
542	Development of a label-free immunosensor based on surface plasmon resonance technique for the detection of anti- <i>Leishmania infantum</i> antibodies in canine serum. <i>Biosensors and Bioelectronics</i> , 2013, 46, 22-29.	5.3	58
543	Dissemination of localized cutaneous leishmaniasis in an organ transplant recipient: case report and literature review. <i>International Journal of Dermatology</i> , 2013, 52, 59-62.	0.5	15
544	Two cases of successful treatment of multilesional cutaneous leishmaniasis with liposomal amphotericin B. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 83-85.	0.4	4
545	Erfolgreiche Behandlung von zwei Patienten mit multiläsionaler kutaner Leishmaniasis mit liposomalem Amphotericin. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 83-85.	0.4	2
546	Quinolinic Alkaloids from <i>Glycyrrhiza glabra</i> suppress production of proinflammatory cytokines in vitro and control inflammation in vivo upon <i>Leishmania</i> infection in mice. <i>Scandinavian Journal of Immunology</i> , 2013, 77, 30-38.	1.3	18
547	<i>Leishmania donovani</i> targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection. <i>Cell Host and Microbe</i> , 2013, 13, 277-288.	5.1	190
548	Childhood parasitic infections endemic to the United States. <i>Pediatric Clinics of North America</i> , 2013, 60, 471-485.	0.9	65
550	Epidemiology of leishmaniasis in the time of drug resistance. , 2013, , 65-83.		4
551	Vaccination as a control measure. , 2013, , 113-141.		0
552	Genetic expression and drug resistance, the role of proteomics. , 2013, , 215-236.		1
553	Activity of antimalarial drugs in vitro and in a murine model of cutaneous leishmaniasis. <i>Journal of Medical Microbiology</i> , 2013, 62, 1001-1010.	0.7	18
554	Benzimidazole derivatives: synthesis, leishmanicidal effectiveness, and molecular docking studies. <i>Medicinal Chemistry Research</i> , 2013, 22, 3606-3620.	1.1	30
555	A natural product inspired hybrid approach towards the synthesis of novel pentamidine based scaffolds as potential anti-parasitic agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 291-296.	1.0	15
556	Detection of <i>Leishmania infantum</i> in animals and their ectoparasites by conventional PCR and real time PCR. <i>Experimental and Applied Acarology</i> , 2013, 59, 473-481.	0.7	19
557	Chronic arsenic exposure and microbial drug resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 19666-19667.	3.3	7
558	Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice. <i>Experimental Parasitology</i> , 2013, 135, 217-222.	0.5	63

#	ARTICLE	IF	CITATIONS
559	The Genome Sequence of <i>Leishmania (Leishmania) amazonensis</i> : Functional Annotation and Extended Analysis of Gene Models. <i>DNA Research</i> , 2013, 20, 567-581.	1.5	109
560	Cutaneous Leishmaniasis of the Eyelid: A Case Report. <i>Case Reports in Infectious Diseases</i> , 2013, 2013, 1-2.	0.2	9
561	<i>Trans-2-Caryophyllene</i> : An Effective Antileishmanial Compound Found in Commercial Copaiba Oil (<i>Copaifera</i> spp.). <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-13.	0.5	50
562	T Cell-Derived IL-10 Determines Leishmaniasis Disease Outcome and Is Suppressed by a Dendritic Cell Based Vaccine. <i>PLoS Pathogens</i> , 2013, 9, e1003476.	2.1	65
563	Determinants for the Development of Visceral Leishmaniasis Disease. <i>PLoS Pathogens</i> , 2013, 9, e1003053.	2.1	175
564	Gene Amplification and Point Mutations in Pyrimidine Metabolic Genes in 5-Fluorouracil Resistant <i>Leishmania infantum</i> . <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2564.	1.3	24
565	<i>In Vitro</i> Antileishmanial Activity of Essential Oil of <i>Vanillosmopsis arborea</i> (Asteraceae) Baker. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-7.	0.5	37
566	MicroRNA Expression Profile in Human Macrophages in Response to <i>Leishmania major</i> Infection. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2478.	1.3	125
567	One More Death from Visceral Leishmaniasis Has Gone by Unnoticed. What Can Be Done?. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2082.	1.3	4
568	<i>Leishmania major</i> Methionine Sulfoxide Reductase A Is Required for Resistance to Oxidative Stress and Efficient Replication in Macrophages. <i>PLoS ONE</i> , 2013, 8, e56064.	1.1	18
569	Deletion of IL-4 Receptor Alpha on Dendritic Cells Renders BALB/c Mice Hypersusceptible to <i>Leishmania major</i> Infection. <i>PLoS Pathogens</i> , 2013, 9, e1003699.	2.1	53
570	Oxidative Stress and Replication-Independent DNA Breakage Induced by Arsenic in <i>Saccharomyces cerevisiae</i> . <i>PLoS Genetics</i> , 2013, 9, e1003640.	1.5	34
571	Nasal, Oral and Ear Swabs for Canine Visceral Leishmaniasis Diagnosis: New Practical Approaches for Detection of <i>Leishmania infantum</i> DNA. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2150.	1.3	33
572	High Content Analysis of Primary Macrophages Hosting Proliferating <i>Leishmania</i> Amastigotes: Application to Anti-leishmanial Drug Discovery. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2154.	1.3	62
573	UCP2 Deficiency Helps to Restrict the Pathogenesis of Experimental Cutaneous and Visceral Leishmaniasis in Mice. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2077.	1.3	15
574	Detection of <i>Leishmania siamensis</i> DNA in Saliva by Polymerase Chain Reaction. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 89, 899-905.	0.6	20
575	Cross-Sectional Study to Assess Risk Factors for Leishmaniasis in an Endemic Region in Sri Lanka. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 89, 742-749.	0.6	21
576	Quantification of <i>Leishmania infantum</i> Kinetoplast DNA for Monitoring the Response to Meglumine Antimoniate Therapy in Visceral Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 868-871.	0.6	21

#	ARTICLE	IF	CITATIONS
577	Heme Uptake Mediated by LHR1 Is Essential for <i>Leishmania amazonensis</i> Virulence. <i>Infection and Immunity</i> , 2013, 81, 3620-3626.	1.0	49
578	First molecular-based detection of mucocutaneous leishmaniasis caused by <i>Leishmania major</i> in Iran. <i>Journal of Infection in Developing Countries</i> , 2013, 7, 413-416.	0.5	9
579	Intermediate/borderline disseminated cutaneous leishmaniasis. <i>International Journal of Dermatology</i> , 2013, 52, 446-455.	0.5	17
580	Randomized, Double-Blinded, Phase 2 Trial of WR 279,396 (Paromomycin and Gentamicin) for Cutaneous Leishmaniasis in Panama. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 89, 557-563.	0.6	51
581	<i>N</i> -Cinnamoylated Aminoquinolines as Promising Antileishmanial Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5112-5115.	1.4	12
582	The Economic Burden of Visceral Leishmaniasis in Sudan: An Assessment of Provider and Household Costs. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 89, 1146-1153.	0.6	33
583	Overexpression of Ubiquitin and Amino Acid Permease Genes in Association with Antimony Resistance in <i>Leishmania tropica</i> Field Isolates. <i>Korean Journal of Parasitology</i> , 2013, 51, 413-419.	0.5	27
584	Antileishmanial activity of diterpene acids in copaiba oil. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2013, 108, 59-64.	0.8	53
585	Prevalence of Asymptomatic Visceral Leishmaniasis among under 5 Years Contacts of Confirmed Cases in Thiagar Governorate, 2012. <i>Journal of Infectious Disease and Therapy</i> , 2013, 01, .	0.1	1
586	Efficacy of voriconazole in experimental rat paracoccidiodomycosis. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2013, 46, 79-83.	0.4	32
587	Divergent Profile of Emerging Cutaneous Leishmaniasis in Subtropical Brazil: New Endemic Areas in the Southern Frontier. <i>PLoS ONE</i> , 2013, 8, e56177.	1.1	19
588	Targeting <i>Leishmania major</i> Antigens to Dendritic Cells In Vivo Induces Protective Immunity. <i>PLoS ONE</i> , 2013, 8, e67453.	1.1	36
589	In Vitro Activity of the Antifungal Azoles Itraconazole and Posaconazole against <i>Leishmania amazonensis</i> . <i>PLoS ONE</i> , 2013, 8, e83247.	1.1	81
590	Trypanosomatidae Diseases: From the Current Therapy to the Efficacious Role of Trypanothione Reductase in Drug Discovery. <i>Current Medicinal Chemistry</i> , 2013, 20, 2673-2696.	1.2	59
591	Pulmonary parasitic infections. , 0, , 288-341.		1
592	Non-Invasive Molecular Diagnosis of Canine Visceral Leishmaniasis Using Conjunctival Swab Samples. , 0, , .		3
593	Diagnosis of Leishmaniasis in Children. , 2014, , .		0
594	Localised Leishmaniasis of Oral Mucosa: Report of an Unusual Clinicopathological Entity. <i>Case Reports in Dentistry</i> , 2014, 2014, 1-5.	0.2	10

#	ARTICLE	IF	CITATIONS
595	Global distribution maps of the leishmaniasis. <i>ELife</i> , 2014, 3, .	2.8	203
596	Cationic Peptides Harboring Antibiotic Capacity is Selective for <i>Leishmania Panamensis</i> and <i>Leishmania Major</i> . <i>Journal of Microbial & Biochemical Technology</i> , 2014, 06, .	0.2	3
597	Poor response to azithromycin in cutaneous leishmaniasis leading to a premature interruption of a multicentric phase III clinical trial in Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2014, 47, 756-762.	0.4	7
598	ANIMAL MODELS FOR THE STUDY OF LEISHMANIASIS IMMUNOLOGY. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2014, 56, 1-11.	0.5	113
599	Visceral Leishmaniasis in Renal Transplant Recipients: Study of 30 Cases. <i>Journal of Nephrology & Therapeutics</i> , 2014, 04, .	0.1	0
600	Parasite load and risk factors for poor outcome among children with visceral leishmaniasis. A cohort study in Belo Horizonte, Brazil, 2010-2011. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2014, 109, 147-153.	0.8	11
601	<i>Leishmania</i> sp., 2014, , 769-769.		0
602	Data collection to characterise the impact of canine leishmaniosis and modelling of the role of animals in spreading <i>Leishmania infantum</i> within the European Union. <i>EFSA Supporting Publications</i> , 2014, 11, 466E.	0.3	1
603	Chemistry and Leishmanicidal Activity of the Essential Oil from <i>Artemisia absinthium</i> from Cuba. <i>Natural Product Communications</i> , 2014, 9, 1934578X1400901.	0.2	15
604	Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2014, 4, 326-337.	1.4	39
605	Aberrant host defense against <i>Leishmania major</i> in the absence of SLPI. <i>Journal of Leukocyte Biology</i> , 2014, 96, 917-929.	1.5	11
606	Immunity to visceral leishmaniasis: implications for immunotherapy. <i>Future Microbiology</i> , 2014, 9, 901-915.	1.0	41
607	Parasitic diseases in travelers: a focus on therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 497-521.	2.0	5
608	Editorial Commentary: Visceral Leishmaniasis and HIV Coinfection in Bihar, India: A Wake-up Call?. <i>Clinical Infectious Diseases</i> , 2014, 59, 556-558.	2.9	7
609	Deficiency of p110 β Isoform of the Phosphoinositide 3 Kinase Leads to Enhanced Resistance to <i>Leishmania donovani</i> . <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2951.	1.3	9
610	A patient with rheumatoid arthritis, cryoglobulinaemia, and an "accidental" finding. <i>BMJ, The</i> , 2014, 348, g2701-g2701.	3.0	2
611	Golgi-Located NTPDase1 of <i>Leishmania major</i> Is Required for Lipophosphoglycan Elongation and Normal Lesion Development whereas Secreted NTPDase2 Is Dispensable for Virulence. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3402.	1.3	16
612	The Diagnosis and Classification of Parasitic Diseases of the Liver. , 2014, , 145-158.		1

#	ARTICLE	IF	CITATIONS
613	Blocking Junctional Adhesion Molecule C Enhances Dendritic Cell Migration and Boosts the Immune Responses against <i>Leishmania major</i> . <i>PLoS Pathogens</i> , 2014, 10, e1004550.	2.1	13
614	Facial Structure Alterations and Abnormalities of the Paranasal Sinuses on Multidetector Computed Tomography Scans of Patients with Treated Mucosal Leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3001.	1.3	12
615	First Isolation of <i>Leishmania</i> from Northern Thailand: Case Report, Identification as <i>Leishmania martiniquensis</i> and Phylogenetic Position within the <i>Leishmania enriettii</i> Complex. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3339.	1.3	77
616	Abortive T Follicular Helper Development Is Associated with a Defective Humoral Response in <i>Leishmania infantum</i> -Infected Macaques. <i>PLoS Pathogens</i> , 2014, 10, e1004096.	2.1	40
617	Formation of Linear Amplicons with Inverted Duplications in <i>Leishmania</i> Requires the MRE11 Nuclease. <i>PLoS Genetics</i> , 2014, 10, e1004805.	1.5	23
618	In Vitro and In Vivo Miltefosine Susceptibility of a <i>Leishmania amazonensis</i> Isolate from a Patient with Diffuse Cutaneous Leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2999.	1.3	40
619	Induction of a Stringent Metabolic Response in Intracellular Stages of <i>Leishmania mexicana</i> Leads to Increased Dependence on Mitochondrial Metabolism. <i>PLoS Pathogens</i> , 2014, 10, e1003888.	2.1	142
620	Genetic Analysis of <i>Leishmania donovani</i> Tropism Using a Naturally Attenuated Cutaneous Strain. <i>PLoS Pathogens</i> , 2014, 10, e1004244.	2.1	97
621	Quantifying the Contribution of Hosts with Different Parasite Concentrations to the Transmission of Visceral Leishmaniasis in Ethiopia. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3288.	1.3	32
622	Leishmaniasis in the Middle East: Incidence and Epidemiology. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3208.	1.3	137
623	Sterol Biosynthesis Is Required for Heat Resistance but Not Extracellular Survival in <i>Leishmania</i> . <i>PLoS Pathogens</i> , 2014, 10, e1004427.	2.1	57
624	Prognostic Factors and Scoring System for Death from Visceral Leishmaniasis: An Historical Cohort Study in Brazil. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3374.	1.3	50
625	Impact of ASHA Training on Active Case Detection of Visceral Leishmaniasis in Bihar, India. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2774.	1.3	16
626	Engagement of NKG2D on Bystander Memory CD8 T Cells Promotes Increased Immunopathology following <i>Leishmania major</i> Infection. <i>PLoS Pathogens</i> , 2014, 10, e1003970.	2.1	79
627	<i>Leishmania donovani</i> Infection Causes Distinct Epigenetic DNA Methylation Changes in Host Macrophages. <i>PLoS Pathogens</i> , 2014, 10, e1004419.	2.1	123
628	Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease. <i>Frontiers in Immunology</i> , 2014, 5, 272.	2.2	73
629	Deception and Manipulation: The Arms of <i>Leishmania</i> , a Successful Parasite. <i>Frontiers in Immunology</i> , 2014, 5, 480.	2.2	80
630	Simultaneous Occurrence of Ocular, Disseminated Mucocutaneous, and Multivisceral Involvement of Leishmaniasis. <i>Case Reports in Infectious Diseases</i> , 2014, 2014, 1-4.	0.2	8

#	ARTICLE	IF	CITATIONS
631	Nuclear Envelope Lamin-A Couples Actin Dynamics with Immunological Synapse Architecture and T Cell Activation. <i>Science Signaling</i> , 2014, 7, ra37.	1.6	81
632	Ongoing Epidemic of Cutaneous Leishmaniasis among Syrian Refugees, Lebanon1. <i>Emerging Infectious Diseases</i> , 2014, 20, 1712-5.	2.0	79
633	Proteomics Advances in the Study of Leishmania Parasites and Leishmaniasis. <i>Sub-Cellular Biochemistry</i> , 2014, 74, 323-349.	1.0	18
634	Analysis of genetic variants in the IL4 promoter and VNTR loci in Indian patients with Visceral Leishmaniasis. <i>Human Immunology</i> , 2014, 75, 1177-1181.	1.2	8
635	Gluconeogenesis in <i>Leishmania mexicana</i> . <i>Journal of Biological Chemistry</i> , 2014, 289, 32989-33000.	1.6	33
636	Orientation of colonized sand flies <i>Phlebotomus papatasi</i> , <i>P. duboscqi</i> , and <i>Lutzomyia longipalpis</i> (Diptera: Psychodidae) to diverse honeys using a 3-chamber in-line olfactometer. <i>Journal of Vector Ecology</i> , 2014, 39, 94-102.	0.5	3
637	An imported case of cutaneous leishmaniasis caused by <i>Leishmania</i> (<i>Leishmania</i>) <i>donovani</i> in Japan. <i>Journal of Dermatology</i> , 2014, 41, 926-928.	0.6	5
638	Discovery of Synthetic <i>Leishmania</i> Inhibitors by Screening of a 2-Arylbenzothiophene Library. <i>Chemical Biology and Drug Design</i> , 2014, 83, 289-296.	1.5	6
639	Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patients. <i>BMC Infectious Diseases</i> , 2014, 14, 662.	1.3	4
640	Concomitant Infection with <i>Leishmania donovani</i> and <i>L. major</i> in Single Ulcers of Cutaneous Leishmaniasis Patients from Sudan. <i>Journal of Tropical Medicine</i> , 2014, 2014, 1-8.	0.6	26
641	Visceral Leishmaniasis in a UK Toddler following a Short Trip to a Popular Holiday Destination in Spain. <i>Case Reports in Infectious Diseases</i> , 2014, 2014, 1-3.	0.2	3
642	Comparative Analysis of the Omics Technologies Used to Study Antimonial, Amphotericin B, and Pentamidine Resistance in <i>Leishmania</i> . <i>Journal of Parasitology Research</i> , 2014, 2014, 1-11.	0.5	33
643	PCR and Microscopic Identification of Isolated <i>Leishmania tropica</i> from Clinical Samples of Cutaneous Leishmaniasis in Human Population of Kohat Region in Khyber Pakhtunkhwa. <i>BioMed Research International</i> , 2014, 2014, 1-5.	0.9	15
644	Is leishmaniasis an "unusual suspect" of infection in allogeneic transplantation?. <i>Transplant Infectious Disease</i> , 2014, 16, 1012-1018.	0.7	16
645	Diagnosis and Management of Oral Leishmaniasis—Case Series and Literature Review. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014, 72, 927-934.	0.5	16
646	Leishmaniasis acquired by travellers to endemic regions in Europe: A EuroTravNet multi-centre study. <i>Travel Medicine and Infectious Disease</i> , 2014, 12, 167-172.	1.5	40
647	Antileishmanial activity of essential oil from <i>Chenopodium ambrosioides</i> and its main components against experimental cutaneous leishmaniasis in BALB/c mice. <i>Phytomedicine</i> , 2014, 21, 1048-1052.	2.3	47
648	Moving from unsequenced to sequenced genome: Reanalysis of the proteome of <i>Leishmania donovani</i> . <i>Journal of Proteomics</i> , 2014, 97, 48-61.	1.2	40

#	ARTICLE	IF	CITATIONS
649	Antiprotozoal Drugs. , 2014, , 97-104.		7
650	Antileishmanial Activity of the Essential Oil from <i>Bixa orellana</i> . <i>Phytotherapy Research</i> , 2014, 28, 753-758.	2.8	41
651	Anti-leishmanial activities of selenium nanoparticles and selenium dioxide on <i>Leishmania infantum</i> . <i>Comparative Clinical Pathology</i> , 2014, 23, 15-20.	0.3	43
652	Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements. <i>Infectious Diseases of Poverty</i> , 2014, 3, 1.	1.5	88
653	Anti- <i>Trypanosoma cruzi</i> and anti-leishmanial activity by quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives. <i>Parasitology Research</i> , 2014, 113, 2027-2035.	0.6	37
654	Synthesis and leishmanicidal activity of cinnamic acid esters: structure-activity relationship. <i>Medicinal Chemistry Research</i> , 2014, 23, 1378-1386.	1.1	29
655	Gene expression profile of cytokines and chemokines in skin lesions from Brazilian Indians with localized cutaneous leishmaniasis. <i>Molecular Immunology</i> , 2014, 57, 74-85.	1.0	27
656	Structure and dynamics studies of sterol 24-C-methyltransferase with mechanism based inactivators for the disruption of ergosterol biosynthesis. <i>Molecular Biology Reports</i> , 2014, 41, 4279-4293.	1.0	21
657	Design, synthesis, ADME characterization and antileishmanial evaluation of novel substituted quinoline analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2046-2052.	1.0	26
658	Synthesis and biological evaluation of chalcones as potential antileishmanial agents. <i>European Journal of Medicinal Chemistry</i> , 2014, 81, 359-366.	2.6	35
659	Immunoregulation in human American leishmaniasis: balancing pathology and protection. <i>Parasite Immunology</i> , 2014, 36, 367-376.	0.7	64
660	Potential therapeutic use of herbal extracts in trypanosomiasis. <i>Pathogens and Global Health</i> , 2014, 108, 30-36.	1.0	20
661	Anti-leishmanial activity of the antimicrobial peptide DRS 01 observed in <i>Leishmania infantum</i> (syn.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.7	18
662	A combined luciferase-expressing <i>Leishmania</i> imaging/RT-qPCR assay provides new insights into the sequential bilateral processes deployed in the ear pinna of C57BL/6 mice. <i>Parasitology International</i> , 2014, 63, 245-253.	0.6	5
664	Leishmaniasis in travelers: A literature review. <i>Travel Medicine and Infectious Disease</i> , 2014, 12, 563-581.	1.5	103
665	Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. <i>Chemical Reviews</i> , 2014, 114, 11305-11347.	23.0	274
666	Leishmaniasis in immunosuppressed individuals. <i>Clinical Microbiology and Infection</i> , 2014, 20, 286-299.	2.8	266
667	Pharmacological Assessment Defines <i>Leishmania donovani</i> Casein Kinase 1 as a Drug Target and Reveals Important Functions in Parasite Viability and Intracellular Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1501-1515.	1.4	44

#	ARTICLE	IF	CITATIONS
668	The Impact of Human Immunodeficiency Virus (HIV) Co-Infection on the Economic Burden of Cutaneous Leishmaniasis (CL) in Brazil and Potential Value of New CL Drug Treatments. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 520-527.	0.6	3
669	Development of targeted 1,2-diacyl-sn-glycero-3-phospho- <i>l</i> -serine-coated gelatin nanoparticles loaded with amphotericin B for improved <i>in vitro</i> and <i>in vivo</i> effect in leishmaniasis. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 633-646.	2.4	47
670	Comparison of Conventional, Molecular, and Immunohistochemical Methods in Diagnosis of Typical and Atypical Cutaneous Leishmaniasis. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 235-240.	1.2	63
671	Comparison of Point-of-Care Tests for the Rapid Diagnosis of Visceral Leishmaniasis in East African Patients. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 1109-1115.	0.6	37
672	Evaluation of IL-22 polymorphism in patients with visceral leishmaniasis. <i>Asian Pacific Journal of Tropical Disease</i> , 2014, 4, S545-S548.	0.5	1
673	±-Aminophosphonates as novel anti-leishmanial chemotypes: synthesis, biological evaluation, and CoMFA studies. <i>MedChemComm</i> , 2014, 5, 665-670.	3.5	57
674	Topical Resiquimod Protects against Visceral Infection with <i>Leishmania infantum chagasi</i> in Mice. <i>Vaccine Journal</i> , 2014, 21, 1314-1322.	3.2	15
675	<i>In vitro</i> anti-leishmanial activity of methanolic extracts of <i>Calendula officinalis</i> flowers, <i>Datura stramonium</i> seeds, and <i>Salvia officinalis</i> leaves. <i>Chinese Journal of Natural Medicines</i> , 2014, 12, 423-427.	0.7	19
676	A new approach for the delivery of artemisinin: Formulation, characterization, and <i>ex-vivo</i> antileishmanial studies. <i>Journal of Colloid and Interface Science</i> , 2014, 432, 258-269.	5.0	29
677	The Direct Boil-LAMP method: A simple and rapid diagnostic method for cutaneous leishmaniasis. <i>Parasitology International</i> , 2014, 63, 785-789.	0.6	38
678	Chronicity of Dermal Leishmaniasis Caused by <i>Leishmania panamensis</i> Is Associated with Parasite-Mediated Induction of Chemokine Gene Expression. <i>Infection and Immunity</i> , 2014, 82, 2872-2880.	1.0	26
680	Regulation Dynamics of <i>Leishmania</i> Differentiation: Deconvoluting Signals and Identifying Phosphorylation Trends. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1787-1799.	2.5	72
681	Colonisation resistance in the sand fly gut: <i>Leishmania</i> protects <i>Lutzomyia longipalpis</i> from bacterial infection. <i>Parasites and Vectors</i> , 2014, 7, 329.	1.0	91
682	Recurrences of Visceral Leishmaniasis Caused by <i>Leishmania siamensis</i> after Treatment with Amphotericin B in a Seronegative Child. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 90, 40-42.	0.6	28
683	Visceral leishmaniasis clinically mimicking lymphoma. <i>Annals of Hematology</i> , 2014, 93, 885-887.	0.8	7
684	Neglected Tropical Diseases and Omics Science: Proteogenomics Analysis of the Promastigote Stage of <i>Leishmania major</i> Parasite. <i>OMICS A Journal of Integrative Biology</i> , 2014, 18, 499-512.	1.0	35
685	SOD1 Plasma Level as a Biomarker for Therapeutic Failure in Cutaneous Leishmaniasis. <i>Journal of Infectious Diseases</i> , 2014, 210, 306-310.	1.9	22
686	CD4 T cell activation by B cells in human <i>Leishmania</i> (Viannia) infection. <i>BMC Infectious Diseases</i> , 2014, 14, 108.	1.3	25

#	ARTICLE	IF	CITATIONS
687	The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis. <i>Trends in Parasitology</i> , 2014, 30, 412-422.	1.5	72
688	Chitosan-Assisted Immunotherapy for Intervention of Experimental Leishmaniasis via Amphotericin B-Loaded Solid Lipid Nanoparticles. <i>Applied Biochemistry and Biotechnology</i> , 2014, 174, 1309-1330.	1.4	82
689	Cutaneous Leishmaniasis in North Dakota. <i>Clinical Infectious Diseases</i> , 2014, 59, e73-e75.	2.9	20
690	Synthesis, Structure-Activity Relationships, and Biological Studies of Chromenochalcones as Potential Antileishmanial Agents. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 3342-3357.	2.9	34
691	Pathogenesis of Leishmaniasis. , 2014, , .		2
692	Hemophagocytic Lymphohistiocytosis in Imported Pediatric Visceral Leishmaniasis in a Nonendemic Area. <i>Journal of Pediatrics</i> , 2014, 165, 147-153.e1.	0.9	46
693	Novel hybrid selenosulfonamides as potent antileishmanial agents. <i>European Journal of Medicinal Chemistry</i> , 2014, 74, 116-123.	2.6	45
694	Current Status and Future Challenges for the Development of Genetically Altered Live Attenuated Leishmania Vaccines. , 2014, , 45-66.		1
695	Identifying vaccine targets for anti-leishmanial vaccine development. <i>Expert Review of Vaccines</i> , 2014, 13, 489-505.	2.0	49
696	Quantitative proteomic analysis of amphotericin B resistance in <i>Leishmania infantum</i> . <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2014, 4, 126-132.	1.4	71
697	In situ cytokines (IL-4, IL-10, IL-12, IFN- γ) and chemokines (MCP-1, MIP-1 α) gene expression in human <i>Leishmania (Leishmania) mexicana</i> infection. <i>Cytokine</i> , 2014, 69, 56-61.	1.4	28
698	Determinants of disease phenotype in trypanosomatid parasites. <i>Trends in Parasitology</i> , 2014, 30, 342-349.	1.5	58
699	Smuggling across the Border: How Arthropod-Borne Pathogens Evade and Exploit the Host Defense System of the Skin. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1211-1219.	0.3	39
700	Mianserin, an antidepressant kills <i>Leishmania donovani</i> by depleting ergosterol levels. <i>Experimental Parasitology</i> , 2014, 144, 84-90.	0.5	19
701	Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) enzyme of <i>Leishmania donovani</i> . <i>Parasitology Research</i> , 2014, 113, 2161-2168.	0.6	21
702	Antileishmanial activity and cytotoxicity of Brazilian plants. <i>Experimental Parasitology</i> , 2014, 143, 60-68.	0.5	52
703	Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. <i>The Cochrane Library</i> , 2014, , CD009135.	1.5	93
704	The <i>Leishmania</i> metaphylome: a comprehensive survey of <i>Leishmania</i> protein phylogenetic relationships. <i>BMC Genomics</i> , 2015, 16, 887.	1.2	21

#	ARTICLE	IF	CITATIONS
705	Scientific Opinion on canine leishmaniosis. EFSA Journal, 2015, 13, 4075.	0.9	23
706	Innate immunity against Leishmania infections. Cellular Microbiology, 2015, 17, 1286-1294.	1.1	68
708	Leishmania infection modulates beta-1 integrin activation and alters the kinetics of monocyte spreading over fibronectin. Scientific Reports, 2015, 5, 12862.	1.6	14
709	Size does matter: 18 amino acids at the N-terminal tip of an amino acid transporter in Leishmania determine substrate specificity. Scientific Reports, 2015, 5, 16289.	1.6	8
710	Attraction and oviposition preferences of Phlebotomus papatasi (Diptera: Phlebotomidae), vector of Old-World cutaneous leishmaniasis, to larval rearing media. Parasites and Vectors, 2015, 8, 663.	1.0	18
711	Neglected diseases prioritized in Brazil under the perspective of metabolomics: A review. Electrophoresis, 2015, 36, 2336-2347.	1.3	8
712	Pharmacotherapy for Leishmaniasis in the United States: Focus on Miltefosine. Pharmacotherapy, 2015, 35, 536-545.	1.2	15
713	Low Seroprevalence of <i>Leishmania infantum</i> and <i>Toxoplasma gondii</i> in the Horse Population in Israel. Vector-Borne and Zoonotic Diseases, 2015, 15, 726-731.	0.6	19
714	Estimation of infection prevalence and sensitivity in a stratified two-stage sampling design employing highly specific diagnostic tests when there is no gold standard. Statistics in Medicine, 2015, 34, 3349-3361.	0.8	2
715	Association between HLA-C*04 and American cutaneous leishmaniasis in endemic region of southern Brazil. Genetics and Molecular Research, 2015, 14, 14929-14935.	0.3	4
716	Epidemiologia da leishmaniose visceral em Bauru, São Paulo, no período de 2004 a 2012: um estudo descritivo. Epidemiologia E Serviços De Saude: Revista Do Sistema Unico De Saude Do Brasil, 2015, 24, 97-104.	0.3	17
717	THE UTILITY OF BLOOD AND BONE MARROW FILMS AND TREPINE BIOPSY SECTIONS IN THE DIAGNOSIS OF PARASITIC INFECTIONS. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015039.	0.5	3
718	Between Armour and Weapons – Cell Death Mechanisms in Trypanosomatid Parasites. , 2015, , .		1
720	Visceral Leishmaniasis and Immunocompromise as a Risk Factor for the Development of Visceral Leishmaniasis: A Changing Pattern at The Hospital for Tropical Diseases, London. PLoS ONE, 2015, 10, e0121418.	1.1	21
721	Efficacy of Thermootherapy to Treat Cutaneous Leishmaniasis: A Meta-Analysis of Controlled Clinical Trials. PLoS ONE, 2015, 10, e0122569.	1.1	45
722	Quantification of Leishmania (Viannia) Kinetoplast DNA in Ulcers of Cutaneous Leishmaniasis Reveals Inter-site and Inter-sampling Variability in Parasite Load. PLoS Neglected Tropical Diseases, 2015, 9, e0003936.	1.3	34
723	Molecular and Functional Characterization of ssDNA Aptamers that Specifically Bind Leishmania infantum PABP. PLoS ONE, 2015, 10, e0140048.	1.1	25
724	Antileishmanial activity of some Brazilian plants, with particular reference to Casearia sylvestris. Anais Da Academia Brasileira De Ciencias, 2015, 87, 733-742.	0.3	15

#	ARTICLE	IF	CITATIONS
725	Design and Synthesis of Novel Antileishmanial Compounds. International Journal of Medicinal Chemistry, 2015, 2015, 1-21.	2.2	1
726	Advances in Development of New Treatment for Leishmaniasis. BioMed Research International, 2015, 2015, 1-11.	0.9	149
727	Transmission routes of visceral leishmaniasis in mammals. Ciencia Rural, 2015, 45, 1622-1628.	0.3	11
728	Leishmaniasis: Epidemiology, Control and Future Perspectives with Special Emphasis on Egypt. Journal of Tropical Diseases, 2015, 03, .	0.1	5
729	Cutaneous Leishmaniasis in Travellers: a Focus on Epidemiology and Treatment in 2015. Current Infectious Disease Reports, 2015, 17, 489.	1.3	24
730	Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice. Immunobiology, 2015, 220, 1031-1038.	0.8	20
731	Drugs for Protozoal Infections Other Than Malaria. , 2015, , 510-518.e3.		4
732	Miltefosine, an FDA-approved drug for the "orphan disease"™, leishmaniasis. Expert Opinion on Orphan Drugs, 2015, 3, 727-735.	0.5	12
733	Comparative genomic analysis of Leishmania (Viannia) peruviana and Leishmania (Viannia) braziliensis. BMC Genomics, 2015, 16, 715.	1.2	54
734	<i>IL2RA</i> Genetic Variants Reduce IL-2-Dependent Responses and Aggravate Human Cutaneous Leishmaniasis. Journal of Immunology, 2015, 194, 2664-2672.	0.4	29
735	Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis. International Journal of Antimicrobial Agents, 2015, 45, 268-277.	1.1	29
736	Studies on cocktails of 31 kDa, 36 kDa and 51 kDa antigens of <i>Leishmania donovani</i> along with saponin against murine visceral leishmaniasis. Parasite Immunology, 2015, 37, 192-203.	0.7	10
737	The role of vitamin D in the control of Leishmania infection. Canadian Journal of Physiology and Pharmacology, 2015, 93, 369-376.	0.7	4
738	Synthesis and Biological Evaluation of Ferrocenylquinoline as a Potential Antileishmanial Agent. ChemMedChem, 2015, 10, 546-554.	1.6	21
739	Developing cutaneous applications of paromomycin entrapped in stimuli-sensitive block copolymer nanogel dispersions. Nanomedicine, 2015, 10, 227-240.	1.7	57
740	All manner of antimony. Nature Chemistry, 2015, 7, 88-88.	6.6	20
741	Current clinical, laboratory, and treatment outcome characteristics of visceral leishmaniasis: results from a seven-year retrospective study in Greece. International Journal of Infectious Diseases, 2015, 34, 46-50.	1.5	26
742	Cutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning Travelers. Current Treatment Options in Infectious Diseases, 2015, 7, 52-62.	0.8	39

#	ARTICLE	IF	CITATIONS
743	Leishmania tarentolae molecular signatures in a 300 hundred-years-old human Brazilian mummy. Parasites and Vectors, 2015, 8, 72.	1.0	35
744	Severe haemophagocytic lymphohistiocytosis triggered by a visceral leishmaniasis in a patient with a Rosai-Dorfman disease. Annals of Hematology, 2015, 94, 701-702.	0.8	1
745	Comparison of Lesion Improvement in Lupoid Leishmaniasis Patients with Two Treatment Approaches. Journal of Cutaneous Medicine and Surgery, 2015, 19, 35-39.	0.6	8
746	The Leishmania donovani peroxin 14 binding domain accommodates a high degeneracy in the pentapeptide motifs present on peroxin 5. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 2203-2212.	1.1	4
747	2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile. Journal of Medicinal Chemistry, 2015, 58, 6422-6434.	2.9	45
748	Potent <i>In Vitro</i> Antiproliferative Synergism of Combinations of Ergosterol Biosynthesis Inhibitors against Leishmania amazonensis. Antimicrobial Agents and Chemotherapy, 2015, 59, 6402-6418.	1.4	34
749	Antileishmanial effect of mevastatin is due to interference with sterol metabolism. Parasitology Research, 2015, 114, 3873-3883.	0.6	15
750	Targeting Ergosterol Biosynthesis in Leishmania donovani: Essentiality of Sterol 14alpha-demethylase. PLoS Neglected Tropical Diseases, 2015, 9, e0003588.	1.3	90
751	New World and Old World Leishmania Infections. Dermatologic Clinics, 2015, 33, 579-593.	1.0	230
752	Characterization of Metabolically Quiescent Leishmania Parasites in Murine Lesions Using Heavy Water Labeling. PLoS Pathogens, 2015, 11, e1004683.	2.1	122
753	Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment. Journal of Translational Internal Medicine, 2015, 3, 43-50.	1.0	128
754	Molecular Diagnostics in the Diagnosis of Parasitic Infection. Methods in Microbiology, 2015, 42, 111-160.	0.4	3
755	Leishmania infantum Modulates Host Macrophage Mitochondrial Metabolism by Hijacking the SIRT1-AMPK Axis. PLoS Pathogens, 2015, 11, e1004684.	2.1	96
756	Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice. PLoS Neglected Tropical Diseases, 2015, 9, e0003751.	1.3	16
757	Mucosal leishmaniasis mimicking squamous cell carcinoma in a liver transplant recipient. Transplant Infectious Disease, 2015, 17, 488-492.	0.7	21
758	Synergistic enhancement of parasitocidal activity of amphotericin <i>B</i> using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non-toxic chemotherapy. British Journal of Pharmacology, 2015, 172, 3596-3610.	2.7	16
759	A 7-year-old Girl from South Sudan with Undulating Fever. , 2015, , 182-184.		0
760	Polymorphisms in tumor necrosis factor genes and susceptibility to visceral leishmaniasis in Moroccan children. Asian Pacific Journal of Tropical Disease, 2015, 5, 380-384.	0.5	2

#	ARTICLE	IF	CITATIONS
761	Epidemiologic, clinical, diagnostic and therapeutic aspects of visceral leishmaniasis in renal transplant recipients: experience from thirty cases. <i>BMC Infectious Diseases</i> , 2015, 15, 96.	1.3	25
762	Neglected Tropical Diseases - Latin America and the Caribbean. <i>Neglected Tropical Diseases</i> , 2015, , .	0.4	9
763	Leishmaniasis in the Americas. <i>Neglected Tropical Diseases</i> , 2015, , 113-128.	0.4	1
764	Synthesis of 5-isoxazol-3-yl-pyrimidine nucleosides as potential antileishmanial agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2617-2620.	1.0	13
765	Correlation between Socioeconomic Status and Clinical Course in Patients with Cutaneous Leishmaniasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 40-44.	0.6	13
766	Novel 3,4-methylenedioxyde-6-X-benzaldehyde-thiosemicarbazones: Synthesis and antileishmanial effects against <i>Leishmania amazonensis</i> . <i>European Journal of Medicinal Chemistry</i> , 2015, 103, 409-417.	2.6	37
767	Evaluation of the leishmanicidal and cytotoxic effects of inhibitors for microorganism metabolic pathway enzymes. <i>Biomedicine and Pharmacotherapy</i> , 2015, 74, 95-100.	2.5	6
768	Slowly Progressive Keratouveitis in a Patient with Known Systemic Leishmaniasis and HIV. <i>Ocular Immunology and Inflammation</i> , 2015, 23, 248-251.	1.0	8
769	The potential of daylight-activated photodynamic therapy for treating localized forms of cutaneous leishmaniasis in resource-limited settings. <i>British Journal of Dermatology</i> , 2015, 172, 1192-1193.	1.4	3
770	A proteomic map of the unsequenced kala-azar vector <i>Phlebotomus papatasi</i> using cell line. <i>Acta Tropica</i> , 2015, 152, 80-89.	0.9	1
771	Outbreak of Cutaneous Leishmaniasis in Peruvian Military Personnel Undertaking Training Activities in the Amazon Basin, 2010. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 340-346.	0.6	29
772	Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic. <i>British Journal of Dermatology</i> , 2015, 172, 861-866.	1.4	7
773	Systematic Review of Biomarkers To Monitor Therapeutic Response in Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1-14.	1.4	62
774	Unexpected co-detection of promastigote and amastigote <i>Leishmania</i> forms in a human cutaneous lesion: implications for leishmaniasis pathophysiology and treatment. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 81, 18-20.	0.8	0
775	Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid-polymer hybrid nanoparticle: Biodistribution and toxicity assessment of encapsulated amphotericin B. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 89, 62-73.	2.0	55
776	Synthesis and biological evaluation of novel 2,3-disubstituted quinoxaline derivatives as antileishmanial and antitrypanosomal agents. <i>European Journal of Medicinal Chemistry</i> , 2015, 90, 107-123.	2.6	56
777	Functional analysis of iron superoxide dismutase-A in wild-type and antimony-resistant <i>Leishmania braziliensis</i> and <i>Leishmania infantum</i> lines. <i>Parasitology International</i> , 2015, 64, 125-129.	0.6	24
778	Parasite Genomics Protocols. <i>Methods in Molecular Biology</i> , 2015, 1201, v-vi.	0.4	2

#	ARTICLE	IF	CITATIONS
779	Miltefosine and BODIPY-labeled alkylphosphocholine with leishmanicidal activity: Aggregation properties and interaction with model membranes. <i>Biophysical Chemistry</i> , 2015, 196, 92-99.	1.5	20
780	Increased tau phosphorylation and receptor for advanced glycation endproducts (RAGE) in the brain of mice infected with <i>Leishmania amazonensis</i> . <i>Brain, Behavior, and Immunity</i> , 2015, 43, 37-45.	2.0	14
781	Probing the Molecular Mechanism of Hypericin-Induced Parasite Death Provides Insight into the Role of Spermidine beyond Redox Metabolism in <i>Leishmania donovani</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 15-24.	1.4	31
783	APAGANDO GENES PARA ILUMINAR LA INTERACCIÓN ENTRE EL MACRÓFAGO Y LEISHMANIA. <i>Acta Biologica Colombiana</i> , 2016, 21, 259-263.	0.1	0
784	Nutritional supplements for patients being treated for active visceral leishmaniasis. <i>The Cochrane Library</i> , 2016, .	1.5	3
785	Cubebin and semisynthetic dibenzyl butyrolactone derivatives: Biological activities. <i>African Journal of Pharmacy and Pharmacology</i> , 2016, 10, 526-532.	0.2	2
786	Î ² -Nitrostyrenes as Potential Anti-leishmanial Agents. <i>Frontiers in Microbiology</i> , 2016, 7, 1379.	1.5	17
787	Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005196.	1.3	40
788	The gp63 Gene Cluster Is Highly Polymorphic in Natural <i>Leishmania</i> (<i>Viannia</i>) <i>braziliensis</i> Populations, but Functional Sites Are Conserved. <i>PLoS ONE</i> , 2016, 11, e0163284.	1.1	14
789	An Arginine Deprivation Response Pathway Is Induced in <i>Leishmania</i> during Macrophage Invasion. <i>PLoS Pathogens</i> , 2016, 12, e1005494.	2.1	86
790	New Approaches to Overcome Transport Related Drug Resistance in Trypanosomatid Parasites. <i>Frontiers in Pharmacology</i> , 2016, 7, 351.	1.6	23
791	Topical treatment with a two-component gel releasing nitric oxide cures C57BL/6 mice from cutaneous leishmaniasis caused by <i>Leishmania major</i> . <i>Experimental Dermatology</i> , 2016, 25, 914-916.	1.4	5
792	An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis. <i>Parasitology Research</i> , 2016, 115, 4083-4095.	0.6	28
793	Palate Perforation. <i>Infectious Diseases in Clinical Practice</i> , 2016, 24, 83-86.	0.1	1
794	Crosstalk between purinergic receptors and lipid mediators in leishmaniasis. <i>Parasites and Vectors</i> , 2016, 9, 489.	1.0	20
795	Clinical Presentation of Cutaneous Leishmaniasis caused by <i>Leishmania major</i> . <i>Dermatology</i> , 2016, 232, 752-759.	0.9	26
796	Attenuated <i>Leishmania</i> induce pro-inflammatory mediators and influence leishmanicidal activity by p38 MAPK dependent phagosome maturation in <i>Leishmania donovani</i> co-infected macrophages. <i>Scientific Reports</i> , 2016, 6, 22335.	1.6	14
797	Decentralized control of human visceral leishmaniasis in endemic urban areas of Brazil: a literature review. <i>Tropical Medicine and Health</i> , 2016, 44, 9.	1.0	14

#	ARTICLE	IF	CITATIONS
798	Involvement of nucleoside diphosphate kinase b and elongation factor 2 in Leishmania braziliensis antimony resistance phenotype. Parasites and Vectors, 2016, 9, 641.	1.0	16
801	<i>In Vitro</i> and <i>In Vivo</i> Activities of 2,3-Diarylsubstituted Quinoxaline Derivatives against Leishmania amazonensis. Antimicrobial Agents and Chemotherapy, 2016, 60, 3433-3444.	1.4	36
802	Antileishmanial activity and mechanism of action from a purified fraction of Zingiber officinalis Roscoe against Leishmania amazonensis. Experimental Parasitology, 2016, 166, 21-28.	0.5	31
803	New serological tools for improved diagnosis of human tegumentary leishmaniasis. Journal of Immunological Methods, 2016, 434, 39-45.	0.6	19
804	Cytokine mRNA expression in Peromyscus yucatanicus (Rodentia: Cricetidae) infected by Leishmania (Leishmania) mexicana. Cytokine, 2016, 83, 176-181.	1.4	2
805	American tegumentary leishmaniasis: T-cell differentiation profile of cutaneous and mucosal forms co-infection with Trypanosoma cruzi. Medical Microbiology and Immunology, 2016, 205, 353-369.	2.6	12
806	Epigenetics: A New Model for Intracellular Parasite Host Cell Regulation. Trends in Parasitology, 2016, 32, 515-521.	1.5	53
807	Differential Role of Leptin as an Immunomodulator in Controlling Visceral Leishmaniasis in Normal and Leptin-Deficient Mice. American Journal of Tropical Medicine and Hygiene, 2016, 95, 109-119.	0.6	16
808	Silver and Nitrate Oppositely Modulate Antimony Susceptibility through Aquaglyceroporin 1 in Leishmania (Viannia) Species. Antimicrobial Agents and Chemotherapy, 2016, 60, 4482-4489.	1.4	9
809	Gold nanoparticles-based biosensing of Leishmania major kDNA genome: Visual and spectrophotometric detections. Sensors and Actuators B: Chemical, 2016, 235, 723-731.	4.0	43
810	Transgenic T cell-specific expression of CXCR3 enhances splenic and hepatic T cell accumulation but does not affect the outcome of visceral leishmaniasis. Cellular Immunology, 2016, 309, 61-68.	1.4	1
811	Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials. BMC Infectious Diseases, 2016, 16, 360.	1.3	30
812	Overview of dendritic cell-based vaccine development for leishmaniasis. Parasite Immunology, 2016, 38, 651-662.	0.7	10
813	T Helper 1 (Th1), Th2, and Th17 Responses to Leishmania major Lipophosphoglycan 3. Immunological Investigations, 2016, 45, 692-702.	1.0	14
814	Evaluation of recombinant K39 antigen and various promastigote antigens in sero-diagnosis of visceral leishmaniasis in Bangladesh. Parasite Epidemiology and Control, 2016, 1, 219-228.	0.6	13
815	Metabolites isolated from the rhizomes of Dorstenia contrajerva with anti-leishmanial activity. Phytochemistry Letters, 2016, 18, 140-143.	0.6	4
816	Deep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistance. Parasitology Research, 2016, 115, 3699-3703.	0.6	16
817	Biodirected synthesis of palladium nanoparticles using Phoenix dactylifera leaves extract and their size dependent biomedical and catalytic applications. RSC Advances, 2016, 6, 85903-85916.	1.7	59

#	ARTICLE	IF	CITATIONS
818	Lipid based delivery and immuno-stimulatory systems: Master tools to combat leishmaniasis. Cellular Immunology, 2016, 309, 55-60.	1.4	14
819	Role of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in protective immunity by Leishmania vaccines. Cellular Immunology, 2016, 309, 37-41.	1.4	61
820	Nonbacterial Microbiology of the Head, Neck, and Orofacial Region. , 2016, , 38-59.		0
821	Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clinical Infectious Diseases, 2016, 63, e202-e264.	2.9	235
822	Trend in cumulative cases and mortality rate among visceral leishmaniasis patients in Eastern Sudan: a 14-year registry, 2002â€“2015. International Journal of Infectious Diseases, 2016, 51, 81-84.	1.5	15
823	In vitro anti-Leishmania activity of tetracyclic iridoids from Morinda lucida, benth. Tropical Medicine and Health, 2016, 44, 25.	1.0	13
824	Regulation of immunity during visceral Leishmania infection. Parasites and Vectors, 2016, 9, 118.	1.0	188
825	Correlation of Genetic Heterogeneity with Cytopathological and Epidemiological Findings of Leishmania major Isolated from Cutaneous Leishmaniasis in Southern Iran. Acta Cytologica, 2016, 60, 97-106.	0.7	6
826	Dual Transcriptome Profiling of <i>Leishmania</i> -Infected Human Macrophages Reveals Distinct Reprogramming Signatures. MBio, 2016, 7, .	1.8	111
827	Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis. Journal of Parasitic Diseases, 2016, 40, 475-484.	0.4	13
828	Seroprevalence of canine leishmaniasis in Kwara, Oyo and Ogun states of Nigeria. Journal of Parasitic Diseases, 2016, 40, 510-514.	0.4	9
829	The TLR2 and TLR4 gene polymorphisms in Moroccan visceral leishmaniasis patients. Acta Tropica, 2016, 158, 77-82.	0.9	7
830	Does Leishmaniasis disease alter the parenchyma and protein expression in salivary glands?. Experimental Biology and Medicine, 2016, 241, 359-366.	1.1	3
831	Natural products from marine invertebrates against Leishmania parasites: a comprehensive review. Phytochemistry Reviews, 2016, 15, 663-697.	3.1	12
832	Impact of vectorborne parasitic neglected tropical diseases on child health. Archives of Disease in Childhood, 2016, 101, 640-647.	1.0	9
833	Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries. Acta Tropica, 2016, 155, 113-123.	0.9	79
834	Up regulation of A2B adenosine receptor on monocytes are crucially required for immune pathogenicity in Indian patients exposed to Leishmania donovani. Cytokine, 2016, 79, 38-44.	1.4	26
835	Major Parasitic Zoonoses Associated with Dogs and Cats in Europe. Journal of Comparative Pathology, 2016, 155, S54-S74.	0.1	112

#	ARTICLE	IF	CITATIONS
836	Molecular characterization and functional analysis of pteridine reductase in wild-type and antimony-resistant <i>Leishmania</i> lines. <i>Experimental Parasitology</i> , 2016, 160, 60-66.	0.5	13
837	Diastereoselective synthesis of substituted hexahydrobenzo[de]isochromanes and evaluation of their antileishmanial activity. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 970-979.	1.5	5
839	Recombinant <i>Leishmania major</i> lipophosphoglycan 3 activates human T-lymphocytes via TLR2-independent pathway. <i>Journal of Immunotoxicology</i> , 2016, 13, 263-269.	0.9	4
840	Conjunctival leishmaniasis in a case of disseminated cutaneous leishmaniasis. <i>Tropical Doctor</i> , 2017, 47, 53-55.	0.2	6
841	Immunization with <i>Leishmania donovani</i> protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb/c mice. <i>Molecular Immunology</i> , 2017, 82, 104-113.	1.0	40
842	Assessment of formulated amodiaquine microparticles in <i>Leishmania donovani</i> infected rats. <i>Journal of Microencapsulation</i> , 2017, 34, 21-28.	1.2	10
843	Comparative genomics of canine-isolated <i>Leishmania (Leishmania) amazonensis</i> from an endemic focus of visceral leishmaniasis in Governador Valadares, southeastern Brazil. <i>Scientific Reports</i> , 2017, 7, 40804.	1.6	65
844	High dilutions of antimony modulate cytokines production and macrophage <i>Leishmania (L.) amazonensis</i> interaction in vitro. <i>Cytokine</i> , 2017, 92, 33-47.	1.4	19
845	Meglumine antimoniate-TiO ₂ @Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect. <i>Acta Tropica</i> , 2017, 169, 30-42.	0.9	34
846	Immunopathological characterization of human cutaneous leishmaniasis lesions caused by <i>Leishmania (Viannia) spp.</i> in Amazonian Brazil. <i>Parasitology Research</i> , 2017, 116, 1423-1431.	0.6	8
847	Evaluation of CAAX prenyl protease II of <i>Leishmania donovani</i> as potential drug target: Infectivity and growth of the parasite is significantly lowered after the gene knockout. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 102, 156-160.	1.9	6
848	Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India. <i>Parasites and Vectors</i> , 2017, 10, 49.	1.0	103
849	Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis. <i>Journal of Evidence-Based Medicine</i> , 2017, 10, 81-90.	2.4	8
850	Effect of 1,2,3-triazole salts, non-classical bioisosteres of miltefosine, on <i>Leishmania amazonensis</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 3034-3045.	1.4	44
851	A time series analysis of environmental and metrological factors impact on cutaneous leishmaniasis incidence in an endemic area of Dehloran, Iran. <i>Environmental Science and Pollution Research</i> , 2017, 24, 14117-14123.	2.7	19
852	New evidence of cutaneous leishmaniasis in north-eastern Italy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1534-1540.	1.3	16
853	Antileishmanial activity study and theoretical calculations for 4-amino-1,2,4-triazole derivatives. <i>Journal of Molecular Structure</i> , 2017, 1144, 80-86.	1.8	34
854	Minimally invasive microbiopsies: a novel sampling method for identifying asymptomatic, potentially infectious carriers of <i>Leishmania donovani</i> . <i>International Journal for Parasitology</i> , 2017, 47, 609-616.	1.3	26

#	ARTICLE	IF	CITATIONS
855	Knockdown of Host Antioxidant Defense Genes Enhances the Effect of Glucantime on Intracellular <i>Leishmania braziliensis</i> in Human Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	7
856	Application of nanotechnology in treatment of leishmaniasis: A Review. <i>Acta Tropica</i> , 2017, 172, 86-90.	0.9	106
857	<i>Leishmania</i> genomics: a brief account. <i>Nucleus (India)</i> , 2017, 60, 227-235.	0.9	1
858	Characterization of the Protein Tyrosine Phosphatase LmPRL-1 Secreted by <i>Leishmania major</i> via the Exosome Pathway. <i>Infection and Immunity</i> , 2017, 85, .	1.0	34
859	Molecular events leading to death of <i>Leishmania donovani</i> under spermidine starvation after hypericin treatment. <i>Chemical Biology and Drug Design</i> , 2017, 90, 962-971.	1.5	8
860	Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with <i>Leishmania amazonensis</i> and Its Inhibitory Effect on Topoisomerase 1B. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	24
861	Atypical presentations of cutaneous leishmaniasis: A systematic review. <i>Acta Tropica</i> , 2017, 172, 240-254.	0.9	83
862	Hydrophilic Acylated Surface Protein A (HASPA) of <i>Leishmania donovani</i> : Expression, Purification and Biophysico-Chemical Characterization. <i>Protein Journal</i> , 2017, 36, 343-351.	0.7	4
863	<i>Leishmania donovani</i> restricts mitochondrial dynamics to enhance miRNP stability and target RNA repression in host macrophages. <i>Molecular Biology of the Cell</i> , 2017, 28, 2091-2105.	0.9	38
864	Biochemical and inhibition studies of glutamine synthetase from <i>Leishmania donovani</i> . <i>Microbial Pathogenesis</i> , 2017, 107, 164-174.	1.3	18
865	New insights into the mechanistic action of methyldehydrodieugenol B towards <i>Leishmania (L.) infantum</i> via a multiplatform based untargeted metabolomics approach. <i>Metabolomics</i> , 2017, 13, 1.	1.4	7
866	Chronic amastigote-negative cutaneous leishmaniasis: A clinical, histopathologic and molecular study of 27 cases with emphasis on atypical and pseudolymphomatous presentations. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 530-537.	0.7	14
867	Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 24-45.	0.6	191
868	Lipidomic alterations of in vitro macrophage infection by <i>L. infantum</i> and <i>L. amazonensis</i> . <i>Molecular BioSystems</i> , 2017, 13, 2401-2406.	2.9	11
869	New insights to structure and immunological features of <i>Leishmania lipophosphoglycan3</i> . <i>Biomedicine and Pharmacotherapy</i> , 2017, 95, 1369-1374.	2.5	4
870	Leech therapy in treatment of cutaneous leishmaniasis: a case report. <i>Journal of Integrative Medicine</i> , 2017, 15, 407-410.	1.4	5
871	Virus-like Particle Display of the β -Gal Carbohydrate for Vaccination against <i>Leishmania</i> Infection. <i>ACS Central Science</i> , 2017, 3, 1026-1031.	5.3	67
872	PEGylation of cationic liposomes encapsulating soluble <i>Leishmania</i> antigens reduces the adjuvant efficacy of liposomes in murine model. <i>Parasite Immunology</i> , 2017, 39, e12492.	0.7	6

#	ARTICLE	IF	CITATIONS
873	Leishmania incidence and prevalence in U.S. hunting hounds maintained via vertical transmission. <i>Veterinary Parasitology: Regional Studies and Reports</i> , 2017, 10, 75-81.	0.3	12
874	The role of asymptomatics and dogs on leishmaniasis propagation. <i>Mathematical Biosciences</i> , 2017, 293, 46-55.	0.9	22
875	The circadian clock in immune cells controls the magnitude of Leishmania parasite infection. <i>Scientific Reports</i> , 2017, 7, 10892.	1.6	76
876	Liposomal formulations in the pharmacological treatment of leishmaniasis: a review. <i>Journal of Liposome Research</i> , 2017, 27, 234-248.	1.5	24
877	An insight into tetrahydro- β -carboline-tetrazole hybrids: synthesis and bioevaluation as potent antileishmanial agents. <i>MedChemComm</i> , 2017, 8, 1824-1834.	3.5	25
878	American cutaneous leishmaniasis in infancy and childhood. <i>International Journal of Dermatology</i> , 2017, 56, 1328-1341.	0.5	22
879	Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of <i>L. donovani</i> . <i>International Journal of Biological Macromolecules</i> , 2017, 105, 625-637.	3.6	21
881	An atypical case of disseminated cutaneous leishmaniasis due to <i>Leishmania peruviana</i> in the valleys of Ancash-Peru. <i>Asian Pacific Journal of Tropical Medicine</i> , 2017, 10, 1101-1103.	0.4	5
883	Visceral Leishmaniasis in Children: Diagnosis, Treatment, and Prevention. <i>Journal of Pediatric Infectious Diseases</i> , 2017, 12, 214-221.	0.1	4
885	SLC11A1 polymorphisms and host susceptibility to cutaneous leishmaniasis in Pakistan. <i>Parasites and Vectors</i> , 2017, 10, 12.	1.0	13
886	The use of kDNA minicircle subclass relative abundance to differentiate between <i>Leishmania (L.) infantum</i> and <i>Leishmania (L.) amazonensis</i> . <i>Parasites and Vectors</i> , 2017, 10, 239.	1.0	34
887	Amiodarone and itraconazole improve the activity of pentavalent antimonial in the treatment of experimental cutaneous leishmaniasis. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 159-165.	1.1	10
888	Comparative genomics of Tunisian <i>Leishmania major</i> isolates causing human cutaneous leishmaniasis with contrasting clinical severity. <i>Infection, Genetics and Evolution</i> , 2017, 50, 110-120.	1.0	16
889	<i>In Vitro</i> Effects of the Neolignan 2,3-Dihydrobenzofuran Against <i>Leishmania Amazonensis</i> . <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 52-58.	1.2	40
890	Effectiveness of Short-Course Meglumine Antimoniate (Glucantime [®]) for Treatment of Visceral Leishmaniasis: A 13-Year, Multistage, Non-Inferiority Study in Iran. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 182-189.	0.6	5
891	Resequencing of the <i>Leishmania infantum</i> (strain JPCM5) genome and de novo assembly into 36 contigs. <i>Scientific Reports</i> , 2017, 7, 18050.	1.6	47
893	Polarity based characterization of biologically active extracts of <i>Ajuga bracteosa</i> Wall. ex Benth. and RP-HPLC analysis. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 443.	3.7	61
894	Visceral leishmaniasis triggering an adult-onset Still's disease: a unique case. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 2111-2116.	0.2	3

#	ARTICLE	IF	CITATIONS
895	Protection mediated by chemokine CXCL10 in BALB/c mice infected by <i>Leishmania infantum</i> . <i>Memorias Do Instituto Oswaldo Cruz</i> , 2017, 112, 561-568.	0.8	14
896	Visceral Leishmaniasis and Natural Infection Rates of <i>Leishmania</i> in <i>Lutzomyia longipalpis</i> in Latin America. , 0, , .		2
897	Carbocyclic Fatty Acids. , 2017, , 147-185.		2
898	In Vitro and In Vivo Evaluation of Essential Oil from <i>Artemisia absinthium</i> L. Formulated in Nanocochleates against Cutaneous Leishmaniasis. <i>Medicines (Basel, Switzerland)</i> , 2017, 4, 38.	0.7	14
899	The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases. <i>Molecules</i> , 2017, 22, 58.	1.7	139
900	Chalcone Derivatives: Promising Starting Points for Drug Design. <i>Molecules</i> , 2017, 22, 1210.	1.7	261
901	Leishmaniasis: a review. <i>F1000Research</i> , 2017, 6, 750.	0.8	699
902	Biophysical and Pharmacological Characterization of Energy-Dependent Efflux of Sb in Laboratory-Selected Resistant Strains of <i>Leishmania (Viannia)</i> Subgenus. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 24.	1.8	4
903	<i>Leishmania infantum</i> Parasites Subvert the Host Inflammatory Response through the Adenosine A2A Receptor to Promote the Establishment of Infection. <i>Frontiers in Immunology</i> , 2017, 8, 815.	2.2	20
904	Function of Macrophage and Parasite Phosphatases in Leishmaniasis. <i>Frontiers in Immunology</i> , 2017, 8, 1838.	2.2	47
905	Alcoholic Fractions F5 and F6 from <i>Withania somnifera</i> Leaves Show a Potent Antileishmanial and Immunomodulatory Activities to Control Experimental Visceral Leishmaniasis. <i>Frontiers in Medicine</i> , 2017, 4, 55.	1.2	17
906	Nanostructures for Improved Antimonial Therapy of Leishmaniasis. , 2017, , 419-437.		2
907	Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 6169-6184.	3.3	44
908	Nanostructured delivery systems with improved leishmanicidal activity: a critical review. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 5289-5311.	3.3	83
909	Mexican Medicinal Plants as an Alternative for the Development of New Compounds Against Protozoan Parasites. , 0, , .		5
910	Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005805.	1.3	44
911	Cytokines and microbicidal molecules regulated by IL-32 in THP-1-derived human macrophages infected with New World <i>Leishmania</i> species. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005413.	1.3	38
912	Dynamics of American tegumentary leishmaniasis in a highly endemic region for <i>Leishmania (Viannia) braziliensis</i> infection in northeast Brazil. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006015.	1.3	16

#	ARTICLE	IF	CITATIONS
913	Distribution and identification of sand flies naturally infected with Leishmania from the Southeastern Peruvian Amazon. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006029.	1.3	14
914	IL-32 β promotes the healing of murine cutaneous lesions caused by <i>Leishmania braziliensis</i> infection in contrast to <i>Leishmania amazonensis</i> . <i>Parasites and Vectors</i> , 2017, 10, 336.	1.0	18
915	<i>Leishmania braziliensis</i> SCD6 and RBP42 proteins, two factors with RNA binding capacity. <i>Parasites and Vectors</i> , 2017, 10, 610.	1.0	5
916	The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1703-1710.	2.9	34
917	Apoptosis-like cell death in <i>Leishmania donovani</i> treated with Kalsome TM 10, a new liposomal amphotericin B. <i>PLoS ONE</i> , 2017, 12, e0171306.	1.1	62
918	Curvas de fusión de regiones genómicas específicas: una herramienta prometedora para el diagnóstico y tipificación de las especies causantes de la leishmaniasis cutánea en Colombia. <i>Biomedica</i> , 2017, 37, 538.	0.3	2
920	Evaluating the Role of Host AMPK in <i>Leishmania</i> Burden. <i>Methods in Molecular Biology</i> , 2018, 1732, 551-563.	0.4	3
921	Revising <i>Leishmania</i> 's life cycle. <i>Nature Microbiology</i> , 2018, 3, 529-530.	5.9	54
922	Locked nucleic acid -anti-let-7a induces apoptosis and necrosis in macrophages infected with <i>Leishmania major</i> . <i>Microbial Pathogenesis</i> , 2018, 119, 193-199.	1.3	10
923	Viscerotropic leishmaniasis: a systematic review of the case reports to highlight spectrum of the infection in endemic countries. <i>Parasitology Open</i> , 2018, 4, .	0.9	10
924	Solution-combustion synthesis of doped TiO ₂ compounds and its potential antileishmanial activity mediated by photodynamic therapy. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2018, 183, 64-74.	1.7	21
925	The effect of different parameters under ultrasound irradiation for synthesis of new nanostructured Fe ₃ O ₄ @bio-MOF as an efficient anti-leishmanial in vitro and in vivo conditions. <i>Ultrasonics Sonochemistry</i> , 2018, 43, 248-261.	3.8	70
926	Safety and efficacy of miltefosine monotherapy and pentoxifylline associated with pentavalent antimony in treating mucosal leishmaniasis. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 219-225.	2.0	14
927	Antiparasitic Agents. , 2018, , 1567-1587.e2.		6
929	Natural Products from Plants as Potential Leads as Novel Antileishmanials: A Preclinical Review. <i>Sustainable Development and Biodiversity</i> , 2018, , 195-214.	1.4	0
930	The Leishmaniasis: Old Neglected Tropical Diseases. , 2018, , .		35
931	Nutritional supplements for patients being treated for active visceral leishmaniasis. <i>The Cochrane Library</i> , 2018, 3, CD012261.	1.5	7
932	Health economic evaluation of moist wound care in chronic cutaneous leishmaniasis ulcers in Afghanistan. <i>Infectious Diseases of Poverty</i> , 2018, 7, 12.	1.5	9

#	ARTICLE	IF	CITATIONS
933	A newly emerged focus of zoonotic cutaneous leishmaniasis in South-western Iran. <i>Microbial Pathogenesis</i> , 2018, 121, 363-368.	1.3	10
934	Discovery of benzimidazole-based <i>Leishmania mexicana</i> cysteine protease <sc>CPB</sc>2.81 ⁹ <sc>CTE</sc> inhibitors as potential therapeutics for leishmaniasis. <i>Chemical Biology and Drug Design</i> , 2018, 92, 1585-1596.	1.5	22
935	Eligibility criteria and outcome measures adopted in clinical trials of treatments of cutaneous leishmaniasis: systematic literature review covering the period 1991-2015. <i>Tropical Medicine and International Health</i> , 2018, 23, 448-475.	1.0	6
936	Identification of <i>Leishmania</i> (Vianna) species and clinical isolates of <i>Leishmania</i> (<i>Leishmania</i>) amazonensis from Brazil using PCR-RFLP of the heat-shock protein 70 gene reveals some unexpected observations. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 312-318.	0.8	24
937	Using proteomics as a powerful tool to develop a vaccine against Mediterranean visceral leishmaniasis. <i>Journal of Parasitic Diseases</i> , 2018, 42, 162-170.	0.4	10
938	Molecular epidemiology and in vitro evidence suggest that <i>Leishmania braziliensis</i> strain helps determine antimony response among American tegumentary leishmaniasis patients. <i>Acta Tropica</i> , 2018, 178, 34-39.	0.9	16
939	Antileishmanial Drug Miltefosine's DNA Interaction <i>in situ</i> Evaluation with a DNA Electrochemical Biosensor. <i>Electroanalysis</i> , 2018, 30, 48-56.	1.5	12
940	Leishmaniasis mucocutánea en paciente inmunocompetente: a propósito de un caso. <i>Revista Española De Cirugía Oral Y Maxilofacial</i> , 2018, 40, 41-43.	0.0	0
941	Benzimidazole derivatives endowed with potent antileishmanial activity. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 210-226.	2.5	33
942	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or Tj ETQq1 1 0.784314 rgBT /Overlo 2018, 59, 983-987.	0.6	4
943	The Polyamine Pathway as a Potential Target for Leishmaniasis Chemotherapy. , 0, , .		2
944	Zoonotic impact and epidemiological changes of leishmaniasis in Ethiopia. <i>Open Veterinary Journal</i> , 2018, 8, 432.	0.3	8
945	<i>Lutzomyia longipalpis</i> Saliva Induces Heme Oxygenase-1 Expression at Bite Sites. <i>Frontiers in Immunology</i> , 2018, 9, 2779.	2.2	13
946	Relationship of peripheral blood mononuclear cells miRNA expression and parasitic load in canine visceral leishmaniasis. <i>PLoS ONE</i> , 2018, 13, e0206876.	1.1	27
947	Chemical Composition and Anti- <i>Leishmania</i> Major Activity of Essential Oils from <i>Artemisia</i> spp. Grown in Central Tunisia. <i>Journal of Essential Oil-bearing Plants: JEOP</i> , 2018, 21, 1186-1198.	0.7	8
948	In vitro activities of glycoalkaloids from the <i>Solanum lycocarpum</i> against <i>Leishmania infantum</i> . <i>Revista Brasileira De Farmacognosia</i> , 2018, 28, 673-677.	0.6	8
949	Cost-Effectiveness Analysis of Thermotherapy Versus Pentavalent Antimonials for the Treatment of Cutaneous Leishmaniasis. <i>SSRN Electronic Journal</i> , 2018, , .	0.4	0
950	Evaluation of the Interventional Approaches in the Management of Cutaneous Leishmaniasis in Jazan: An Observational Study. <i>Annals of Dermatology</i> , 2018, 30, 575.	0.3	0

#	ARTICLE	IF	CITATIONS
951	Alternative Treatment for Leishmaniasis. , 2018, , .		5
952	Early Suppression of Macrophage Gene Expression by <i>Leishmania braziliensis</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 2464.	1.5	9
953	Incidence and Trends of Leishmaniasis and Its Risk Factors in Humera, Western Tigray. <i>Journal of Parasitology Research</i> , 2018, 2018, 1-9.	0.5	35
954	SB-83, a 2-Amino-thiophene derivative orally bioavailable candidate for the leishmaniasis treatment. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1670-1678.	2.5	5
955	Insights on a putative aminoacyl-tRNA-protein transferase of <i>Leishmania major</i> . <i>PLoS ONE</i> , 2018, 13, e0203369.	1.1	0
956	Biomarkers in Leishmaniasis: From Basic Research to Clinical Application. , 2018, , .		1
957	In vitro antileishmanial activity of ravuconazole, a triazole antifungal drug, as a potential treatment for leishmaniasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2360-2373.	1.3	25
958	Solid Organ Transplant and Parasitic Diseases: A Review of the Clinical Cases in the Last Two Decades. <i>Pathogens</i> , 2018, 7, 65.	1.2	37
959	Non-Hepatotropic Viral, Bacterial, and Parasitic Infections of the Liver. , 2018, , 416-490.		3
960	Infection of Human Monocytes with <i>Leishmania infantum</i> Strains Induces a Downmodulated Response when Compared with Infection with <i>Leishmania braziliensis</i> . <i>Frontiers in Immunology</i> , 2017, 8, 1896.	2.2	22
961	Trypanosomatid Infections: How Do Parasites and Their Excretedâ€“Secreted Factors Modulate the Inducible Metabolism of l-Arginine in Macrophages?. <i>Frontiers in Immunology</i> , 2018, 9, 778.	2.2	13
962	Arginine and Polyamines Fate in <i>Leishmania</i> Infection. <i>Frontiers in Microbiology</i> , 2017, 8, 2682.	1.5	85
963	Molecular Modeling and Structural Stability of Wild-Type and Mutant CYP51 from <i>Leishmania major</i> : In Vitro and In Silico Analysis of a Laboratory Strain. <i>Molecules</i> , 2018, 23, 696.	1.7	10
964	Preparation of live attenuated leishmania parasites by using laser technology. <i>AIP Conference Proceedings</i> , 2018, , .	0.3	0
965	Molecular diagnosis of cutaneous leishmaniasis in an endemic area of Acre State in the Amazonian Region of Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2018, 51, 376-381.	0.4	11
966	<i>In vitro</i> antiprotozoan activity and mechanisms of action of selected Ghanaian medicinal plants against <i>Trypanosoma</i> , <i>Leishmania</i> , and <i>Plasmodium</i> parasites. <i>Phytotherapy Research</i> , 2018, 32, 1617-1630.	2.8	42
967	Synthesis and evaluation of novel triazolyl quinoline derivatives as potential antileishmanial agents. <i>European Journal of Medicinal Chemistry</i> , 2018, 154, 172-181.	2.6	55
968	Why miltefosineâ€“a life-saving drug for leishmaniasisâ€“is unavailable to people who need it the most. <i>BMJ Global Health</i> , 2018, 3, e000709.	2.0	104

#	ARTICLE	IF	CITATIONS
969	Drug Resistance in Leishmania Parasites. , 2018, , .		3
970	The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study. PLoS Neglected Tropical Diseases, 2018, 12, e0006527.	1.3	19
971	Bioinformatics in Leishmania Drug Design. , 2018, , 297-317.		0
972	The Role of Proteomics in the Study of Drug Resistance. , 2018, , 209-245.		1
973	In vitro anti-Leishmania activity of T6 synthetic compound encapsulated in yeast-derived β -(1,3)-d-glucan particles. International Journal of Biological Macromolecules, 2018, 119, 1264-1275.	3.6	14
974	Finding a model for the study of Leishmania (Leishmania) mexicana infection: The Yucatan Deer mouse (Peromyscus yucatanicus) as a suitable option. Acta Tropica, 2018, 187, 158-164.	0.9	4
975	Efficacy of Meglumine Antimoniate in a Low Polymerization State Orally Administered in a Murine Model of Visceral Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	7
976	Identification of lead molecules against potential drug target protein MAPK4 from <i>L. donovani</i> : An in-silico approach using docking, molecular dynamics and binding free energy calculation. PLoS ONE, 2019, 14, e0221331.	1.1	39
977	Effect of educational intervention based on the PRECEDE-PROCEED model on preventive behaviors of cutaneous leishmaniasis among housewives. Cadernos De Saude Publica, 2019, 35, e00158818.	0.4	6
978	Non-specific effects of BCG in protozoal infections: tegumentary leishmaniasis and malaria. Clinical Microbiology and Infection, 2019, 25, 1479-1483.	2.8	18
979	The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate. Postepy Dermatologii I Alergologii, 2019, 36, 227-231.	0.4	6
980	Indirect Evidence of Circulating Parasite Hapten Immune Complexes in Visceral Leishmaniasis. journal of applied laboratory medicine, The, 2019, 4, 404-409.	0.6	3
981	Endlicheria bracteolata (Meisn.) Essential Oil as a Weapon Against Leishmania amazonensis: In Vitro Assay. Molecules, 2019, 24, 2525.	1.7	18
982	Combined chemotherapy manifest less severe immunopathology effects in helminth-protozoa comorbidity. Experimental Parasitology, 2019, 204, 107728.	0.5	0
983	The host cell secretory pathway mediates the export of Leishmania virulence factors out of the parasitophorous vacuole. PLoS Pathogens, 2019, 15, e1007982.	2.1	36
984	¹⁸ F-FDG PET/CT in visceral leishmaniasis: uptake patterns in the context of a multiannual outbreak in Northern Italy. Annals of Nuclear Medicine, 2019, 33, 716-723.	1.2	7
985	Nutritional status of visceral leishmaniasis patients: A comparative cross-sectional study. Clinical Nutrition ESPEN, 2019, 33, 139-142.	0.5	5
986	BLIMP-1 Plays Important Role in the Regulation of Macrophage Pyroptosis for the Growth and Multiplication of <i>Leishmania donovani</i> . ACS Infectious Diseases, 2019, 5, 2087-2095.	1.8	10

#	ARTICLE	IF	CITATIONS
987	High levels of serum glycans monovalent IgG immune complexes detected by dissociative <scp>ELISA</scp> in experimental visceral leishmaniasis. Immunology, 2019, 158, 314-321.	2.0	5
988	A Versatile Pre and Post Ugi Modification for the Synthesis of Natural Product Inspired Fused Peptideâ€Carboline Scaffolds as Potential Antiâ€Leishmanial Agents. ChemistrySelect, 2019, 4, 12260-12267.	0.7	5
989	Recent Advances in the Discovery of Novel Antiprotozoal Agents. Molecules, 2019, 24, 3886.	1.7	38
990	Prevalence of cutaneous leishmaniasis in different regions of Larestan and its relationship with public health condition during 2014â€2015. Gene Reports, 2019, 17, 100530.	0.4	1
991	Recombinant Cysteine Proteinase B from Leishmania braziliensis and Its Domains: Promising Antigens for Serodiagnosis of Cutaneous and Visceral Leishmaniasis in Dogs. Journal of Clinical Microbiology, 2019, 57, .	1.8	2
992	Meta-taxonomic analysis of prokaryotic and eukaryotic gut flora in stool samples from visceral leishmaniasis cases and endemic controls in Bihar State India. PLoS Neglected Tropical Diseases, 2019, 13, e0007444.	1.3	37
993	Heme synthesis through the life cycle of the heme auxotrophic parasite <i>Leishmania major</i>. FASEB Journal, 2019, 33, 13367-13385.	0.2	15
994	Ability of real-time PCR for differential diagnosis of various forms of cutaneous leishmaniasis: a comparative study with histopathology. BMC Research Notes, 2019, 12, 615.	0.6	8
996	Micellar curcumin improves the antibacterial activity of the alkylphosphocholines erufosine and miltefosine against pathogenic<i>Staphylococcus aureus</i> strains. Biotechnology and Biotechnological Equipment, 2019, 33, 38-53.	0.5	18
997	Visceral Leishmaniasis. Infectious Disease Clinics of North America, 2019, 33, 79-99.	1.9	99
998	Cell death pathways in pathogenic trypanosomatids: lessons of (over)kill. Cell Death and Disease, 2019, 10, 93.	2.7	82
999	Synthesis, Biological Evaluation, Structureâ€Activity Relationship, and Mechanism of Action Studies of Quinolineâ€Metronidazole Derivatives Against Experimental Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2019, 62, 5655-5671.	2.9	40
1000	Arab worldâ€™s growing contribution to global leishmaniasis research (1998â€2017): a bibliometric study. BMC Public Health, 2019, 19, 625.	1.2	17
1001	Targeted delivery of antimicrobial peptide by Cry protein crystal to treat intramacrophage infection. Biomaterials, 2019, 217, 119286.	5.7	30
1002	Allergic contact dermatitis caused by paromomycin. Contact Dermatitis, 2019, 81, 393-394.	0.8	5
1003	Non-canonical NLRP3 inflammasome activation and IL-1 ^{Î²} signaling are necessary to L. amazonensis control mediated by P2X7 receptor and leukotriene B4. PLoS Pathogens, 2019, 15, e1007887.	2.1	38
1004	Novel Therapeutic Approaches for the Treatment of Leishmaniasis. , 2019, , 263-300.		0
1005	Mitochondrial proteome profiling of Leishmania tropica. Microbial Pathogenesis, 2019, 133, 103542.	1.3	7

#	ARTICLE	IF	CITATIONS
1006	Diffuse cutaneous leishmaniasis with oral involvement in a patient of Northern Mexico. <i>Tropical Doctor</i> , 2019, 49, 303-306.	0.2	2
1007	CD4+ T Cell-Mediated Immunity against the Phagosomal Pathogen <i>Leishmania</i> : Implications for Vaccination. <i>Trends in Parasitology</i> , 2019, 35, 423-435.	1.5	42
1008	A novel multilocus sequence typing scheme identifying genetic diversity amongst <i>Leishmania donovani</i> isolates from a genetically homogeneous population in the Indian subcontinent. <i>International Journal for Parasitology</i> , 2019, 49, 555-567.	1.3	15
1009	Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	30
1010	Asymptomatic <i>Leishmania</i> infection in blood donors from the Southern of Spain. <i>Infection</i> , 2019, 47, 739-747.	2.3	12
1011	Quercetin promotes antipromastigote effect by increasing the ROS production and anti-amastigote by upregulating Nrf2/HO-1 expression, affecting iron availability. <i>Biomedicine and Pharmacotherapy</i> , 2019, 113, 108745.	2.5	43
1012	Diel periodicity and visual cues guide oviposition behavior in <i>Phlebotomus papatasi</i> , vector of old-world cutaneous leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007165.	1.3	9
1013	Synthesis of a novel brominated vinylic fatty acid with antileishmanial activity that effectively inhibits the <i>Leishmania</i> topoisomerase IB enzyme mediated by halogen bond formation. <i>Pure and Applied Chemistry</i> , 2019, 91, 1405-1416.	0.9	3
1014	Host and parasite responses in human diffuse cutaneous leishmaniasis caused by <i>L. amazonensis</i> . <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007152.	1.3	58
1015	Dynamic spatiotemporal modeling of the infected rate of visceral leishmaniasis in human in an endemic area of Amhara regional state, Ethiopia. <i>PLoS ONE</i> , 2019, 14, e0212934.	1.1	9
1016	<i>Leishmania</i> . <i>Methods in Molecular Biology</i> , 2019, , .	0.4	1
1017	Quantification of <i>Leishmania</i> Parasites in Murine Models of Visceral Infection. <i>Methods in Molecular Biology</i> , 2019, 1971, 289-301.	0.4	5
1018	Synthesis, Characterization, and Antileishmanial Activity of Certain Quinoline-4-carboxylic Acids. <i>Journal of Chemistry</i> , 2019, 2019, 1-9.	0.9	14
1019	Gene expression of some cytokines in patients with Cutaneous leishmaniasis in Al-Diwanyah province. <i>Journal of Physics: Conference Series</i> , 2019, 1294, 062094.	0.3	0
1020	Transcriptional Analysis of Human Skin Lesions Identifies Tryptophan-2,3-Deoxygenase as a Restriction Factor for Cutaneous <i>Leishmania</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 338.	1.8	14
1021	Differential immune response modulation in early <i>Leishmania amazonensis</i> infection of BALB/c and C57BL/6 macrophages based on transcriptome profiles. <i>Scientific Reports</i> , 2019, 9, 19841.	1.6	24
1022	Pathogenic <i>Leishmania</i> spp. detected in lizards from Northwest China using molecular methods. <i>BMC Veterinary Research</i> , 2019, 15, 446.	0.7	11
1023	Expression of a rK39 homologue from an Iranian <i>Leishmania infantum</i> isolate in <i>Leishmania tarentolae</i> for serodiagnosis of visceral leishmaniasis. <i>Parasites and Vectors</i> , 2019, 12, 593.	1.0	10

#	ARTICLE	IF	CITATIONS
1024	Induction of miR 21 impairs the anti-Leishmania response through inhibition of IL-12 in canine splenic leukocytes. <i>PLoS ONE</i> , 2019, 14, e0226192.	1.1	16
1025	<i>Leishmania donovani</i> evades Caspase 1 dependent host defense mechanism during infection. <i>International Journal of Biological Macromolecules</i> , 2019, 126, 392-401.	3.6	13
1026	Synthesis of novel quinoline-based thiadiazole, evaluation of their antileishmanial potential and molecular docking studies. <i>Bioorganic Chemistry</i> , 2019, 85, 109-116.	2.0	25
1027	Synthesis and comparison of antileishmanial and cytotoxic activities of S-(α)-limonene benzaldehyde thiosemicarbazones with their R-(+)-analogues. <i>Journal of Molecular Structure</i> , 2019, 1179, 252-262.	1.8	19
1028	Microneedle-Based Delivery of Amphotericin B for Treatment of Cutaneous Leishmaniasis. <i>Biomedical Microdevices</i> , 2019, 21, 8.	1.4	18
1029	An Unusual Cause of Acute Severe Hepatitis. <i>Gastroenterology</i> , 2019, 156, e3-e4.	0.6	6
1030	Gene expression analysis of antimony resistance in <i>Leishmania tropica</i> using quantitative real-time PCR focused on genes involved in trypanothione metabolism and drug transport. <i>Archives of Dermatological Research</i> , 2019, 311, 9-17.	1.1	25
1031	Gene expression profile of cytokines produced in biopsies from patients with American cutaneous leishmaniasis. <i>Acta Tropica</i> , 2019, 189, 69-75.	0.9	6
1032	Ethnopharmacology, phytochemistry, biological activities, and therapeutic applications of <i>Cedrela serrata</i> Royle: A mini review. <i>Journal of Ethnopharmacology</i> , 2020, 246, 112206.	2.0	5
1033	Cutaneous leishmaniasis: A great imitator. <i>Clinics in Dermatology</i> , 2020, 38, 140-151.	0.8	59
1034	Lipid nanoparticles for amphotericin delivery in the treatment of American tegumentary leishmaniasis. <i>Drug Delivery and Translational Research</i> , 2020, 10, 403-412.	3.0	8
1035	Novel functionalized 1,2,3-triazole derivatives exhibit antileishmanial activity, increase in total and mitochondrial-ROS and depolarization of mitochondrial membrane potential of <i>Leishmania amazonensis</i> . <i>Chemico-Biological Interactions</i> , 2020, 315, 108850.	1.7	22
1037	2-furyl(phenyl)methanol isolated from <i>Atractilis gummifera</i> rhizome exhibits anti-leishmanial activity. <i>FÄ-toterapÄ-Äç</i> , 2020, 140, 104420.	1.1	1
1038	1,4-Disubstituted-1,2,3-Triazole Compounds Induce Ultrastructural Alterations in <i>Leishmania amazonensis</i> Promastigote: An in Vitro Antileishmanial and in Silico Pharmacokinetic Study. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6839.	1.8	21
1039	Genetic variability of molecules involved in the disease pathogenesis in <i>Leishmania</i> infection. <i>Experimental Parasitology</i> , 2020, 218, 108007.	0.5	4
1040	Integrative genomic, proteomic and phenotypic studies of <i>Leishmania donovani</i> strains revealed genetic features associated with virulence and antimony-resistance. <i>Parasites and Vectors</i> , 2020, 13, 510.	1.0	10
1041	Cytokines and metabolic regulation: A framework of bidirectional influences affecting <i>Leishmania</i> infection. <i>Cytokine</i> , 2021, 147, 155267.	1.4	7
1042	Review on the Role of Host Immune Response in Protection and Immunopathogenesis during Cutaneous Leishmaniasis Infection. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	28

#	ARTICLE	IF	CITATIONS
1043	Frequency of <i>Leishmania</i> spp. infection among HIV-infected patients living in an urban area in Brazil: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2020, 20, 885.	1.3	6
1044	The potential of live attenuated vaccines against Cutaneous Leishmaniasis. <i>Experimental Parasitology</i> , 2020, 210, 107849.	0.5	22
1045	Can We Harness Immune Responses to Improve Drug Treatment in Leishmaniasis?. <i>Microorganisms</i> , 2020, 8, 1069.	1.6	16
1046	Protein glycosylation in <i>Leishmania</i> spp.. <i>Molecular Omics</i> , 2020, 16, 407-424.	1.4	17
1047	Sensing Host Arginine Is Essential for <i>Leishmania</i> Parasites'™ Intracellular Development. <i>MBio</i> , 2020, 11, .	1.8	17
1048	Modulation of Cytokines and Extracellular Matrix Proteins Expression by <i>Leishmania amazonensis</i> in Susceptible and Resistant Mice. <i>Frontiers in Microbiology</i> , 2020, 11, 1986.	1.5	10
1049	Primera aproximación a la fauna flebotomínea (Psychodidae: Phlebotominae) del departamento de Atlántico. <i>Acta Biologica Colombiana</i> , 2020, 25, 284-292.	0.1	1
1050	Optimized DNA-based biosensor for monitoring <i>Leishmania infantum</i> in human plasma samples using biomacromolecular interaction: a novel platform for infectious disease diagnosis. <i>Analytical Methods</i> , 2020, 12, 4759-4768.	1.3	25
1051	Cellular and molecular mechanisms of DEET toxicity and disease-carrying insect vectors: a review. <i>Genes and Genomics</i> , 2020, 42, 1131-1144.	0.5	11
1052	In-depth quantitative proteomics uncovers specie-specific metabolic programs in <i>Leishmania</i> (Viannia) species. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008509.	1.3	10
1053	The role of senescent T cells in immunopathology. <i>Aging Cell</i> , 2020, 19, e13272.	3.0	50
1054	Activity of paromomycin against <i>Leishmania amazonensis</i> : Direct correlation between susceptibility in vitro and the treatment outcome in vivo. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2020, 14, 91-98.	1.4	10
1055	Macrophages as host, effector and immunoregulatory cells in leishmaniasis: Impact of tissue micro-environment and metabolism. <i>Cytokine: X</i> , 2020, 2, 100041.	0.5	58
1056	A spotlight on the diagnostic methods of a fatal disease Visceral Leishmaniasis. <i>Parasite Immunology</i> , 2020, 42, e12727.	0.7	33
1057	Prognostic factors for mortality among patients with visceral leishmaniasis in East Africa: Systematic review and meta-analysis. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008319.	1.3	10
1058	Systems Studies Uncover miR-146a as a Target in <i>Leishmania major</i> Infection Model. <i>ACS Omega</i> , 2020, 5, 12516-12526.	1.6	21
1060	Genetic validation of <i>Leishmania</i> genes essential for amastigote survival in vivo using N-myristoyltransferase as a model. <i>Parasites and Vectors</i> , 2020, 13, 132.	1.0	10
1061	In Vivo Infection with <i>Leishmania amazonensis</i> to Evaluate Parasite Virulence in Mice. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	3

#	ARTICLE	IF	CITATIONS
1062	Leishmaniasis immunopathologyâ€™ impact on design and use of vaccines, diagnostics and drugs. <i>Seminars in Immunopathology</i> , 2020, 42, 247-264.	2.8	51
1063	Sugar-based colloidal nanocarriers for topical meglumine antimoniate application to cutaneous leishmaniasis treatment: Ex vivo cutaneous retention and in vivo evaluation. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 147, 105295.	1.9	13
1064	Visceral Leishmaniasis in a Liver Transplant Patient: A Case Report. <i>Transplantation Proceedings</i> , 2020, 52, 1417-1421.	0.3	4
1065	The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 647-658.	2.5	5
1066	Development and Characterization of an Avirulent <i>Leishmania major</i> Strain. <i>Journal of Immunology</i> , 2020, 204, 2734-2753.	0.4	10
1067	Post kala-azar dermal leishmaniasis: A threat to elimination program. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008221.	1.3	42
1068	The potential role of nicotinamide on <i>Leishmania tropica</i> : An assessment of inhibitory effect, cytokines gene expression and arginase profiling. <i>International Immunopharmacology</i> , 2020, 86, 106704.	1.7	12
1069	The effect of UV radiation in the presence of TiO ₂ -NPs on <i>Leishmania major</i> promastigotes. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129558.	1.1	12
1070	Chitin binding protein as a possible RNA binding protein in <i>Leishmania</i> parasites. <i>Pathogens and Disease</i> , 2020, 78, .	0.8	2
1071	Bioinformatics analyses of immunogenic T-cell epitopes of LelF and PpSP15 proteins from <i>Leishmania major</i> and sand fly saliva used as model antigens for the design of a multi-epitope vaccine to control leishmaniasis. <i>Infection, Genetics and Evolution</i> , 2020, 80, 104189.	1.0	11
1072	Leishmaniadualâ€™specificity tyrosineâ€™regulated kinase 1 (DYRK1) is required for sustainingLeishmaniastationary phase phenotype. <i>Molecular Microbiology</i> , 2020, 113, 983-1002.	1.2	7
1073	N-acetyl-L-cysteine reduces <i>Leishmania amazonensis</i> -induced inflammation in BALB/c mice. <i>BMC Veterinary Research</i> , 2020, 16, 13.	0.7	6
1074	Application of laser for treatment of cutaneous leishmaniasis: a review of literature. <i>Lasers in Medical Science</i> , 2020, 35, 1451-1457.	1.0	7
1075	Cytotoxicity of 4-substituted quinoline derivatives: Anticancer and antileishmanial potential. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115511.	1.4	30
1076	Regulation of Translation in the Protozoan Parasite <i>Leishmania</i> . <i>International Journal of Molecular Sciences</i> , 2020, 21, 2981.	1.8	24
1077	Elucidation of the interaction between human serum albumin (HSA) and 3,4-methylenedioxy-6-iodo-benzaldehyde-thiosemicarbazone, a potential drug for <i>Leishmania amazonensis</i> : Multiple spectroscopic and dynamics simulation approach. <i>Journal of Molecular Liquids</i> , 2020. 310. 113117.	2.3	24
1078	Immune Profile of the Nasal Mucosa in Patients with Cutaneous Leishmaniasis. <i>Infection and Immunity</i> , 2020, 88, .	1.0	5
1079	Evaluation of potential drugs against leishmaniasis targeting catalytic subunit of <i>Leishmania donovani</i> nuclear DNA primase using ligand based virtual screening, docking and molecular dynamics approaches. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 1838-1852.	2.0	13

#	ARTICLE	IF	CITATIONS
1080	Prevalence and Risk Factors of Human Leishmaniasis in Ethiopia: A Systematic Review and Meta-Analysis. <i>Infectious Diseases and Therapy</i> , 2021, 10, 47-60.	1.8	10
1081	The Effect of <i>Naja naja oxiana</i> Snake Venom Against <i>Leishmania tropica</i> Confirmed by Advanced Assays. <i>Acta Parasitologica</i> , 2021, 66, 475-486.	0.4	6
1082	<i>Leishmania infantum</i> Infection in a Domestic Cat: A Real Threat or an Occasional Finding?. <i>Acta Parasitologica</i> , 2021, 66, 673-676.	0.4	10
1083	Leishmanial CpG DNA nanovesicles: A propitious prophylactic approach against visceral leishmaniasis. <i>International Immunopharmacology</i> , 2021, 90, 107181.	1.7	9
1084	Quantitative analysis of proteins secreted by <i>Leishmania (Viannia) braziliensis</i> strains associated to distinct clinical manifestations of American Tegumentary Leishmaniasis. <i>Journal of Proteomics</i> , 2021, 232, 104077.	1.2	10
1085	Enhanced production of pro-inflammatory cytokines and chemokines in Ethiopian cutaneous leishmaniasis upon exposure to <i>Leishmania aethiopica</i> . <i>Cytokine</i> , 2021, 145, 155289.	1.4	1
1087	Leishmaniasis. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, S166-S170.	0.3	4
1088	Differential expression of miRNAs in canine peripheral blood mononuclear cells (PBMC) exposed to <i>Leishmania infantum</i> in vitro. <i>Research in Veterinary Science</i> , 2021, 134, 58-63.	0.9	6
1090	Antileishmanial Activity of Lignans, Neolignans, and Other Plant Phenols. <i>Progress in the Chemistry of Organic Natural Products</i> , 2021, 115, 115-176.	0.8	1
1092	Vaccine as immunotherapy for leishmaniasis. , 2021, , 29-46.		0
1093	Leishmaniasis and Trace Element Alterations: a Systematic Review. <i>Biological Trace Element Research</i> , 2021, 199, 3918-3938.	1.9	9
1094	Drug resistance and repurposing of existing drugs in Leishmaniasis. , 2021, , 103-124.		3
1095	Leishmaniasis: an overview of evolution, classification, distribution, and historical aspects of parasite and its vector. , 2021, , 1-25.		3
1096	Cynaroside inhibits <i>Leishmania donovani</i> UDP-galactopyranose mutase and induces reactive oxygen species to exert antileishmanial response. <i>Bioscience Reports</i> , 2021, 41, .	1.1	11
1097	Interferon- β : a key cytokine in leishmaniasis. , 2021, , 197-208.		1
1099	Diversity, distribution and natural <i>Leishmania</i> infection of sand flies from communities along the Interoceanic Highway in the Southeastern Peruvian Amazon. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009000.	1.3	2
1100	Evolution of antigen-specific immune responses in cutaneous leishmaniasis patients. <i>Parasite Immunology</i> , 2021, 43, e12814.	0.7	0
1101	2-aminobenzimidazoles for leishmaniasis: From initial hit discovery to in vivo profiling. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009196.	1.3	8

#	ARTICLE	IF	CITATIONS
1102	Antileishmanial Evaluation of Bark Methanolic Extract of <i>Acacia nilotica</i> : In Vitro and In Silico Studies. ACS Omega, 2021, 6, 8548-8560.	1.6	16
1103	New Epidemiological Aspects of Animal Leishmaniasis in Europe: The Role of Vertebrate Hosts Other Than Dogs. Pathogens, 2021, 10, 307.	1.2	35
1104	Epidemiological and genetic characteristics of asymptomatic canine leishmaniasis and implications for human Leishmania infections in Egypt. Zoonoses and Public Health, 2021, 68, 413-430.	0.9	5
1105	HLA-DRB1 Alleles Associated with Lower Leishmaniasis Susceptibility Share Common Amino Acid Polymorphisms and Epitope Binding Repertoires. Vaccines, 2021, 9, 270.	2.1	5
1106	The Impact of Neutrophil Recruitment to the Skin on the Pathology Induced by Leishmania Infection. Frontiers in Immunology, 2021, 12, 649348.	2.2	25
1107	Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review. PLoS Neglected Tropical Diseases, 2021, 15, e0009099.	1.3	32
1108	Comparison between cutaneous leishmaniasis patients with facial and non-facial lesions. International Journal of Dermatology, 2021, 60, 1109-1113.	0.5	1
1109	Repurposing of FDA-approved drugs as inhibitors of sterol C ₂₄ methyltransferase of <i>Leishmania donovani</i> to fight against leishmaniasis. Drug Development Research, 2021, 82, 1154-1161.	1.4	13
1110	The Association Between the Syrian Crisis and Cutaneous Leishmaniasis in Lebanon. Acta Parasitologica, 2021, 66, 1240-1245.	0.4	9
1111	Spatiotemporal patterns and spatial risk factors for visceral leishmaniasis from 2007 to 2017 in Western and Central China: A modelling analysis. Science of the Total Environment, 2021, 764, 144275.	3.9	18
1112	Characterization of Glycoside Hydrolase Families 13 and 31 Reveals Expansion and Diversification of Î±-Amylase Genes in the Phlebotomine <i>Lutzomyia longipalpis</i> and Modulation of Sandfly Glycosidase Activities by Leishmania Infection. Frontiers in Physiology, 2021, 12, 635633.	1.3	11
1114	Complement protein C1q binds soluble antigens of <i>Leishmania major</i> (SLA) via the globular head region, activates the classical pathway, and modulates macrophage immune response. Journal of King Saud University - Science, 2021, 33, 101365.	1.6	3
1115	Design, Synthesis of Biaryl Piperidine Derivatives and Their Evaluation as Potential Antileishmanial Agents against <i>Leishmania donovani</i> Strain Ag83. Chemistry and Biodiversity, 2021, 18, e2100105.	1.0	3
1116	Unexpected Role of Sterol Synthesis in RNA Stability and Translation in <i>Leishmania</i> . Biomedicines, 2021, 9, 696.	1.4	3
1117	In Vitro and In Vivo Anti-parasitic Activity of Artemisinin Combined With Glucantime and Shark Cartilage Extract on Iranian Strain of <i>Leishmania major</i> (MRHO/IR/75/ER). Jundishapur Journal of Microbiology, 2021, 14, .	0.2	2
1118	Alkaloids in Contemporary Drug Discovery to Meet Global Disease Needs. Molecules, 2021, 26, 3800.	1.7	28
1119	Purinergic signaling: A new front-line determinant of resistance and susceptibility in leishmaniasis. Biomedical Journal, 2021, . .	1.4	4
1120	Preparation and Characterization of A Nanoliposomal Vaccine of pLACK Candidate Against Cutaneous Leishmaniasis. Infectious Disorders - Drug Targets, 2021, 21, 527-533.	0.4	2

#	ARTICLE	IF	CITATIONS
1121	Chemotaxonomic and biological potential of highly therapeutic plant <i>Pedicularis groenlandica</i> Retz. using multiple microscopic techniques. <i>Microscopy Research and Technique</i> , 2021, 84, 2890-2905.	1.2	15
1122	Leishmaniasis through the lens of the host. <i>Bios</i> , 2021, 91, .	0.0	0
1123	Relapsing leishmanial arthritis: report of a tricky localization and evidence of miltefosine diffusion in synovial fluid. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2740-2741.	1.3	1
1124	Metabolomic Reprogramming of C57BL/6-Macrophages during Early Infection with <i>L. amazonensis</i> . <i>International Journal of Molecular Sciences</i> , 2021, 22, 6883.	1.8	11
1125	Prevalence and associated risk factors of <i>Leishmania</i> infection among immunocompetent hosts, a community-based study in Chiang Rai, Thailand. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009545.	1.3	17
1126	Hematological Changes in Dogs with Visceral Leishmaniasis Are Associated with Increased IFN- γ and TNF Gene Expression Levels in the Bone Marrow. <i>Microorganisms</i> , 2021, 9, 1618.	1.6	6
1127	Comparative genomics of <i>Leishmania</i> isolates from Brazil confirms the presence of <i>Leishmania major</i> in the Americas. <i>International Journal for Parasitology</i> , 2021, 51, 1047-1057.	1.3	7
1128	Micro-CT visualization of a promastigote secretory gel (PSG) and parasite plug in the digestive tract of the sand fly <i>Lutzomyia longipalpis</i> infected with <i>Leishmania mexicana</i> . <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009682.	1.3	4
1129	Novel azoles with potent antileishmanial activity. <i>Future Microbiology</i> , 2021, 16, 871-877.	1.0	1
1130	Cysteine proteases: Battling pathogenic parasitic protozoans with omnipresent enzymes. <i>Microbiological Research</i> , 2021, 249, 126784.	2.5	17
1131	Evaluation of Cellular Immune Responses in Dogs Immunized with Alum-Precipitated Autoclaved <i>Leishmania major</i> along with BCG and Imiquimod. <i>Iranian Journal of Parasitology</i> , 2021, 16, 348-356.	0.6	0
1132	Early Leukocyte Responses in Ex-Vivo Models of Healing and Non-Healing Human <i>Leishmania (Viannia) panamensis</i> Infections. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 687607.	1.8	2
1133	Recurrence and Driving Factors of Visceral Leishmaniasis in Central China. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9535.	1.2	7
1134	Characterization of sand fly breeding sites in district Malakand, Khyber Pakhtunkhwa, Pakistan, and evaluation of risk factors for cutaneous leishmaniasis in the region. <i>Zoonoses and Public Health</i> , 2022, 69, 33-45.	0.9	3
1136	An overview of the fatty acid biosynthesis in the protozoan parasite <i>Leishmania</i> and its relevance as a drug target against leishmaniasis. <i>Molecular and Biochemical Parasitology</i> , 2021, 246, 111416.	0.5	7
1137	Recent advancements in anti-leishmanial research: Synthetic strategies and structural activity relationships. <i>European Journal of Medicinal Chemistry</i> , 2021, 223, 113606.	2.6	22
1138	Systems biology and bioinformatics approaches in leishmaniasis. , 2021, , 509-548.		6
1139	Use of ¹³ C Stable Isotope Labelling for Pathway and Metabolic Flux Analysis in <i>Leishmania</i> Parasites. <i>Methods in Molecular Biology</i> , 2015, 1201, 281-296.	0.4	12

#	ARTICLE	IF	CITATIONS
1140	Screening <i>Leishmania donovani</i> Complex-Specific Genes Required for Visceral Disease. <i>Methods in Molecular Biology</i> , 2015, 1201, 339-361.	0.4	4
1141	A2 and Other Visceralizing Proteins of <i>Leishmania</i> : Role in Pathogenesis and Application for Vaccine Development. <i>Sub-Cellular Biochemistry</i> , 2014, 74, 77-101.	1.0	11
1142	Drugs Acting on Infectious Organisms. , 2006, , 87-160.		1
1143	Other viral and infectious diseases and HIV-related liver disease. , 2012, , 403-466.		8
1144	Infectious diseases of the skin. , 2012, , 760-895.		12
1145	<i>Leishmania</i> Species (Leishmaniasis). , 2012, , 1285-1291.e2.		3
1146	Synthesis, crystal structure, cytotoxic, antileishmanial activities and docking studies on N,Nâ€²-(ethane-1,2-diyl)bis(3-methylbenzamide). <i>Journal of Molecular Structure</i> , 2018, 1156, 627-631.	1.8	6
1148	Oviposition-Site Selection of <i>Phlebotomus papatasi</i> (Diptera: Psychodidae) Sand Flies: Attraction to Bacterial Isolates From an Attractive Rearing Medium. <i>Journal of Medical Entomology</i> , 2021, 58, 518-527.	0.9	10
1149	Management of Old World Cutaneous Leishmaniasis in Refugee Children. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 357-359.	1.1	6
1151	Application of Quantum Dots to the Study of Liposome Targeting in Leishmaniasis and Malaria. <i>International Journal of Theoretical and Applied Nanotechnology</i> , 0, , .	0.0	3
1152	The Parasite Point of View: Insights and Questions on the Cell Biology of <i>Trypanosoma</i> and <i>Leishmania</i> Parasite-Phagocyte Interactions. , 0, , 453-462.		3
1153	A case of severe visceral leishmaniasis resulting from travel to Greece. <i>BMJ Case Reports</i> , 2009, 2009, bcr0620092036-bcr0620092036.	0.2	2
1154	Leishmaniasis in Uganda: historical account and a review of the literature. <i>Pan African Medical Journal</i> , 2014, 18, 16.	0.3	7
1155	IL-17 and IL-22 are associated with protection against human kala azar caused by <i>Leishmania donovani</i> . <i>Journal of Clinical Investigation</i> , 2009, 119, 2379-87.	3.9	196
1156	<i>Leishmania</i> carbon metabolism in the macrophage phagolysosome- feast or famine?. <i>F1000Research</i> , 2015, 4, 938.	0.8	71
1157	Plasticity of the <i>Leishmania</i> genome leading to gene copy number variations and drug resistance. <i>F1000Research</i> , 2016, 5, 2350.	0.8	111
1158	Medicinal Plant <i>Scrophularia striata</i> Evaluation Anti-parasitic Effects on <i>Leishmania major</i> : In vitro and In vivo Study. <i>Biosciences, Biotechnology Research Asia</i> , 2014, 11, 627-634.	0.2	6
1159	A Genomic-Based Approach Combining In Vivo Selection in Mice to Identify a Novel Virulence Gene in <i>Leishmania</i> . <i>PLoS Neglected Tropical Diseases</i> , 2008, 2, e248.	1.3	25

#	ARTICLE	IF	CITATIONS
1160	Marring Leishmaniasis: The Stigmatization and the Impact of Cutaneous Leishmaniasis in Pakistan and Afghanistan. <i>PLoS Neglected Tropical Diseases</i> , 2008, 2, e259.	1.3	114
1161	The Neglected Tropical Diseases of Latin America and the Caribbean: A Review of Disease Burden and Distribution and a Roadmap for Control and Elimination. <i>PLoS Neglected Tropical Diseases</i> , 2008, 2, e300.	1.3	562
1162	Comparative Expression Profiling of Leishmania: Modulation in Gene Expression between Species and in Different Host Genetic Backgrounds. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e476.	1.3	86
1163	Kinetic Analysis of Ex Vivo Human Blood Infection by Leishmania. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e743.	1.3	20
1164	A Luciferase-Expressing <i>Leishmania braziliensis</i> Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004660.	1.3	17
1165	Characterization of a Novel Endoplasmic Reticulum Protein Involved in Tubercidin Resistance in <i>Leishmania major</i> . <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004972.	1.3	11
1166	Sterol 14 α -demethylase mutation leads to amphotericin B resistance in <i>Leishmania mexicana</i> . <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005649.	1.3	43
1167	Spatial distribution, <i>Leishmania</i> species and clinical traits of Cutaneous Leishmaniasis cases in the Colombian army. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005876.	1.3	53
1168	Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005951.	1.3	36
1169	Tegumentary leishmaniasis and coinfections other than HIV. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006125.	1.3	33
1170	Infectivity of <i>Leishmania mexicana</i> Is Associated with Differential Expression of Protein Kinase C-Like Triggered during a Cell-Cell Contact. <i>PLoS ONE</i> , 2009, 4, e7581.	1.1	21
1171	DETC Induces <i>Leishmania</i> Parasite Killing in Human In Vitro and Murine In Vivo Models: A Promising Therapeutic Alternative in Leishmaniasis. <i>PLoS ONE</i> , 2010, 5, e14394.	1.1	40
1172	Intracellular Targeting Specificity of Novel Phthalocyanines Assessed in a Host-Parasite Model for Developing Potential Photodynamic Medicine. <i>PLoS ONE</i> , 2011, 6, e20786.	1.1	43
1173	Benzaldehyde Thiosemicarbazone Derived from Limonene Complexed with Copper Induced Mitochondrial Dysfunction in <i>Leishmania amazonensis</i> . <i>PLoS ONE</i> , 2012, 7, e41440.	1.1	34
1174	Functional Analysis of <i>Leishmania</i> Cyclopropane Fatty Acid Synthetase. <i>PLoS ONE</i> , 2012, 7, e51300.	1.1	25
1175	<i>Leishmania donovani</i> Infection Induces Anemia in Hamsters by Differentially Altering Erythropoiesis in Bone Marrow and Spleen. <i>PLoS ONE</i> , 2013, 8, e59509.	1.1	36
1176	Proteomic and Genomic Analyses of Antimony Resistant <i>Leishmania infantum</i> Mutant. <i>PLoS ONE</i> , 2013, 8, e81899.	1.1	63
1177	Detection and Characterization of <i>Leishmania</i> (<i>Leishmania</i>) and <i>Leishmania</i> (<i>Viannia</i>) by SYBR Green-Based Real-Time PCR and High Resolution Melt Analysis Targeting Kinetoplast Minicircle DNA. <i>PLoS ONE</i> , 2014, 9, e88845.	1.1	76

#	ARTICLE	IF	CITATIONS
1178	Quinone-Amino Acid Conjugates Targeting Leishmania Amino Acid Transporters. PLoS ONE, 2014, 9, e107994.	1.1	18
1179	Pterocarpanquinone LQB-118 Induces Apoptosis in Leishmania (Viannia) braziliensis and Controls Lesions in Infected Hamsters. PLoS ONE, 2014, 9, e109672.	1.1	20
1180	Prediction of T Cell Epitopes from Leishmania major Potentially Excreted/Secreted Proteins Inducing Granzyme B Production. PLoS ONE, 2016, 11, e0147076.	1.1	10
1181	Control of Cutaneous Leishmaniasis Using Geographic Information Systems from 2010 to 2014 in Khuzestan Province, Iran. PLoS ONE, 2016, 11, e0159546.	1.1	9
1182	Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia. PLoS ONE, 2017, 12, e0178996.	1.1	5
1183	A community survey on the knowledge of neglected tropical diseases in Cameroon. International Journal of Medicine and Biomedical Research, 2012, 1, 131-140.	0.0	9
1184	Ethanol extract of Croton blanchetianus Ball induces mitochondrial defects in Leishmania amazonensis promastigotes. Anais Da Academia Brasileira De Ciencias, 2020, 92, e20180968.	0.3	3
1185	Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2009, 51, 231-236.	0.5	12
1187	Effects of Bothrops moojeni venom on Leishmania amazonensis promastigote forms. Journal of Venomous Animals and Toxins Including Tropical Diseases, 2011, 17, 150-158.	0.8	4
1188	Comparison Between Intralesional Meglumine Antimoniate and Combination of Trichloroacetic Acid 50% and Intralesional Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis: A Randomized Clinical Trial. Journal of Skin and Stem Cell, 2014, 1, .	0.1	2
1189	The Effect of Educational Intervention on Preventive Behaviors towards Cutaneous Leishmaniasis at Kharameh City in 2014. Shiraz E Medical Journal, 2016, 17, .	0.1	14
1190	Comparative Expression Profile Analysis of Apoptosis-Related miRNA and Its Target Gene in Leishmania major Infected Macrophages. Iranian Journal of Parasitology, 2020, 15, 332-340.	0.6	7
1191	Lived Experiences of Patients Suffering from Acute Old World Cutaneous Leishmaniasis: A Qualitative Content Analysis Study from Iran. Iranian Journal of Arthropod-borne Diseases, 0, , 180-195.	0.8	16
1192	Repurposing Glyburide as Antileishmanial Agent to Fight Against Leishmaniasis. Protein and Peptide Letters, 2019, 26, 371-376.	0.4	6
1193	Nanoparticles Loaded with a New Thiourea Derivative: Development and In vitro Evaluation Against Leishmania amazonensis. Current Drug Delivery, 2020, 17, 694-702.	0.8	4
1194	Bioactive Natural and Synthetic Peroxides for the Treatment of Helminth and Protozoan Pathogens: Synthesis and Properties. Current Topics in Medicinal Chemistry, 2019, 19, 1201-1225.	1.0	6
1195	Selected Natural and Synthetic Phenolic Compounds with Antileishmanial Activity: A Five-year Review. Current Bioactive Compounds, 2013, 8, 307-333.	0.2	10
1196	A Therapeutic Approach Against Leishmania donovani by Predicting RNAi Molecules Against the Surface Protein, gp63. Current Bioinformatics, 2019, 14, 541-550.	0.7	11

#	ARTICLE	IF	CITATIONS
1197	Conjugated Eicosapentaenoic Acid (cEPA) Inhibits <i>L. donovani</i> Topoisomerase I and has an Antiproliferative Activity Against <i>L. donovani</i> Promastigotes. <i>The Open Antimicrobial Agents Journal</i> , 2011, 3, 23-29.	0.2	6
1198	Cutaneous leishmaniasis caused by <i>Leishmania major</i> in Morocco: still a topical question. <i>Eastern Mediterranean Health Journal</i> , 2013, 19, 495-501.	0.3	17
1199	A molecular epidemiology survey of cutaneous leishmaniasis in patients referring to Parasitology Lab at Shiraz School of Medicine and the importance of PCR assay. <i>Pars of Jahrom University of Medical Sciences</i> , 2010, 8, 2-6.	0.1	3
1200	Viscerotropic growth pattern of <i>Leishmania tropica</i> in BALB/c mice is suggestive of a murine model for human viscerotropic leishmaniasis. <i>Korean Journal of Parasitology</i> , 2007, 45, 247.	0.5	17
1201	A Novel Organotellurium Compound (RT-01) as a New Antileishmanial Agent. <i>Korean Journal of Parasitology</i> , 2009, 47, 213.	0.5	35
1202	Cutaneous Leishmaniasis of the Eyelids: A Case Series with Molecular Identification and Literature Review. <i>Korean Journal of Parasitology</i> , 2016, 54, 787-792.	0.5	9
1203	Visceral leishmaniasis: a global overview. <i>Journal of Global Health Science</i> , 2020, 2, .	1.7	42
1204	In silico Studies on Complete Inhibition of Trypanothione Reductase of <i>Leishmania Infantum</i> by β -sitosterol and Antcin-A: Novel Target for Anti-leishmanial Activity. <i>American Journal of Biochemistry and Molecular Biology</i> , 2013, 3, 322-328.	0.6	2
1205	Comparative Effect of Topical Trichloroacetic Acid and Intralesional Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis. <i>International Journal of Pharmacology</i> , 2006, 2, 633-636.	0.1	15
1206	Bioactive Compounds and in vitro Antimicrobial Activities of Ethanol Stem Bark Extract of <i>Trilepisium madagascariense</i> DC.. <i>International Journal of Pharmacology</i> , 2018, 14, 901-912.	0.1	9
1207	Molecular Diagnosis of Clinical Isolates of Cutaneous Leishmaniasis Using ITS1 and KDNA Genes and Genetic Polymorphism of <i>Leishmania</i> in Kashan, Iran. <i>Pakistan Journal of Biological Sciences</i> , 2016, 19, 136-142.	0.2	8
1208	Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis. <i>Indian Journal of Dermatology</i> , 2014, 59, 631.	0.1	17
1209	Effect of hydroalcoholic extract of <i>Echinacea purpurea</i> in combination with meglumine antimoniate on treatment of <i>Leishmania major</i> -induced cutaneous leishmaniasis in BALB/c mice. <i>International Journal of Applied & Basic Medical Research</i> , 2017, 7, 53.	0.2	8
1210	Comparison of efficacy of two different concentrations of intralesional amphotericin B in the treatment of cutaneous leishmaniasis; A randomized controlled trial. <i>Indian Dermatology Online Journal</i> , 2019, 10, 627.	0.2	5
1211	Epidemiological, Biological and Clinical Aspects of Leishmaniasis with Special Emphasis on Busi Yasi in Suriname. <i>Journal of Clinical & Experimental Dermatology Research</i> , 2017, 08, .	0.1	7
1212	A Review on Biology, Epidemiology and Public Health Significance of Leishmaniasis. <i>Journal of Bacteriology & Parasitology</i> , 2013, 04, .	0.2	24
1213	Miltefosine Susceptibility and Resistance in <i>Leishmania</i> : From the Laboratory to the Field. <i>Journal of Tropical Diseases</i> , 2016, 04, .	0.1	3
1214	Public health aspects of visceral leishmaniasis in Montenegro. <i>Open Journal of Clinical Diagnostics</i> , 2013, 03, 195-201.	0.3	5

#	ARTICLE	IF	CITATIONS
1215	Variability of Cutaneous Leishmaniasis Lesions Is Not Associated with Genetic Diversity of <i>Leishmania tropica</i> in Khyber Pakhtunkhwa Province of Pakistan. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1489-1497.	0.6	4
1216	Regulatory T-Cell Dynamics in Cutaneous and Mucocutaneous Leishmaniasis due to <i>Leishmania braziliensis</i> . <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 753-758.	0.6	6
1217	ORAL REHYDRATION SOLUTION TO PREVENT NEPHROTOXICITY OF AMPHOTERICIN B. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 75, 1108-1112.	0.6	20
1218	A Randomized Clinical Trial Comparing Oral Azithromycin and Meglumine Antimoniate for the Treatment of American Cutaneous Leishmaniasis Caused by <i>Leishmania (Viannia) braziliensis</i> . <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 77, 640-646.	0.6	25
1219	Efficacy of Miltefosine for Bolivian Cutaneous Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 78, 210-211.	0.6	109
1220	Optimization of Microculture and Evaluation of Miniculture for the Isolation of <i>Leishmania</i> Parasites from Cutaneous Lesions in Peru. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 79, 847-852.	0.6	28
1221	Cutaneous Leishmaniasis with Boggy Induration and Simultaneous Mucosal Disease. <i>American Journal of Tropical Medicine and Hygiene</i> , 2009, 80, 3-5.	0.6	7
1222	Antimoniato de meglumine perilesional en leishmaniasis cutánea con falla terapéutica sistémica: serie de casos. <i>Gaceta Medica Boliviana</i> , 2019, 42, 74-78.	0.0	4
1223	Investigation of <i>Toxoplasma gondii</i> Infection in Cutaneous Leishmaniasis Patients of the Isfahan Province. <i>International Journal of Infection</i> , 2016, 4, .	0.4	4
1224	Recent Epidemiological Profile of Cutaneous Leishmaniasis in Iranian Military Personnel. <i>Journal of Archives in Military Medicine</i> , 2014, 2, .	0.0	1
1225	Isobologram Curve of Leishmanicidal Effects of Amiodarone and Ketoconazole. <i>Jundishapur Journal of Health Sciences</i> , 2017, 9, .	0.1	4
1226	Clinical, Histopathologic, and Cytologic Diagnosis of Mucosal Leishmaniasis and Literature Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 478-482.	1.2	55
1227	Evaluation of antiparasitic activity of hydroethanolic extracts from root, stem and leaf of <i>Bixa orellana</i> L. ON <i>Leishmania amazonensis</i> samples. <i>Revista Da Universidade Vale Do Rio Verde</i> , 2012, 10, 384-391.	0.1	3
1228	A gp63 based vaccine candidate against Visceral Leishmaniasis. <i>Bioinformation</i> , 2011, 5, 320-325.	0.2	19
1229	A comprehensive analysis of LACK (<i>Leishmania</i> homologue of receptors for activated C kinase) in the context of Visceral Leishmaniasis. <i>Bioinformation</i> , 2013, 9, 832-837.	0.2	8
1230	An analysis of phosphorylation sites in protein kinases from <i>Leishmania</i> . <i>Bioinformation</i> , 2016, 12, 249-253.	0.2	3
1231	<i>Leishmania amazonensis</i> promastigotes in 3D Collagen I culture: an <i>in vitro</i> physiological environment for the study of extracellular matrix and host cell interactions. <i>PeerJ</i> , 2014, 2, e317.	0.9	21
1232	Developing, Modifying, and Validating a TaqMan Real-Time PCR Technique for Accurate Identification of <i>Leishmania</i> Parasites Causing Most Leishmaniasis in Iran. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 731595.	1.8	8

#	ARTICLE	IF	CITATIONS
1233	An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106459.	1.1	32
1234	Multicomponent Reactions in the Synthesis of Antiviral Compounds. <i>Current Medicinal Chemistry</i> , 2022, 29, 2013-2050.	1.2	7
1235	Identification and Characterization of the miRNAs and Cytokines in Response to <i>Leishmania infantum</i> Infection with Different Response to Treatment. <i>Acta Parasitologica</i> , 2021, , 1.	0.4	2
1236	Network-Based Approaches Reveal Potential Therapeutic Targets for Host-Directed Antileishmanial Therapy Driving Drug Repurposing. <i>Microbiology Spectrum</i> , 2021, 9, e0101821.	1.2	9
1237	Biological synthesis of titanium dioxide nanoparticles from plants and microorganisms and their potential biomedical applications. <i>Inorganic Chemistry Communication</i> , 2021, 133, 108968.	1.8	29
1241	Viral, fungal, protozoal and helminthic infections. , 2008, , 225-249.		1
1242	<i>Leishmania</i> Species (Leishmaniasis). , 2008, , 1246-1253.		0
1244	Vector control in cutaneous leishmaniasis of the old world: A review of literature. <i>Dermatology Online Journal</i> , 2008, 14, .	0.2	14
1245	Células Dendríticas (CDs) diferenciadas a partir de Monocitos humanos como herramienta para el estudio de agentes antileishmaniales. <i>Nova</i> , 2008, 6, 162.	0.2	1
1246	PROTOZOAN AND HELMINTHIC INFECTIONS. , 2009, , 1171-1186.		1
1247	Protozoal Infections. , 2009, , 311-322.		0
1248	Amebic Liver Abscess and Other Protozoal Diseases. , 2010, , 843-848.		0
1249	Lymphadenopathy, splenomegaly and anemia in a returned traveler from Sudan. , 2010, , 1093-1095.		0
1251	Intracellular Bacteria and Protozoa. <i>Fundamental Biomedical Technologies</i> , 2011, , 745-811.	0.2	0
1252	A prática de diagnóstico no combate a tripanossomatídeos de importância médica: uma perspectiva terapêutica para doença de Chagas e Leishmaniose. <i>Journal of Tropical Pathology</i> , 2011, 40, .	0.1	0
1253	Nanomedicine in the Development of Drugs for Poverty-Related Diseases. , 2012, , 407-429.		0
1254	Viral, fungal, protozoal and helminthic infections. , 2012, , 213-239.		2
1256	Visceral Leishmaniosis: An Old Disease with Continuous Impact on Public Health. , 0, , .		1

#	ARTICLE	IF	CITATIONS
1258	Infectious Emergencies in Dermatology. , 2013, , 19-41.		0
1260	Immunology of Leishmania. SpringerBriefs in Immunology, 2013, , 13-27.	0.1	0
1263	Alkylphospholipids and Leishmaniasis. , 0, , .		0
1265	A Pediatric Case of Concomitant Leishmania and Brucella Infection. Guncel Pediatri, 2014, 12, 103-106.	0.1	0
1266	OBSERVATION ON TOXICITY OF INTRAVENOUS AMPHOTERICIN - B IN DIAGNOSED CASES OF KALA - AZAR IN DAILY VERSUS ALTERNATE DAY REGIMEN. Journal of Evidence Based Medicine and Healthcare, 2014, 1, 1639-1645.	0.0	0
1267	A Clinical Experience: A Cutaneous Leishmaniasis Case with Spontan Abortus Following To Meglumine Antimoniata Therapy. Journal of Drug Metabolism & Toxicology, 2015, 06, .	0.1	0
1268	The Seasonality of Cutaneous Leishmaniasis in Asir Region, Saudi Arabia. International Journal of Environment and Sustainability, 2015, 3, .	0.3	4
1269	Therapeutic Arsenal against Leishmaniasis: A Review. International Journal of Tropical Disease & Health, 2015, 5, 101-122.	0.1	0
1270	1-jÄhriges MÄdchen mit BlÄsse und ausladendem Abdomen. , 2015, , 189-192.		0
1271	In vitro Studies on the Antileishmanial Activity of Herbicides and Plant Extracts Against Leishmania major Parasites. Research Journal of Medicinal Plant, 2015, 9, 90-104.	0.3	7
1272	Chronic lymphedema with recurrent blistering and ulceration arising in a leishmaniasis scar. Indian Dermatology Online Journal, 2016, 7, 210.	0.2	0
1273	Loop-Mediated Isothermal Amplification (LAMPLAMP): Molecular Diagnosis for the Field Survey of Visceral Leishmaniasis. , 2016, , 167-171.		1
1274	Investigation of Toxoplasma gondii Infection in Cutaneous Leishmaniasis Patients of the Isfahan Province. International Journal of Infection, 2016, 4, .	0.4	1
1275	Omics and Their Impact on the Development of Chemotherapy Against <i>Leishmania</i>. RSC Drug Discovery Series, 2017, , 101-129.	0.2	0
1276	Chapter 11: LipidÄBased Nanocarriers for the Treatment of Infected Skin Lesions. , 2017, , 385-430.		0
1277	Ocular parasitosis caused by protozoan infection during travel: Focus on prevention and treatment. International Journal of Preventive Medicine, 2018, 9, 79.	0.2	1
1278	Skin Infections. , 2018, , 542-647.		5
1280	COMPARISON OF THE EFFICACY OF CRYOTHERAPY, INTRALESIONAL SODIUM STIBOGLUCONATE AND 7% SODIUM CHLORIDE IN THE TREATMENT OF CUTANEOUS LEISHMANIASIS. Journal of Sulaimani Medical College, 2018, 8, 291-298.	0.0	0

#	ARTICLE	IF	CITATIONS
1281	Study on Knowledge, Attitude and Practice of Health Workers of East Azerbaijan, Ilam and Khorasan Razavi Provinces about Leishmaniasis During 2015 - 2016: A Comparative Study Before and After Intervention. Archives of Clinical Infectious Diseases, 2019, In Press, .	0.1	1
1282	An outbreak of cutaneous leishmaniasis among a displaced population in North Sudan: Review of cases. Journal of Family Medicine and Primary Care, 2019, 8, 556.	0.3	3
1283	Transient Down-Regulation of Nucleoside Transporter 3 Gene Expression as a Drug Target in Leishmania major Using Antisense RNA Technology. Iranian Journal of Parasitology, 0, , .	0.6	0
1285	Integration of Bioinformatics and in vitro Analysis Reveal Anti-leishmanial Effects of Azithromycin and Nystatin. Current Bioinformatics, 2019, 14, 450-459.	0.7	3
1286	Emerging Epidemics of Cutaneous Leishmaniasis in Iran: Operational Aspects, Management and Implemented Control Approaches. Journal of Medical Microbiology and Infectious Diseases, 2019, 7, 52-60.	0.1	3
1287	Comparison of Cysteine Protease B Gene Expression between Clinical Isolates of Leishmania tropica, Leishmania major and Leishmania infantum. Journal of Medical Microbiology and Infectious Diseases, 2019, 7, 72-78.	0.1	1
1288	A Novel Strategy for Enhance Potentiation of Meglumine antimo-niate against Leishmania major In Vitro. Iranian Journal of Parasitology, 0, , .	0.6	2
1291	Nutritional Intake and Chronicity Associated with the Old World Cutaneous Leishmaniasis: Role of Vitamin A. Iranian Journal of Public Health, 0, , .	0.3	2
1292	Effects of hydroalcoholic extract of Glycyrrhiza glabra and glycyrrhizic acid on promastigote and amastigote of Leishmania major (MRHO/IR/75/ER). Journal of Medicinal Plants, 2020, 19, 73-83.	0.3	0
1293	Cutaneous Disorders of the External Ear. , 2022, , 793-880.		0
1294	Innate Resistance to Leishmania amazonensis Infection in Rat Is Dependent on NOS2. Frontiers in Microbiology, 2021, 12, 733286.	1.5	0
1295	Transfersomes as alternative topical nanodosage forms for the treatment of skin disorders. Nanomedicine, 2021, 16, 2465-2489.	1.7	9
1296	Akute und chronische Hepatitis. Pathologie, 2020, , 187-254.	0.0	0
1297	Pathological roles of MRP14 in anemia and splenomegaly during experimental visceral leishmaniasis. PLoS Neglected Tropical Diseases, 2020, 14, e0008020.	1.3	3
1299	Visceral Leishmaniasis (Kala-Azar) Nephropathy. , 2020, , 249-262.		1
1300	The case of family cutaneous leishmaniasis at a pediatric dermatologist's practice. Klinicheskaya Dermatologiya I Venerologiya, 2020, 19, 640.	0.0	0
1301	Risk factors associated with Leishmania exposure among dogs in a rural area of Ilha Solteira, SP, Brazil. Revista Da Sociedade Brasileira De Medicina Tropical, 2020, 53, e20200059.	0.4	2
1302	The Treatment of Bacterial and Parasitic Diseases of the Liver. , 2020, , 211-225.		1

#	ARTICLE	IF	CITATIONS
1303	Cutaneous Disorders of the External Ear. , 2020, , 1-87.		0
1305	Quantitative proteomic analysis reveals differential modulation of crucial stage specific proteins during promastigote to amastigote differentiation in <i>Leishmania donovani</i> . <i>Journal of Proteins and Proteomics</i> , 2022, 13, 17-27.	1.0	3
1306	In Vitro Effect of Some Medicinal Plants on <i>Leishmania major</i> Strain MRHO/IR/75/ER. <i>Medical Laboratory Journal</i> , 2020, 14, 46-52.	0.1	3
1307	Evaluation of Different Attractive Traps for Capturing Sand Flies (Diptera: Psychodidae) in an Endemic Area of Leishmaniasis, Southeast of Iran. <i>Iranian Journal of Arthropod-borne Diseases</i> , 2020, 14, 202-213.	0.8	2
1309	Modelling habitat suitability in Jordan for the cutaneous leishmaniasis vector (<i>Phlebotomus papatasi</i>) using multicriteria decision analysis. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008852.	1.3	6
1310	Cutaneous and presumed visceral leishmaniasis in a soldier deployed to Afghanistan. <i>MedGenMed: Medscape General Medicine</i> , 2006, 8, 43.	0.2	4
1311	The Multiple Forms of <i>Leishmania major</i> in BALB/C Mice Lung in Iran. <i>Iranian Journal of Parasitology</i> , 2012, 7, 99-102.	0.6	3
1312	Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil. <i>American Journal of Tropical Medicine and Hygiene</i> , 2009, 80, 574-9.	0.6	47
1313	Causes of pediatric visceral leishmaniasis in southeastern iran. <i>Iranian Journal of Parasitology</i> , 2014, 9, 584-7.	0.6	10
1314	The activity of ozonated olive oil against <i>Leishmania major</i> promastigotes. <i>Iranian Journal of Basic Medical Sciences</i> , 2015, 18, 915-9.	1.0	13
1315	<i>Leishmania tropica</i> in Stray Dogs in Southeast Iran. <i>Iranian Journal of Public Health</i> , 2015, 44, 1359-66.	0.3	18
1316	Species Identification and Molecular Typing of Spp. Using Targeting HSP70 Gene in Suspected Patients of Cutaneous Leishmaniasis from Sistan and Baluchestan Province, Southeast Iran. <i>Iranian Journal of Parasitology</i> , 2016, 11, 489-498.	0.6	9
1317	Clinical Features of Anthroponotic Cutaneous Leishmaniasis in a Major Focus, Southeastern Iran, 1994-2014. <i>Iranian Journal of Parasitology</i> , 2017, 12, 544-553.	0.6	17
1318	Molecular-Based Detection of in Human Blood Samples in a New Focus of Visceral Leishmaniasis in Lorestan Province, Iran. <i>Journal of Arthropod-Borne Diseases</i> , 2018, 12, 67-75.	0.9	9
1319	Lived Experiences of Patients Suffering from Acute Old World Cutaneous Leishmaniasis: A Qualitative Content Analysis Study from Iran. <i>Journal of Arthropod-Borne Diseases</i> , 2018, 12, 180-195.	0.9	4
1320	Diffuse Cutaneous Leishmaniasis in an Immunocompromised Patient Resembling Histoid Hansen's Disease. <i>Indian Dermatology Online Journal</i> , 2018, 9, 452-454.	0.2	3
1321	Antimicrobial activity of an antimicrobial peptide against amastigote forms of. <i>Veterinary Research Forum</i> , 2018, 9, 323-328.	0.3	6
1322	Transient Down-Regulation of Nucleoside Transporter 3 Gene Expression as a Drug Target in Antisense RNA Technology. <i>Iranian Journal of Parasitology</i> , 2019, 14, 111-119.	0.6	0

#	ARTICLE	IF	CITATIONS
1323	A Novel Strategy for Enhance Potentiation of Meglumine antimoniate against In Vitro. Iranian Journal of Parasitology, 2019, 14, 542-551.	0.6	1
1324	Nutritional Intake and Chronicity Associated with the Old World Cutaneous Leishmaniasis: Role of Vitamin A. Iranian Journal of Public Health, 2020, 49, 167-172.	0.3	2
1325	Protective immune response mediated by neutrophils in experimental visceral leishmaniasis is enhanced by IL-32 ^β . Cellular Immunology, 2022, 371, 104449.	1.4	3
1326	Discovery of New Chemical Tools against <i>Leishmania amazonensis</i> via the MMV Pathogen Box. Pharmaceuticals, 2021, 14, 1219.	1.7	5
1327	<i>Leishmania donovani</i> and HIV co-infection in vitro: Identification and characterization of main molecular players. Acta Tropica, 2022, 228, 106248.	0.9	3
1328	Some novel antileishmanial compounds inhibit normal cell cycle progression of <i>Leishmania donovani</i> promastigotes and exhibits pro-oxidative potential. PLoS ONE, 2021, 16, e0258996.	1.1	0
1329	Classical and Modern Drug Treatments for Leishmaniasis. Topics in Medicinal Chemistry, 2021, , 1-21.	0.4	2
1330	An In-depth Proteomic Map of <i>Leishmania donovani</i> Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient. Acta Parasitologica, 2022, 67, 687-696.	0.4	1
1331	Visceral Leishmaniasis Associated with B-Cell Chronic Lymphocytic Leukemia: Report of a Case and Review of the Literature. Life, 2022, 12, 185.	1.1	0
1332	Antileishmanial Activity of BNIPDaoct- and BNIPDanon-loaded Emulsomes on <i>Leishmania infantum</i> Parasites. Frontiers in Nanotechnology, 2022, 3, .	2.4	3
1333	Axenic interspecies and intraclonal hybrid formation in <i>Leishmania</i> : Successful crossings between visceral and cutaneous strains. PLoS Neglected Tropical Diseases, 2022, 16, e0010170.	1.3	7
1334	Exploration of potential inhibitors for autophagy-related protein 8 as antileishmanial agents. Chemical Biology and Drug Design, 2022, 99, 816-827.	1.5	3
1337	OUP accepted manuscript. Briefings in Functional Genomics, 2022, , .	1.3	3
1338	Functionalized 1,2,3-triazolium salts as potential agents against visceral leishmaniasis. Parasitology Research, 2022, 121, 1389-1406.	0.6	2
1339	Host-Pathogen Interaction in Leishmaniasis: Immune Response and Vaccination Strategies. Immuno, 2022, 2, 218-254.	0.6	21
1340	In-Depth Quantitative Proteomics Characterization of In Vitro Selected Miltefosine Resistance in <i>Leishmania infantum</i> . Proteomes, 2022, 10, 10.	1.7	2
1341	Molecular Informatics of Trypanothione Reductase of <i>Leishmania major</i> Reveals Novel Chromen-2-One Analogues as Potential Leishmanicides. , 0, , .		0
1342	A Promising Cutaneous Leishmaniasis Treatment with a Nanoemulsion-Based Cream with a Generic Pentavalent Antimony (Ulamina) as the Active Ingredient. Cosmetics, 2021, 8, 115.	1.5	4

#	ARTICLE	IF	CITATIONS
1343	Novel 3-chloro-6-nitro-1 <i>H</i> -indazole derivatives as promising antileishmanial candidates: synthesis, biological activity, and molecular modelling studies. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 151-167.	2.5	4
1366	Diffuse cutaneous leishmaniasis in an immunocompromised patient resembling histoid Hansen's disease. <i>Indian Dermatology Online Journal</i> , 2018, 9, 452.	0.2	5
1367	A case report and literature review: diagnosis and treatment of human immunodeficiency virus coinfecting with visceral leishmania by metagenomic next-generation sequencing in China. <i>Annals of Translational Medicine</i> , 2022, 10, 497-497.	0.7	2
1368	Review of Molecular Approaches in Leishmaniasis Vaccines: Implications and Restrictions. <i>International Journal of Infection</i> , 2022, 9, .	0.4	0
1369	Genetic diversity and population structure of <i>Leishmania (Viannia) braziliensis</i> in the Peruvian jungle. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010374.	1.3	2
1370	Epigenetic paradigms/exemplars of the macrophage: inflammasome axis in Leishmaniasis. <i>Molecular and Cellular Biochemistry</i> , 0, , .	1.4	0
1371	<i>Leishmania braziliensis</i> causing human disease in Northeast Brazil presents loci with genotypes in long-term equilibrium. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010390.	1.3	0
1372	<i>Leishmania infantum</i> Infection of Primary Human Myeloid Cells. <i>Microorganisms</i> , 2022, 10, 1243.	1.6	2
1373	Replacement of <i>Leishmania (Leishmania) infantum</i> Populations in an Endemic Focus of Visceral Leishmaniasis in Brazil. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	0
1374	Desert boil strikes hard: An outbreak of cutaneous leishmaniasis in Sindh, Pakistan. <i>Tropical Doctor</i> , 0, , 004947552210934.	0.2	0
1375	Biophysical and modeling-based approach for the identification of inhibitors against DOHH from <i>Leishmania donovani</i> . <i>Briefings in Functional Genomics</i> , 2023, 22, 217-226.	1.3	2
1376	Activation of TLR-pathway to induce host Th1 immune response against visceral leishmaniasis: Involvement of galactosylated-flavonoids. <i>Heliyon</i> , 2022, 8, e09868.	1.4	0
1377	Unwelcome prevalence of leishmaniasis with several other infectious diseases. <i>International Immunopharmacology</i> , 2022, 110, 109059.	1.7	8
1378	Eosinophils, but Not Type 2 Innate Lymphoid Cells, Are the Predominant Source of Interleukin 4 during the Innate Phase of <i>Leishmania major</i> Infection. <i>Pathogens</i> , 2022, 11, 828.	1.2	6
1379	A new immunochemotherapy schedule for visceral leishmaniasis in a hamster model. <i>Parasitology Research</i> , 2022, 121, 2849-2860.	0.6	2
1380	Large scale systemic control short-circuits pathogen transmission by interrupting the sand rat (<i>Psammomys obesus</i>) sand fly (<i>Phlebotomus papatasi</i>) <i>Leishmania major</i> transmission cycle. <i>Medical and Veterinary Entomology</i> , 2023, 37, 4-13.	0.7	1
1381	Retrospective Analysis of Leishmaniasis in Sicily (Italy) from 2013 to 2021: One-Health Impact and Future Control Strategies. <i>Microorganisms</i> , 2022, 10, 1704.	1.6	4
1382	Patterns of cutaneous leishmaniasis during the COVID-19 pandemic in four endemic regions of Iran. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2023, 117, 38-44.	0.7	2

#	ARTICLE	IF	CITATIONS
1402	In vitro miltefosine and amphotericin B susceptibility of strains and clinical isolates of Leishmania species endemic in Brazil that cause tegumentary leishmaniasis. <i>Experimental Parasitology</i> , 2023, 246, 108462.	0.5	3
1403	Natural products in the treatment of Leishmaniasis. , 2023, , 417-428.		0
1404	Co-infection of <i>Phlebotomus papatasi</i> (Diptera: Phlebotomidae) gut bacteria with <i>Leishmania major</i> exacerbates the pathological responses of BALB/c mice. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	1
1405	Mucocutaneous leishmaniasis in a 10-year-old female patient from the ecuadorian amazon. Case report. , 0, 3, 249.		0
1406	Intertwining of Retinoic Acid and Cholesterol Pathway and its Consequences in <i>Leishmania donovani</i> -Infected Macrophages. , 2023, , 19-43.		0
1407	The paradigm of intracellular parasite survival and drug resistance in leishmanial parasite through genome plasticity and epigenetics: Perception and future perspective. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	0
1408	A Sero-Epidemiological Study on Visceral Leishmaniasis among Volunteer Children and Adults in Rural Areas of Shahroud, Iran 2018â€“2019. <i>Iranian Journal of Arthropod-borne Diseases</i> , 0, , .	0.8	0
1409	Fatty Acid Composition and Metabolism in <i>Leishmania</i> Parasite Species: Potential Biomarkers or Drug Targets for Leishmaniasis?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4702.	1.8	3
1410	Metallopeptidases as Key Virulence Attributes of Clinically Relevant Protozoa: New Discoveries, Perspectives, and Frontiers of Knowledge. <i>Current Protein and Peptide Science</i> , 2023, 24, .	0.7	1
1411	Drug Repurposing against Phosphomannomutase for the Treatment of Cutaneous Leishmaniasis. <i>Oriental Journal of Chemistry</i> , 2023, 39, 01-10.	0.1	2
1412	Leishmaniasis Epidemiology and Psychosocial Aspect. , 0, , .		1
1413	Antiprotozoal Drugs. , 2021, , 140-148.		0
1414	The cytokine/chemokine response in <i>Leishmania</i> /HIV infection and co-infection. <i>Heliyon</i> , 2023, 9, e15055.	1.4	10
1415	The effect of health literacy and other factors on the delays in applying to the health center of cutaneous leishmaniasis patients. <i>AdÄ±yaman Äœniversitesi SaÄŸYÄ± Bilimleri Dergisi</i> , 0, , 10-16.	0.3	0
1416	Non-Hepatotropic Viral, Bacterial and Parasitic Infections of the Liver. , 2024, , 448-526.		0
1417	In Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis. <i>Pharmaceutics</i> , 2023, 15, 1163.	2.0	2
1418	The roles of autophagy and mitophagy in corneal pathology: current knowledge and future perspectives. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	1
1443	<i>Leishmania</i> Proteomics: Insight into Diagnostics and Vaccine Development. , 2023, , 81-107.		0

#	ARTICLE	IF	CITATIONS
1445	Zoonotic diseases of dogs and cats. , 2024, , 559-572.		0
1446	Leishmania. , 2024, , 3061-3068.		0